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1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3St Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, UK
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*Corresponding author h.squires@sheffield.ac.uk
Background: Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a heterogeneous
group of inflammatory eye disorders. Management includes local and systemic corticosteroids,
immunosuppressants and biological drugs.
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of subcutaneous adalimumab
(Humira®; AbbVie Ltd, Maidenhead, UK) and a dexamethasone intravitreal implant (Ozurdex®; Allergan Ltd,
Marlow, UK) in adults with non-infectious intermediate uveitis, posterior uveitis or panuveitis.
Data sources: Electronic databases and clinical trials registries including MEDLINE, EMBASE, Cochrane
Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and the World Health
Organization’s International Clinical Trials Registry Platform were searched to June 2016, with an update
search carried out in October 2016.
Review methods: Review methods followed published guidelines. A Markov model was developed to
assess the cost-effectiveness of dexamethasone and adalimumab, each compared with current practice,
from a NHS and Personal Social Services (PSS) perspective over a lifetime horizon, parameterised with
published evidence. Costs and benefits were discounted at 3.5%. Substantial sensitivity analyses were
undertaken.
Results: Of the 134 full-text articles screened, three studies (four articles) were included in the clinical
effectiveness review. Two randomised controlled trials (RCTs) [VISUAL I (active uveitis) and VISUAL II
(inactive uveitis)] compared adalimumab with placebo, with limited standard care also provided in both
arms. Time to treatment failure (reduced visual acuity, intraocular inflammation, new vascular lesions) was
longer in the adalimumab group than in the placebo group, with a hazard ratio of 0.50 [95% confidence
interval (CI) 0.36 to 0.70; p < 0.001] in the VISUAL I trial and 0.57 (95% CI 0.39 to 0.84; p = 0.004) in the
VISUAL II trial. The adalimumab group showed a significantly greater improvement than the placebo group
in the 25-item Visual Function Questionnaire (VFQ-25) composite score in the VISUAL I trial (mean difference
4.20; p = 0.010) but not the VISUAL II trial (mean difference 2.12; p = 0.16). Some systemic adverse effects
occurred more frequently with adalimumab than with placebo. One RCT [HURON (active uveitis)] compared
a single 0.7-mg dexamethasone implant against a sham procedure, with limited standard care also provided
in both arms. Dexamethasone provided significant benefits over the sham procedure at 8 and 26 weeks in
the percentage of patients with a vitreous haze score of zero (p < 0.014), the mean best corrected visual
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acuity improvement (p ≤ 0.002) and the percentage of patients with a ≥ 5-point improvement in VFQ-25
score (p < 0.05). Raised intraocular pressure and cataracts occurred more frequently with dexamethasone
than with the sham procedure. The incremental cost-effectiveness ratio (ICER) for one dexamethasone
implant in one eye for a combination of patients with unilateral and bilateral uveitis compared with limited
current practice, as per the HURON trial, was estimated to be £19,509 per quality-adjusted life-year (QALY)
gained. The ICER of adalimumab for patients with mainly bilateral uveitis compared with limited current
practice, as per the VISUAL trials, was estimated to be £94,523 and £317,547 per QALY gained in active
and inactive uveitis respectively. Sensitivity analyses suggested that the rate of blindness has the biggest
impact on the model results. The interventions may be more cost-effective in populations in which there is a
greater risk of blindness.
Limitations: The clinical trials did not fully reflect clinical practice. Thirteen additional studies of clinically
relevant comparator treatments were identified; however, network meta-analysis was not feasible.
The model results are highly uncertain because of the limited evidence base.
Conclusions: Two RCTs of systemic adalimumab and one RCT of a unilateral, single dexamethasone
implant showed significant benefits over placebo or a sham procedure. The ICERs for adalimumab were
estimated to be above generally accepted thresholds for cost-effectiveness. The cost-effectiveness of
dexamethasone was estimated to fall below standard thresholds. However, there is substantial uncertainty
around the model assumptions. In future work, primary research should compare dexamethasone and
adalimumab with current treatments over the long term and in important subgroups and consider how
short-term improvements relate to long-term effects on vision.
Study registration: This study is registered as PROSPERO CRD42016041799.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Active systemic disease Systemic disease that is currently requiring symptomatic treatment (in these
patients, systemic treatment may be more appropriate to treat both the uveitis and the underlying disease).
Anterior chamber of the eye The fluid-filled space in the front part of the eye located between the iris
and the inner surface of the cornea.
Anterior segment of the eye The part of the eye composed of the cornea, iris, lens, ciliary body and
front part of the sclera (white part of the eye). In general, it forms the anterior (front) one-third of the eye.
Bilateral Uveitis affecting both eyes. For the purposes of this report, to avoid confusion, this does not
relate to treatment for both eyes. In the case of local treatment, it may be for one or both eyes and will be
referred to as such.
Cataract A cloudiness of the lens of the eye.
Corticosteroid-sparing therapy A single treatment or treatment regimen that allows the reduction or
discontinuation of ongoing corticosteroids.
Cycloplegic drug A drug that causes relaxation of the ciliary muscle of the eye.
Extended dominance When the incremental cost-effectiveness ratio for a given treatment alternative is
higher than that of the next more effective (non-dominated) comparator.
Fluorescein angiography An eye test that uses a specialised camera and a fluorescent dye to examine
the circulation of the retina and choroid.
Glaucoma An eye condition characterised by damage to the optic nerve caused by intraocular pressure.
Immunosuppression Reducing or lowering the immune response with the use of drugs.
Indirect ophthalmoscope A magnifying instrument with a light source for examining the inside of the
eye through the pupil, especially the space between the lens and the retina.
Intraocular pressure Pressure exerted by fluid in the eye. The normal range is between 10 and 20 mmHg
and may vary in an individual at different times of the day.
Legal blindness best corrected visual acuity of ≤ 20/200 in the better-seeing eye and/or a visual field
of ≤ 20°.
Local treatment/local pathway Treatments that are local to the eye (may be given to one or both eyes;
little effect on systemic disease).
Macula The pigmented area or ‘yellow spot’ near the centre of the retina.
Macular oedema Fluid collection in the region of the macula.
Meta-analysis A statistical method by which the results of a number of studies are pooled to give a
combined summary statistic.
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xv
Mydriatic drug A drug instilled in the eye to dilate the pupil.
No active systemic disease Either no systemic disease related to uveitis or systemic disease that is
currently controlled (in these patients, treatment local to the eye may be more appropriate).
Optic nerve A nerve that transmits visual information from the retina to the brain.
Optical coherence tomography A non-invasive technique for cross-sectional imaging of the retina and
light-sensitive areas of the eye.
Posterior segment of the eye The part of the eye encompassing the vitreous, choroid, retina and optic
nerve. It forms the posterior (back) two-thirds of the eye.
Relative risk The ratio of the probability of an event occurring in an exposed group relative to the
probability of an event occurring in a non-exposed or control group.
Simple dominance When an intervention is less effective and more expensive than its comparator.
Systemic disease Known underlying systemic disease related to the uveitis.
Systemic treatment/systemic pathway Treatments that are given systemically (and by their nature treat
both eyes and may also treat systemic disease).
Unilateral Uveitis affecting one eye. For the purposes of this report, to avoid confusion, this does not
relate to treatment for one eye.
Visual acuity This refers to how well a person sees, that is, clarity of vision.
Vitreous A clear jelly-like fluid that fills the middle of the eye, between the lens and the retina.
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List of abbreviations
AC anterior chamber
ADA adalimumab
AE adverse event
AG Assessment Group
AIC Akaike information criterion
BCVA best corrected visual acuity
BIC Bayesian information criterion
CEAC cost-effectiveness acceptability
curve
CI confidence interval
CINAHL Cumulative Index to Nursing and
Allied Health Literature
CPCI Conference Proceedings
Citation Index
CP(M) current practice as provided in the
MUST trial
DEX dexamethasone
DEX 350 dexamethasone 0.35 mg
DEX 700 dexamethasone 0.7 mg
EMA European Medicines Agency
EQ-5D EuroQol-5 Dimensions
ETDRS Early Treatment Diabetic
Retinopathy Study
HADS Hospital Anxiety and Depression
Scale
HR hazard ratio
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
IOP intraocular pressure
ITT intention to treat
LCP(H) limited current practice based on
the HURON trial
LCP(VI) limited current practice based on
the VISUAL I trial
LCP(VII) limited current practice based on
the VISUAL II trial
LOCF last observation carried forward
logMAR logarithm of the minimum angle
of resolution
MD mean difference
MeSH medical subject heading
MUST Multicenter Uveitis Steroid
Treatment
NEI National Eye Institute
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NMA network meta-analysis
NSAID non-steroidal anti-inflammatory
drug
PROM patient-reported outcome measure
PSA probabilistic sensitivity analysis
PSS Personal Social Services
QALY quality-adjusted life-year
RCT randomised controlled trial
RR relative risk
SAE serious adverse event
ScHARR School of Health and Related
Research
SD standard deviation
SF-36 Short Form questionnaire-36 items
SmPC Summary of Product Characteristics
SUN Standardization of Uveitis
Nomenclature
TNF tumour necrosis factor
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VCM Vision Core Measure
VFQ-25 25-item Visual Function
Questionnaire
VH vitreous haze
VKH Vogt–Koyanagi–Harada disease
WHO World Health Organization
WPAI Work Productivity and Activity
Impairment
WTP willingness to pay
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Plain English summary
Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a group of conditions causinginflammation in the eye, which if untreated may lead to sight loss. Treatment may include injections or
implants into the eye or medicines taken by mouth or via injection.
This assessment evaluated whether adalimumab (as an injection under the skin) (Humira®; AbbieVie Ltd,
Maidenhead, UK) or dexamethasone (as an implant in the eye) (Ozurdex®; Allergan Ltd, Marlow, UK)
improved patients’ eye inflammation, vision and quality of life. We also examined the harmful effects of
treatment as well as the associated costs. Data were combined from published sources in an economic model
to estimate the cost-effectiveness of adalimumab and dexamethasone compared with current treatment.
Evidence from three studies showed that adalimumab and dexamethasone were each better than placebo
at improving eye inflammation, vision and quality of life. In terms of safety, adalimumab resulted in more
generalised effects such as infections and injection site reactions. The dexamethasone implant resulted in
more eye-related complications such as raised pressure in the eye and cataracts.
For dexamethasone, the additional cost for each additional year of life in full health (cost per quality-adjusted
life-year gained) was estimated as £19,509 compared with current practice. The equivalent figure for
adalimumab was estimated to be > £90,000, which is higher than the values reported by the National
Institute for Health and Care Excellence as thresholds for a treatment to be considered cost-effective. There
is substantial uncertainty around the evidence, in particular with regard to the impact of the interventions on
patient blindness and differences between trial evidence and clinical practice.
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Scientific summary
Background
Uveitis describes a group of conditions characterised by inflammation of the uveal tract. The underlying
cause may be infectious or non-infectious. In the UK and the developed world, uveitis is most commonly
non-infectious and likely autoimmune in origin, either isolated to the eye or associated with systemic
autoimmune disorders. This study covers the most sight-threatening forms of non-infectious uveitis, those
affecting the posterior structures of the eye, termed intermediate uveitis (vitreous humour and posterior
ciliary body), posterior uveitis (retina and choroid) and panuveitis (front and back of the eye). It does not
cover anterior uveitis (iris and anterior ciliary body). Symptoms include blurred vision, floaters and sometimes
pain and redness. Consequences leading to potential vision loss include early complications such as cystoid
macular oedema (retinal swelling) and vitreous haze (VH) (inflammatory cell debris in the vitreous) and late
complications such as cataracts (lens cloudiness), glaucoma [optic nerve damage from increased intraocular
pressure (IOP)] and irreversible retinal damage. Between 3 and 16 in 100,000 people are estimated to have
non-infectious posterior segment-involving uveitis. Uveitis generally presents in working-age people,
is the fifth leading cause of visual impairment in developed countries and accounts for 10% of cases of
legal blindness.
Current treatment includes corticosteroids (systemic or local injection or implant) as first-line treatment and
immunosuppressive drugs (such as methotrexate, mycophenolate mofetil, ciclosporin, tacrolimus and
azathioprine) as second-line treatment for uveitis unresponsive to corticosteroids or which recurs on steroid
tapering. Tumour necrosis factor (TNF)-alpha inhibitors are considered a third-line option. The majority of
these treatments are not currently licensed. The technologies assessed in this study were adalimumab (ADA)
(Humira®; AbbVie Ltd, Maidenhead, UK), a monoclonal antibody TNF-alpha inhibitor, and dexamethasone
(DEX) (Ozurdex®; Allergan Ltd, Marlow, UK), a corticosteroid intravitreal implant.
Aims
The aims of this study were to:
l evaluate the clinical effectiveness and safety of ADA (via subcutaneous injections) and a DEX intravitreal
implant within their marketing authorisations for non-infectious intermediate uveitis, posterior uveitis or
panuveitis in adults
l estimate the incremental cost-effectiveness of ADA and a DEX intravitreal implant for non-infectious
intermediate uveitis, posterior uveitis or panuveitis compared with each other and current treatment
l estimate the expected overall cost of ADA and DEX treatment in England
l identify areas for primary research.
Methods
Searches of nine databases to June/October 2016 including MEDLINE, EMBASE, Cochrane Database of
Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Cumulative Index to
Nursing and Allied Health Literature (CINAHL) identified randomised controlled trials (RCTs) of ADA, DEX
implants and relevant comparators. Study quality was assessed using the Cochrane risk-of-bias tool. Results
were synthesised using narrative synthesis. The use of a network meta-analysis (NMA) was explored.
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Searches were undertaken for existing cost-effectiveness studies in non-infectious uveitis. A de novo
Markov model was developed by the Assessment Group (AG) to assess the cost-effectiveness of DEX and
ADA, each compared with (limited) current practice, from a NHS and Personal Social Services (PSS)
perspective over a lifetime horizon. The two interventions were not compared directly as they are often
used in different patient scenarios and, when comparison would be clinically appropriate, there was
insufficient trial evidence. The cost-effectiveness of ADA was assessed separately for active and inactive
uveitis and the cost-effectiveness of DEX was assessed only for active uveitis. The model included five
health states: (1) treatment: no permanent blindness, (2) treatment failure: no permanent blindness,
(3) permanent blindness, (4) remission and (5) death. Effectiveness was modelled using EuroQol-5 Dimensions
(EQ-5D) utility data from the ADA trials and by regression analysis, mapping scores from the 25-item Visual
Function Questionnaire (VFQ-25) reported within the DEX trial to EQ-5D utilities. Health-related quality
of life (HRQoL) (VFQ-25 or EQ-5D) could be improved by a reduction in inflammation, improvements in vision
or a reduction in adverse events (AEs). Treatment may reduce the risk of permanent damage to the eye,
resulting in a decreased risk of legal blindness. Given the uncertainties around the comparators and
long-term outcomes, substantial exploratory and sensitivity analyses were undertaken.
Results
Of the 134 full-text articles screened, three studies (four articles) were included in the clinical effectiveness
review. Two RCTs compared ADA (40 mg every 2 weeks by subcutaneous injection) with placebo: VISUAL I
(active uveitis, n = 223) and VISUAL II (inactive uveitis, n = 229). Over 90% of patients had bilateral uveitis.
As ADA is a systemic treatment, both eyes were treated. All patients were on high-dose corticosteroids at
baseline and patients in the VISUAL I trial received an initial high-dose steroid burst; steroids were then
tapered in both studies. One concomitant immunosuppressant was received by 30% of participants in the
VISUAL I trial and 47% of participants in the VISUAL II trial. Follow-up was carried out up to 80 weeks or
until treatment failure and outcomes were measured from the best response following the steroid burst
(VISUAL I) or from baseline (VISUAL II) to treatment failure or the study end. One RCT of DEX implants
(HURON, n = 229) compared a dose of 0.7 mg (DEX 700) or 0.35 mg (DEX 350) with a sham procedure
over 26 weeks. This assessment was limited to the licensed DEX 700 group compared with the sham
group. One eye per patient received a single implant (right eye if bilateral; worse-seeing eye in 84% of all
patients). Systemic therapies were received by 25% of participants at baseline and could be continued
throughout the trial. The proportion of bilateral cases was not recorded. Thirteen additional trials of
clinically relevant comparator treatments [vs. placebo or one another as per the National Institute for Health
and Care Excellence (NICE) scope] were identified. However, pairwise meta-analysis and NMA were not
feasible because of clinical heterogeneity, lack of common comparators (the network was disconnected)
and differences in reported outcomes.
Clinical effectiveness
The primary outcome for the VISUAL trials of ADA was treatment failure, defined as worsening of any of
the following in either eye: anterior chamber (AC) cell grade, VH grade, best corrected visual acuity (BCVA)
or new inflammatory lesions. In the VISUAL I trial (active uveitis), the median time to treatment failure was
5.6 months in the ADA arm compared with 3.0 months in the placebo arm [hazard ratio (HR) 0.50, 95%
confidence interval (CI) 0.36 to 0.70; p < 0.001]. In the VISUAL II trial (inactive uveitis), the median time to
treatment failure was not estimable in the ADA arm and was 8.3 months in the placebo arm [HR 0.57,
95% CI 0.39 to 0.84; p = 0.004). The VISUAL I trial reported significant benefits for ADA compared with
placebo for changes in the following (averaged across both eyes): visual acuity [mean difference (MD) –0.07;
p = 0.003), VH (MD –0.27; p < 0.001), AC cell grade (MD –0.29; p = 0.011), macular oedema (percentage
change in central retinal thickness: MD –11.4%; p = 0.020), VFQ-25 composite score (MD 4.20; p = 0.010)
and EQ-5D score (MD 0.04; p = 0.044). In the VISUAL II trial, differences were not significant for ADA
compared with placebo for changes in any of visual acuity (MD –0.04; p = 0.096), VH (MD –0.13; p < 0.070),
AC cell grade (MD –0.14; p = 0.218), macular oedema (percentage change in central retinal thickness:
MD –2.3%; p = 0.451), VFQ-25 composite score (MD 2.12; p = 0.160) or EQ-5D score (MD 0.00; p = 0.836).
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Secondary outcomes in the VISUAL I and II trials were measured only to treatment failure or the study end
and, as treatment failure occurred in more patients on placebo than on ADA, the last observation carried
forward method may have introduced bias as data post treatment failure were not missing at random.
In the HURON trial there were significant benefits of DEX 700 compared with the sham procedure for the
following (measured in the study eye only): percentage of patients with a VH score of zero at 8 weeks
(MD 34.9%; p < 0.001) and 26 weeks (MD 16.7%; p = 0.014), percentage with a VH improvement of
≥ 2 units at 8 weeks (MD not reported; p < 0.001) and 26 weeks (MD not reported; p = 0.001), percentage
with a BCVA improvement of three or more lines at week 26 (MD 24.5%; p < 0.001), mean BCVA
improvement over weeks 3–26 (no values reported; p ≤ 0.002), decrease in central retinal thickness at 8 weeks
(MD –87.0 µm; p = 0.004) although not at 26 weeks (MD –14.7 µm; p = 0.58), change in VFQ-25 composite
score at 8 weeks (MD 5.4; p = 0.007) and 26 weeks (MD 7.3; p = 0.001) and percentage of patients with a
≥ 5-point improvement in VFQ-25 score at 8 weeks (54.8% vs. 27%; p < 0.001) and 26 weeks (57.5% vs.
32.4%; p < 0.05). Rescue medications (corticosteroid injections or new/increased use of systemic therapies)
were required in 22% of the DEX 700 group compared with 38% of the sham group (p= 0.030).
As ADA affects the immune system, potential risks of treatment include infections and malignancy. Serious
infections were higher in the ADA group than in the placebo group in the VISUAL I trial (4.5% vs. 1.8%)
but not in the VISUAL II trial (1.7% vs. 1.8%). Across both trials, malignancies and chronic renal failure each
occurred in three patients in the ADA group, with no cases in the placebo group. Systemic AEs that had a
higher rate in the ADA group than in the placebo group in at least one RCT included infections, injection
site reactions, fatigue, arthralgia, myalgia, paraesthesia, hypertension and elevated levels of liver enzymes.
Anti-ADA antibodies occurred in 2.7% of participants in the VISUAL I trial and 5% of participants in the
VISUAL II trial. There was little difference in ocular AEs between the groups.
In the HURON trial, the following AEs were reported: raised IOP (DEX 700 25% vs. sham 7%), IOP of
≥ 25 mmHg (DEX 700 7.1% vs. sham 1.4%), glaucoma (DEX 700 0% vs. sham 2.7%), cataracts in phakic
eyes (DEX 700 15% vs. sham 7%), endophthalmitis (severe eye infection) (DEX 700 1.3% vs. sham 0%)
and conjunctival haemorrhage (DEX 700 30% vs. sham 21%). No systemic AEs had a significantly higher
rate in the DEX 700 group than in the sham group.
No patients required incisional surgery, 2.6% of participants in the DEX 700 group required a laser
iridotomy and, at any one time, up to 23% of participants in the DEX 700 group required IOP-lowering
medication (not reported for the sham group). Cataract surgery was required in 1.6% of participants in the
DEX 700 group compared with 3.6% of participants in the sham group.
Cost-effectiveness
The base-case analysis undertaken by the AG estimated the incremental cost-effectiveness ratio (ICER) of
one DEX implant in one eye for a combination of patients with unilateral and bilateral uveitis compared
with limited current practice, as per the HURON trial, to be £19,509 per quality-adjusted life-year (QALY)
gained. The ICER of ADA (systemic, therefore treatment for both eyes) for patients with mainly bilateral
uveitis compared with limited current practice, as per the VISUAL trials, was estimated to be £94,523 and
£317,547 per QALY gained in active and inactive uveitis respectively.
Exploratory analyses suggested that the two factors that have the largest impact on the ICERs, both highly
uncertain, are the rate of blindness in the comparator group and the relative risk of blindness for ADA or
DEX compared with the comparator. The ICER for DEX compared with (limited) current practice varied from
dominating to £56,329 per QALY gained when varying these parameters. When the rate of legal blindness
was set to zero to explore the cost-effectiveness of DEX for unilateral uveitis, the estimated ICER was
£50,627 per QALY gained. Under all assumptions tested for these parameters, the ICER for ADA compared
with (limited) current practice, based on the VISUAL trials, remained above £30,000 and £82,000 per QALY
for active and inactive uveitis respectively. The factor that had the largest impact on the ICER for ADA was
the proportion of patients who were assumed to stop ADA treatment following remission and maintain the
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same quality of life; assuming that all patients go into remission after 2 years on ADA, the ICER was
reduced to £35,299 and £84,132 per QALY for active and inactive uveitis respectively.
Discussion
The results of the economic model are highly uncertain because of the limited evidence base. In addition to
the issues explored within the sensitivity analyses, several further differences between evidence and practice
were not possible to quantify. First, clinical advisors to the AG (three of the authors, AD, IP and FQ, who
provided clinical advice throughout) suggested that the proportion of patients remaining on ADA may be
underestimated within the VISUAL trials because of strict criteria for treatment failure. If more people
remained on treatment, the additional patients would incur the same costs but experience reduced
effectiveness of ADA and hence the ICERs for ADA would increase. Second, clinical advisors suggested that
ADA use in ‘inactive’ patients would be restricted to patients discontinuing immunosuppressants because
they are ineffective or not tolerated; however, there are no data for this group. Third, the model assumed
the use of only one DEX implant per patient. There is no RCT evidence assessing more than one implant,
either in both eyes or consecutively. Although the AG explored the impact of consecutive implants, there
were insufficient data to consider the cost-effectiveness of DEX implants in both eyes. However, because
costs would essentially be doubled and the HRQoL increase would probably be lower for the second eye,
implants in both eyes are expected to be less cost-effective than treatment in one eye only. Fourth, clinical
advisors suggested that ADA and DEX are likely to be provided alongside other treatments. In the trials,
around one-third of patients in both arms received other treatments. However, it is unclear whether or not
the relative effectiveness of ADA and DEX predicted within the trials would remain if the use of alternative
treatments in both the intervention group and the comparator group was increased. Finally, because of a
lack of evidence for a comparator representing current practice, it is unclear how ADA and DEX may affect
the use of other treatments. The model incorporated the impact of DEX on use of rescue therapy, but this
was based on the analysis using a sham comparator. If treatment with DEX or ADA led to a reduction in use
of immunosuppressants and/or corticosteroids without having an impact on efficacy, then they would be
more cost-effective than currently predicted.
The population considered in the model was heterogeneous and the interventions may be more cost-effective
in some groups than others. However, there was no trial evidence to facilitate subgroup analyses. Patients
with more severe uveitis, such as those with macular oedema, may benefit more from ADA or DEX; hence,
the treatments may be more cost-effective as baseline disease worsens. In addition, ADA used to concurrently
treat uveitis and systemic symptoms may be more cost-effective than ADA used to treat uveitis alone. The
analysis in which the rate of blindness was set to zero, which could be used to explore the cost-effectiveness
of DEX for patients with unilateral uveitis, suggested that the ICER compared with (limited) current practice
increases substantially.
The analysis presented here takes a NHS and PSS perspective. Non-infectious uveitis affects a working-age
population and can affect workplace productivity and leisure time. Therefore, there are likely to be
additional non-NHS and non-PSS costs and benefits associated with the treatments that are not captured
within our analyses.
Conclusions
Two RCTs of systemic ADA and one RCT of a unilateral single DEX implant showed significant benefits of the
treatments compared with placebo or a sham procedure for outcomes including visual acuity, inflammation,
macular oedema, VFQ-25 score and time to treatment failure. Use of one DEX implant in a mixed group of
unilateral and bilateral patients had an estimated ICER of £19,509 per QALY gained compared with (limited)
current practice. The ICER associated with ADA compared with (limited) current practice did not fall below
£30,000 per QALY gained in any of the analyses carried out.
SCIENTIFIC SUMMARY
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There is substantial uncertainty around the evidence, in particular with regard to the comparative effectiveness
and cost-effectiveness of DEX and ADA and their effectiveness and cost-effectiveness compared with those
of systemic immunosuppressants and corticosteroids and how short-term improvements in visual acuity and
inflammation relate to long-term effects on vision loss and blindness. The impact of differences between
clinical practice and trial evidence is uncertain. Finally, there is insufficient evidence from patient subgroups in
which the interventions may be more or less effective and cost-effective.
Study registration
This study is registered as PROSPERO CRD42016041799.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Uveitis is a heterogeneous group of ocular disorders involving inflammation of the uveal tract of the eye,
which consists of the iris, the ciliary body and the choroid,1–5 or surrounding tissues (e.g. sclera, retina and
optic nerve).6
Criteria for the classification of uveitis according to anatomical site of inflammation were formally
developed by the International Uveitis Study Group in 1987.7 These were later revised in 2004 following
the Standardization of Uveitis Nomenclature (SUN) Workshop.8 The SUN criteria included onset, duration
and course of uveitis in the classification of the condition. There are currently no agreed guidelines for
describing uveitis-related systemic conditions.9 A summary of uveitis classification according to the SUN
criteria8 is presented in Table 1.
Anterior uveitis is inflammation of the anterior chamber (AC) involving the iris and the anterior aspect of
the ciliary body; this is outside the scope of this assessment. Intermediate uveitis affects the posterior part
of the ciliary body and the vitreous humour. Posterior uveitis affects the back of the eye, including the
retina or the choroid. Intermediate and posterior uveitis may be referred to collectively as posterior
segment-involving uveitis. Panuveitis is inflammation of the whole of the uveal tract (front and back of the
eye), extending from the AC to the choroid or retina.3 A diagram of the eye and the parts affected in
anterior, intermediate and posterior uveitis is shown in Figure 1.
Intermediate uveitis, posterior uveitis and panuveitis account for around 10% of uveitis cases in the UK10
but are more severe and more likely to cause vision loss.11
TABLE 1 Classification of uveitis: SUN8
Type of uveitis Primary site of inflammation
Anterior uveitis Anterior chamber
Intermediate uveitis Vitreous
Posterior uveitis Retina and choroid
Panuveitis Anterior chamber, vitreous, retina or choroid
Criteria Description
Onset
Sudden (No detail provided)
Insidious (No detail provided)
Duration
Limited < 3 months’ duration
Persistent > 3 months’ duration
Course
Acute Episode characterised by sudden onset and limited duration
Recurrent Repeated episodes with intermittent periods of inactivity not requiring treatment for > 3 months
Chronic Persistent episodes with relapse in < 3 months of treatment discontinuation
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Aetiology, pathology and prognosis
Uveitis may have an infectious or a non-infectious cause; this appraisal is restricted to non-infectious
uveitis. Non-infectious uveitis may occur as an ocular manifestation of a systemic autoimmune condition
such as Behçet’s disease, sarcoidosis, multiple sclerosis or Vogt–Koyanagi–Harada disease (VKH).13,14
A study from the Netherlands including almost 400 patients with posterior uveitis, intermediate uveitis or
panuveitis reported that around half of all cases were likely to be related to systemic disease.15 In the
remaining cases, no systemic association could be found; these cases are known as idiopathic uveitis,
although it is presumed that the disease is still likely to be autoimmune in nature.14 Specific forms of uveitis
include birdshot chorioretinopathy (also referred to as birdshot uveitis).
One or both eyes may be affected in uveitis. Estimates of the proportion of bilateral cases from studies
of uveitis patients in tertiary centres in the UK and Europe range from 41% to 67%.11,16–18 Each of these
centres included patients with both anterior and posterior segment-involving uveitis. Three of the authors
(AD, IP and FQ) provided clinical advice throughout, hereafter referred to as clinical advisors to the
Assessment Group (AG). They suggested that the proportion of bilateral cases is higher for posterior
segment-involving uveitis patients only, with the proportion of bilateral cases in this group estimated to be
70–80%. Many patients have asymmetric disease, with some inflammation in both eyes but more severe
disease in one eye (these patients may or may not be included in the above estimates for bilateral uveitis).
Symptoms of uveitis depend on the parts of the eye affected. The main symptoms of the forms of uveitis
considered in this study include blurred vision and floaters in the eye. However, pain and redness in the
eye, sensitivity to light, loss of peripheral vision and headaches may also be reported.13 In general, clinical
manifestations of uveitis of different aetiologies may be similar but treatment strategies are predominantly
determined by the underlying pathophysiology3 and may often require a multidisciplinary approach.
The consequences of uveitis that may lead to loss of vision include early complications, such as cystoid
macular oedema (swelling of the retina) and vitreous haze (VH) (inflammatory cell debris in the vitreous),
and late complications, such as cataracts (cloudiness of the lens), glaucoma (optic nerve damage associated
with increased pressure inside the eye) and irreversible damage to the retina.14 Many patients with
posterior segment-involving uveitis require cataract surgery at a relatively early age; however, as cataract
surgery is relatively efficacious and safe, clinicians may be less concerned about cataract formation than
other complications of uveitis (clinical advisors to the AG, personal communication).
Eyelids
Pars plana
Sclera Choroid
Retina
Vitreous
PosteriorAnterior
Intermediate
Uvea
Optic
nerveCornea
Iris
Lens
Ciliary body
FIGURE 1 Types of uveitis based on parts of the eye affected. Reproduced with permission from Phil Hibbert,
Uveitis Information Group (Scotland).12
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Dick et al.19 conducted a retrospective analysis of insurance claim data from 1998 to 2012 for patients
with a diagnosis of non-infectious intermediate uveitis, posterior uveitis or panuveitis in the USA. In total,
1769 patients with uveitis were followed up for a mean period of 5.6 years. The reported 5-year risks for
patients with non-infectious intermediate uveitis, posterior uveitis or panuveitis were as follows: glaucoma
20%, cataracts 35%, visual disturbance 29%, blindness or low vision 4.5%, retinal detachment 11%
and retinal disorder 28%. The supplemental material included a Kaplan–Meier curve of time to blindness,
which showed a 10-year risk of blindness or low vision of 6.6%.
Tomkins-Netzer et al.18 conducted a cross-sectional study of all patients (n = 1076) who attended the
uveitis clinic of a single consultant at Moorfields Eye Hospital in London. The mean follow-up duration was
7.97 years and vision loss [best corrected visual acuity (BCVA) ≤ 20/50] was reported in 19.2% of eyes.
Macular scarring (4%), retinal detachment (1.33%) and chronic macular oedema (1.16%) were the most
common causes of irreversible severe vision loss (BCVA ≤ 20/200). Twenty patients had bilateral severe
vision loss and were registered as legally blind.
Another retrospective review of records of 315 patients with uveitis in the UK from January 1998 to
December 2000 described visual impairment (BCVA ≤ 6/18 in at least one eye) in 220 out of 315 uveitis
patients (70%) overall and in 149 of 192 patients with intermediate uveitis, posterior uveitis or panuveitis
(78%) after a mean follow-up duration of 36.7 months.11 Severe visual impairment (BCVA ≤ 6/60)
occurred in 38% (n = 120/315) of patients. Permanent visual impairment was present in 17% (n = 54/315)
of patients, with 15% (n = 46/315) of patients experiencing bilateral impairment. The World Health
Organization (WHO)’s criteria for blindness (BCVA in better eye of < 3/60 or a visual field of ≤ 10°)20 were
met in 36 out of 315 patients (11.4%). Cystoid macular oedema, cataract and the coexistence of both
conditions were the predominant causes of visual loss in 26.8% (n = 59/220), 17.7% (n = 39/220) and
20% (n = 44/220) of uveitic patients respectively. Reported predictors of poor visual outcome were older
age (p = 0.02 via logistic regression), bilateral inflammation (p = 0.0005 via t-test), panuveitis (p = 0.0005
via logistic regression) and increasing duration of reduced vision (p = 0.0005 via t-test).11 Overall, around
10% of cases of blindness in the developed world are caused by uveitis.18,21
Epidemiology and prevalence
Uveitis affects people of any age but generally presents in people of working age, aged 20–50 years.3,14
The mean age at presentation for patients with all types of uveitis attending tertiary centres has been
reported to range from 35 to 48 years across studies in the UK,11,18 the Netherlands15 and France.16
There is extensive variation in the causes of uveitis worldwide, genetic factors and environmental features
contributing significantly to its pathology.14 Whereas infectious uveitis is frequently seen in developing
countries, idiopathic non-infectious uveitis is more common in most of the developed world, including
England.3
Earlier epidemiological studies in Europe and the USA have estimated annual incidence rates of uveitis
ranging from 14 to 22.5 per 100,000 people and prevalence rates of between 38 and 380 per 100,000
people.11 Wide variations in epidemiological statistics have been explained by differences in the classification
of uveitis, aetiological causes and demographic risk factors.14 There are limited data on the prevalence
of non-infectious posterior segment-involving uveitis in England. The Scottish Uveitis Network reported
prevalence rates for patients with uveitis treated with immunosuppression (systemic corticosteroids, second-line
immunosuppressants or a combined treatment of the two agents) collected prospectively over a 4-month
period between August and November 2005; estimates ranged from 2 to 59 per 100,000 people.22 A
claims-based analysis conducted in the USA based on 2012 data from the OptumHealth Reporting and
Insights claims database reported an overall prevalence of adult non-infectious uveitis (n = 4827 cases; 2086
men and 2741 women) of 121 cases per 100,000 people [95% confidence interval (CI) 117.5 to 124.3 cases
per 100,000 people].23 The observed prevalence rates of non-infectious intermediate uveitis, posterior uveitis
and panuveitis in adults were 1 case (95% CI 0.8 to 1.5 cases), 10 cases (95% CI 9.4 to 11.5 cases) and
12 cases (95% CI 10.6 to 12.7 cases) per 100,000 people respectively.23 Earlier studies have generally
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provided no or limited data for patients with non-infectious uveitis24,25 or have had issues (e.g. missing data,
use of administrative data, variations in referral patterns), making estimates less generalisable.22,26 Between
3 and 16 out of 100,000 people are estimated to have non-infectious posterior segment-involving uveitis
(see Chapter 5).
Impact of the health problem
Uveitis is the fifth leading cause of visual impairment in developed countries and accounts for 10% of
cases of legal blindness.23,27 Patients may experience sudden and temporary or progressive and permanent
visual impairment.11
With regard to anatomical classification of uveitis, patients with posterior segment-involving uveitis and
panuveitis tend to suffer more severe visual impairment than those with anterior uveitis.27 Compared with
uveitis affecting only the posterior segment, patients with panuveitis (both posterior and anterior) tend to
have a poorer prognosis.11 Additionally, the underlying cause of uveitis may also significantly influence the
prognosis of intraocular inflammation.11 For example, patients with uveitis as a result of Behçet’s disease
have poorer visual outcomes than patients with non-infectious uveitis without an associated systemic
condition, even when intense treatment is initiated at early stages of the disease.11 Complications of
uveitis, namely cystoid macular oedema, cataract, glaucoma or a combination of any of these, significantly
influence the visual morbidity.
A post hoc analysis of health-related quality of life (HRQoL) in patients with non-infectious intermediate or
posterior uveitis participating in the HURON trial compared with that in a matched set of the general US
population found that the uveitis group had lower mean scores on the following subscales of the National
Eye Institute (NEI) 25-item Visual Function Questionnaire (VFQ-25):28 role emotional (p < 0.001), mental
health (p < 0.001), role physical (p < 0.001), vitality (p < 0.001), general health (p = 0.01) and mental
component summary (p < 0.001).29 No statistically significant differences between the groups were found
for the physical component summary, physical functioning, bodily pain and social functioning subscales of
the VFQ-25 or for EuroQol-5 Dimensions (EQ-5D)30 scores.
Loss of visual function can lead to an inability to work and drive. It can also affect the ability to take
part in leisure activities. In addition, the currently available treatments, including corticosteroids and
immunosuppressants, are associated with substantial adverse events (AEs). The most common AEs
associated with long-term use of corticosteroids include osteoporosis and fractures, gastric conditions,
psychiatric conditions, skin conditions, hyperglycaemia, weight gain, ocular conditions (including cataract)
and cerebrovascular disease.31 The most common AEs associated with immunosuppressants include
cataracts, ocular hypertension, headache, fever, nausea, diarrhoea, fatigue, paraesthesia, tremors and
systemic infection.32,33 These can lead to substantial reductions in HRQoL for the patient and may also have
an impact on the patient’s family.
Significance for the NHS
Patients with uveitis often require referral to secondary care to confirm the diagnosis and for the provision
of treatment. Patients require regular monitoring. There are substantial costs to the NHS and Personal
Social Services (PSS) associated with treatment of the complications of uveitis and blindness, as well as
treatment for the AEs associated with current practice. As the cause and presentation of uveitis varies
between individuals, it is important for clinicians to have a range of treatment options available. In
practice, a range of unlicensed immunosuppressants and corticosteroids are used to treat patients with
uveitis. Clinical advisors to the AG suggest that dexamethasone (DEX) implants and adalimumab (ADA) are
both used variably in current practice depending on funding availability. The number of patients who
would be eligible for these treatments annually is uncertain, but Allergan and AbbVie, the manufacturers
of DEX and ADA, respectively, estimate that it would be 589 and 175 patients respectively (see Chapter 5).
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Measurement of disease
Outcome measures in uveitis may be grouped according to the different aspects that they measure:
(1) disease activity or inflammation in the eye (e.g. VH, which is the degree of cloudiness in the vitreous
humour, and acute cystoid macular oedema); (2) disease-associated tissue damage or complications
(e.g. cataract, glaucoma, chronic cystoid macular oedema); (3) visual loss (e.g. visual acuity, visual field
loss); and (4) patient-reported visual function (e.g. via the VFQ-25).34
There are some issues worth highlighting about outcome measurements in patients with uveitis. Vision loss
has a complex interaction with visual acuity [which is a measure of central vision according to a validated
measure such as the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, Snellen chart or another
similar tool35], visual field contrast sensitivity and colour vision. Visual acuity in patients with uveitis may
reflect both the degree of intraocular inflammation and the extent of damage in the eye; whereas
inflammation may vary over short time periods (days or weeks), damage may accrue slowly (months or years)
and, with the important exception of cataract and acute cystoid macular oedema, is usually irreversible. It
will be immediately evident that, whereas short-term effects on vision (related to inflammation) may be
captured within a clinical trial, the commonly used time frames in studies are too short to capture important
long-term consequences for vision of damage to the eye caused by inadequately controlled uveitis. This may
lead to systematic underestimates of the effects of interventions for treating uveitis in clinical trials.
Markers of structural damage to the eye, such as macular oedema (swelling of the retina), cataract and
glaucoma, are important outcomes because they are the mechanisms by which uveitis patients lose vision
and they are objective measures. However, they may not be good markers of whether or not a treatment
reduces inflammation because they indicate structural damage to the eye, which might not resolve when
the inflammation is treated.
In clinical practice, a combination of several outcomes is used to assess the response of uveitic activity
to treatment. Generally, outcomes related to uveitis are assessed by clinical examination (visual acuity,
slit-lamp examination of AC cells, VH grading) and by imaging (e.g. optical coherence tomography).
The NEI system for VH grading and AC cell grading proposed by the SUN Working Group8 is the ‘current
gold standard’ for assessing intraocular inflammation (i.e. AC cell grade and VH grade).36 The SUN system
was a formalisation and adoption of the Nussenblatt scale.8,37 Grading requires the examination of a
patient’s eye by an indirect ophthalmoscope followed by a comparison of the appearance with a series of
photographs of varying grades of fundus VH.37 Although the grading system is accepted by the US Food and
Drug Administration and has been used in a number of recent studies of uveitis,36 it is a subjective grading
of cloudiness in the vitreous humour caused by inflammatory cells and cell debris on a non-continuous scale
(0, 0.5+, 1, 2, 3 and 4+).7,8,34,37 Its poor discriminatory property for detecting changes in the lower VH grades
and extensive inter-rater variations have been reported to be limitations of this system.29,36,38
Inflammation in the AC is assessed on the basis of the number of cells per one field on standard slit-lamp
examination or by high-speed optical coherence tomography.8
Complications of structural changes in the eye as a result of uveitis are typically reported according to the
type of complication. For example, the SUN Working Group suggests that macular oedema could be
determined by clinical examination and additional tests, for example optical coherence tomography or
fluorescein angiography.8 A patient is considered to have an increased or elevated intraocular pressure
(IOP) if the pressure rises above a specified limit or increases from a baseline value in a study in which
patients are followed over time (i.e. longitudinal data).8 Although no consensus has been reached on the
threshold for considering elevated IOP, an increase of ≥ 10 mmHg is considered to be important.8
However, the SUN Working Group recommends the reporting of IOPs above the following thresholds:
21 mmHg (above the accepted upper limit of normal), 24 mmHg (associated with a significant risk of
glaucoma) and 30 mmHg (when treatment for raised IOP is often started).8
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Other outcomes reported in studies of patients with uveitis include generic utility measures such as the
EQ-5D and vision-specific measures such as the VFQ-25.39 These outcome measures capture broader
considerations and hence may overcome some of the issues associated with the alternative outcome measures.
The EQ-5D also allows treatments to be compared with treatments for other diseases and patient populations,
although it may not be as sensitive as the VFQ-25.40
Current service provision
Non-infectious intermediate uveitis, posterior uveitis and panuveitis are initially treated with corticosteroids.
Corticosteroids may be administered systemically (oral or parenteral) or locally via periocular or intravitreal
injections or intravitreal implants. Additionally, if the front of the eye is also affected, topical corticosteroids
and dilating eye drops may be offered. Systemic corticosteroids carry significant morbidity (e.g. cataract,
glaucoma, diabetes, osteoporosis, weight gain, raised blood pressure) and long-term use above 7.5 mg per
day is not recommended.41,42
In terms of second-line treatment, people with severe or chronic non-infectious uveitis whose disease has
not adequately responded to corticosteroid treatment, for whom corticosteroids are not appropriate or
whose uveitis recurs after tapering the corticosteroid dose may be given immunosuppressive drugs (such as
methotrexate, mycophenolate mofetil, ciclosporin, tacrolimus and azathioprine). Immunosuppressive drugs can
allow a reduction in the corticosteroid dose and associated complications. If the disease does not respond to
these treatments or if they are not tolerated, especially in patients at high risk of losing their vision or those with
systemic disease related to uveitis, biological tumour necrosis factor (TNF)-alpha inhibitors may be used. The
majority of these treatments are not currently licensed.
There are currently no national guidelines on treating non-infectious uveitis; however, all three clinical
advisors to the AG, who practise within different regions of the UK (Birmingham, Liverpool and Sheffield),
were in agreement that the above description represents the general treatment pathway. This description
is also consistent with three local treatment pathways, two referenced in the DEX submission from
Allergan43 (North East Retinal Group4 and NHS Southern Derbyshire Clinical Commissioning Group5) and
one obtained by personal communication from Alastair Denniston (West Midlands Regional Uveitis Service,
August 2016). The general treatment pathway does not differ according to whether a patient has
intermediate uveitis, posterior uveitis or panuveitis. However, specific treatment is individualised based on a
broad range of factors. In particular, treatment depends on whether or not systemic disease is known to
be present, whether or not any systemic disease is controlled (i.e. whether or not current inflammation is
restricted to the eye) and whether the disease affects one or both eyes. Figure 2 shows the general
treatment pathway developed based on the three local treatment pathways and input from the clinical
advisors to the AG.
For the purposes of this report, the following terminology is used:
l Systemic disease. Known underlying systemic disease related to the uveitis.
l Active systemic disease. Systemic disease that is currently requiring symptomatic treatment (in these
patients, systemic treatment may be more appropriate to treat both the uveitis and the underlying
disease).
l No active systemic disease. Either no systemic disease related to uveitis or systemic disease that is
currently controlled (in these patients, treatment local to the eye may be more appropriate).
l Local treatment/local pathway. Treatments that are local to the eye (may be given to one or both eyes;
little effect on systemic disease).
l Systemic treatment/systemic pathway. Treatments that are given systemically (and by their nature treat
both eyes and may also treat systemic disease).
l Unilateral. Uveitis affecting one eye. This does not relate to treatment for one eye.
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Systemic steroids
First line
Second line
Third line
Immunosuppressants (may also continue
steroids ≤ 7.5 mg/day):
(1) mycophenolate mofetil
(or methotrexate)
(2) mycophenolate mofetil 
(or methotrexate) + tacrolimus
(or ciclosporin)
Anti-TNFs
(ADA, infliximab,
etanercept)
Periocular steroids
(e.g. triamcinolone)
(may repeat)
DEX steroid 
implant
(may repeat)
Unresponsive
Intolerant
Requires > 7.5 mg/day
Options for placement of dexamethasone:
• only after periocular steroids AND systemic steroids or
   immunosuppressants AND cycloplegic mydriatic eye drops
   (based on two local pathways)
• after periocular steroids (clinical advisors and West Midlands pathway)38,39
• first line, if periocular steroids (triamcinolone) considered out of scope
Systemic pathway
For patients with
• bilateral + active systemic disease
• unilateral + active systemic disease
• bilateral + no active systemic disease 
   (via either pathway)
For patients with
• unilateral or asymmetric
   bilateral + no active systemic disease
• bilateral + no active systemic disease
   (via either pathway)
Local pathway
FIGURE 2 General treatment pathway in patients with non-infectious uveitis.
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l Bilateral. Uveitis affecting both eyes. This does not relate to treatment for both eyes. In the case of
local treatment, it may be for one or both eyes and will be referred to as such.
l Legal blindness. BCVA of ≤ 20/200 in the better-seeing eye and/or a visual field of ≤ 20°.
Description of the technologies under assessment
Adalimumab (Humira®; AbbVie Ltd, Maidenhead, UK) is a monoclonal antibody that inhibits the
proinflammatory cytokine, TNF-alpha. ADA has a marketing authorisation from the European Medicines
Agency (EMA) for the treatment of non-infectious intermediate uveitis, posterior uveitis and panuveitis in
adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid
sparing or in patients for whom corticosteroid treatment is inappropriate.44 ADA is administered as a
subcutaneous injection containing a 40-mg preparation of the active drug.
Dexamethasone intravitreal implant (Ozurdex®; Allergan Ltd, Marlow, UK) is a corticosteroid that suppresses
inflammation by inhibiting the expression of proinflammatory mediators. The implant has a marketing
authorisation from the EMA for treating adults with inflammation of the posterior segment of the eye
presenting as non-infectious uveitis (i.e. intermediate uveitis, posterior uveitis and panuveitis). DEX
intravitreal implant is a biodegradable ophthalmic implant that contains 0.7 mg of the active drug. Each
implant is intravitreally administered using a single-use solid polymer drug delivery system or applicator.45
The Summary of Product Characteristics (SmPC) for DEX notes that administration to both eyes concurrently
is not recommended because of a lack of data.45
Place of the interventions in the treatment pathway
Clinical advisors to the AG and three local treatment pathways from the North East Retinal Group4 and the
NHS Southern Derbyshire Clinical Commissioning Group5 (as referenced in the DEX submission43) and the
West Midlands Regional Uveitis Service (Alastair Denniston, personal communication) were consulted to
determine the place of the interventions in the treatment pathway. A general view was that DEX and ADA
would generally not be used for the same patients or at the same point in the pathway. Treatments local
to the eye (including the DEX implant) are considered to be appropriate for unilateral uveitis or asymmetric
bilateral uveitis (when disease is more severe in one eye) when systemic disease is not present or is well
controlled. Systemic treatments (including ADA) are considered to be appropriate to treat patients with
bilateral uveitis (i.e. affecting both eyes) and/or active systemic disease. According to clinical advice provided
to the AG, systemic treatments would generally not be given to a patient with unilateral uveitis and no active
systemic disease because of the adverse effects associated with them. Patients with bilateral uveitis but no
active systemic disease could be treated using either a local or a systemic approach. Although the inclusion
criteria for the clinical trials of these drugs46–48 were not limited by these factors, our clinical experts suggest
that clinicians may have selected patients for the trials accordingly.
In addition, the licensing of ADA and DEX differ in that, to be eligible for ADA, patients must have had an
inadequate response to corticosteroids or require steroid-sparing treatment or corticosteroid treatment
must be inappropriate, whereas DEX implants can used as first-line treatment. Clinical advisors to the AG
suggest that in practice it is likely that DEX would be used as second-line treatment following local or
systemic treatment with corticosteroids, whereas ADA would be used as a third-line option for patients
with insufficient control with, or intolerance to, systemic corticosteroids and immunosuppressants;
however, for some patients this may be as a result of current funding availability rather than clinical need.
Figure 2 shows the general treatment pathway, indicating the most likely place of DEX and ADA (based on
the opinion of the clinical advisors to the AG).
Although for most patients there is a clear clinical rationale for providing DEX and ADA at different points
in the treatment pathway, the licensing allows both treatments to be given at overlapping points in the
pathway (i.e. for patients with an inadequate response to corticosteroids, in need of corticosteroid sparing
or in whom corticosteroid treatment is inappropriate),44 although the DEX implant is also licensed in a less
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restricted group.45 This overlap is reflected somewhat by their use in clinical trials (see Chapter 3). Table 2
presents the situations in which ADA and DEX may be used according to both licensing and clinical
appropriateness. The most likely places in the pathway where these treatments would be used according
to clinicians are shown in bold.
In addition to the issues described above, because uveitis covers a heterogeneous group of diseases, clinical
advice suggests that maintaining a range of options is important depending on a patient’s requirements.
Identification of important subgroups
The following have been identified as important subgroups that might affect the treatment offered:
l unilateral or bilateral uveitis
l the presence or absence of underlying autoimmune or inflammatory disease
l whether any underlying systemic disease is active or controlled
l existing treatment with long-term systemic immunosuppressants
l baseline visual acuity
l patients for whom systemic or local corticosteroid treatments are not appropriate.
Current usage in the NHS
Dexamethasone implants and subcutaneous ADA injections are both used variably in current practice,
which may partly depend on funding availability and/or clinician and patient preference.
Anticipated costs associated with the interventions
Table 3 shows the 6-monthly costs of DEX and ADA. One DEX implant is expected to last around 6 months,
based on observational trial data18,50,51 and clinical advice. It should be noted that patients could receive
TABLE 3 Costs of ADA and the DEX vitreal implant
Drug Licensed dose Company Cost (£) Six-monthly cost (£)
ADA 40mg once every 2 weeks AbbVie 352.14 4578
DEX One 0.70-mg implant Allergan 870 870
Data from British National Formulary.49
TABLE 2 Situations in which ADA and DEX may be used
Line of therapy
(see Figure 2)
Unilateral (or
temporary flare in
one eye), no active
systemic disease,
local treatment
appropriate
Bilateral, no
active systemic
disease, systemic
or local treatment
appropriate
Unilateral (or
temporary flare in
one eye), active
systemic disease,
systemic or local
treatment appropriate
Bilateral, active
systemic disease,
systemic treatment
appropriate
First line DEX or ADA licensed if corticosteroid treatment is inappropriate ADA licensed if
corticosteroid
treatment is
inappropriate
Second line (after
systemic corticosteroids)
DEX or ADAa DEX or ADAa DEX or ADAa ADA
Third line (after systemic
corticosteroids and
immunosuppressants)
DEX or ADAa DEX or ADA DEX or ADA ADA
a In practice ADA would be used only if there was a specific contraindication to DEX.
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more than one implant, either in succession or in the other eye, with staggered implementation; however,
these options have not been assessed within a randomised controlled trial (RCT). ADA is administered every
2 weeks until treatment failure. In the VISUAL I trial of ADA in active patients, 50% of patients had failed
on treatment by 6 months and 66% had failed by 1 year.52 Clinical advisors to the AG suggest that some
patients may remain on ADA treatment for many years.
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Chapter 2 Definition of the decision problem
This study assessed the clinical effectiveness and cost-effectiveness of ADA (via subcutaneous injections)and a DEX intravitreal implant for treating inflammation of the posterior segment of the eye presenting
as non-infectious uveitis. ADA is licensed for the treatment of non-infectious intermediate uveitis, posterior
uveitis and panuveitis in adult patients who have had an inadequate response to corticosteroids or who
are in need of corticosteroid-sparing therapy or for whom corticosteroid treatment is inappropriate,
whereas DEX intravitreal implant is licensed for the treatment of adults with inflammation of the posterior
segment of the eye presenting as non-infectious uveitis.
Decision problem
The decision problem was specified as in the following sections.
Population
l Adults (aged ≥ 18 years) with non-infectious intermediate uveitis, posterior uveitis or panuveitis.
Interventions
l Adalimumab (via subcutaneous injections).
l Dexamethasone intravitreal implant.
Relevant comparators
Relevant comparators included:
l periocular or intravitreal corticosteroid injections
l intravitreal corticosteroid implants
l systemic corticosteroids
l systemic immunosuppressive therapies including azathioprine, methotrexate, cyclophosphamide,
ciclosporin, chlorambucil, tacrolimus, mycophenolate mofetil and TNF-alpha inhibitors
l intravitreal methotrexate
l best supportive care (when all other treatment options have been tried)
l placebo or a sham procedure.
Combinations of the above treatments were also considered as relevant comparators.
Outcomes
The following outcomes were considered relevant for this assessment:
l visual acuity (the affected eye)
l visual acuity (both eyes)
¢ measured as the mean difference (MD) in BCVA according to a validated measure such as the
ETDRS chart, Snellen chart or a similar tool
¢ other measures of visual acuity would be considered if outcomes could be justified and validated in
relation to accepted relevant standard measures
l improvement in disease activity (e.g. VH grade, AC cell grade)
l uveitis-related tissue damage or complications (e.g. cataract, macular oedema, retinal vascular occlusion)
l reduction in systemic steroid use
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l mortality
l adverse effects of treatment
l HRQoL, including generic measures such as the EQ-5D and functional measures such as the VFQ-25
l composite end points incorporating more than one of the above.
Overall aims and objectives of the study
The aims of the study were to:
1. evaluate the clinical effectiveness and safety of ADA subcutaneous injection and DEX intravitreal
implant within their marketing authorisations for treating non-infectious intermediate uveitis, posterior
uveitis or panuveitis in adults
2. estimate the incremental cost-effectiveness of ADA subcutaneous injection and DEX intravitreal implant
within their marketing authorisations for treating non-infectious intermediate uveitis, posterior uveitis or
panuveitis compared with each other and with current treatment
3. estimate the expected overall costs of ADA and DEX in England
4. identify key areas for primary research.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
A systematic review was undertaken to assess the clinical effectiveness and safety of ADA subcutaneousinjection and DEX intravitreal implant within their marketing authorisations in adults with non-infectious
intermediate uveitis, posterior uveitis or panuveitis. The review of the evidence of clinical effectiveness was
carried out in accordance with the principles recommended in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement.53 First, the methods used in the systematic review of the
clinical effectiveness evidence are presented. The results of the review are then reported followed by a
summary of the results.
Methods for reviewing effectiveness
A registered protocol of this systematic review (CRD42016041799) is available on the PROSPERO website
at www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016041799 (accessed 1 September 2016).
Identification of studies
The scope of the searches took into account the potential need to make simultaneous comparisons
between all interventions, including, when appropriate, a network meta-analysis (NMA). The search
strategy was designed to identify RCTs and systematic reviews of the relevant interventions, ADA and DEX
intravitreal implant, as well as studies reporting on any comparators relevant to the scope, in patients with
non-infectious intermediate uveitis, posterior uveitis and/or panuveitis. Given the broad range of possible
comparators, the searches consisted only of terms for ‘uveitis’ combined with search filters for relevant
study types and did not include terms for the interventions.
The search strategy consisted of medical subject headings (MeSH) or EMTREE Thesauri terms and free-text
synonyms for ‘uveitis’. Searches were translated across databases and were not limited by language or
publication date. Search strategies are presented in Appendix 1. Search filters designed to retrieve clinical trials,
systematic reviews and economic evaluations were used in MEDLINE and other databases when appropriate.
Electronic database searches
The search approach involved the following:
l searching of electronic databases and clinical trials registries
l contact with experts in the field
l examination of bibliographies of retrieved papers.
The following electronic databases and clinical trials registries were searched from inception for RCTs and
systematic reviews:
l MEDLINE (via Ovid) (1946 to 2016)
l MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
(1946 to 2016)
l EMBASE (via Ovid) (1974 to 2016)
l Cochrane Database of Systematic Reviews (CDSR) (via Wiley Online Library) (1996 to 2016)
l Database of Abstracts of Reviews of Effects (DARE) (via Wiley Online Library) (1995–2015)
l Cochrane Central Register of Controlled Trials (CENTRAL) (via Wiley Online Library) (1995 to 2016)
l Health Technology Assessment (HTA) database (via Wiley Online Library) (1995 to 2016)
l NHS Economic Evaluation Database (NHS EED) (via Wiley Online Library) (1995–2015)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost) (1982 to 2016)
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l Conference Proceedings Citation Index (CPCI) (Thomson Reuters) (1990 to June 2016)
l the WHO’s International Clinical Trials Registry Platform [see http://apps.who.int/trialsearch/ (accessed
15 June 2016)].
Literature searching was undertaken in June 2016. Further searches were conducted in MEDLINE and
CINAHL in October 2016.
Supplementary searches
References of relevant systematic reviews, primary studies and company submissions were checked to
identify additional studies. Citation searching using Web of Science Citation Index (Thomson Reuters,
1899 to June 2016) was also undertaken. Searches were also conducted in Toxicology Literature Online
(TOXLINE) in October 2016 to identify records reporting AEs for the technologies of interest.
Inclusion and exclusion criteria
The inclusion and exclusion criteria for selecting studies with relevant clinical effectiveness and safety data
for ADA subcutaneous injection, DEX intravitreal implant or clinically relevant comparators in adults with
non-infectious intermediate uveitis, posterior uveitis or panuveitis were consistent with the decision
problem outlined in the National Institute for Health and Care Excellence (NICE) scope.54
Population
The population of interest was adults with non-infectious intermediate uveitis, posterior uveitis or
panuveitis. Eligible participants were considered for inclusion regardless of type of non-infectious posterior
segment-involving uveitis (i.e. active or inactive uveitis; unilateral or bilateral uveitis; presence or absence of
uveitis-related systemic disease or previous treatments for uveitis). Patients with infectious uveitis or uveitis
as part of a masquerade syndrome were excluded from this review. In terms of patient age, studies were
eligible if the enrolled patients were aged ≥ 18 years, or if separate data were provided for adults, or if at
≥ 80% of patients were adults. Studies conducted in paediatric populations were excluded.
Intervention
Interventions of interest were subcutaneous injection of ADA (40 mg) and DEX intravitreal implant (0.7 mg).
Comparators
Relevant comparators considered were as outlined in the NICE scope.54 Studies reporting a comparison
between subcutaneous injection of ADA and DEX intravitreal implant or between one of these
interventions and any of the following comparator treatments were considered for inclusion:
l periocular or intravitreal corticosteroid injections
l intravitreal corticosteroid implants
l systemic corticosteroids
l systemic immunosuppressive therapies including azathioprine, methotrexate, cyclophosphamide,
ciclosporin, chlorambucil, tacrolimus, mycophenolate mofetil and TNF-alpha inhibitors
l intravitreal methotrexate
l best supportive care (when all other treatment options have been tried)
l placebo or a sham procedure.
In addition, studies reporting on any of the comparator treatments were considered for inclusion in a
potential NMA.
Combinations of the above-mentioned interventions were also considered as relevant comparators.
Comparative studies in uveitis including interventions not specifically covered in the scope, or not
considered to be clinically relevant comparators following consultation with clinical advisors to the AG,
were excluded from the review. Excluded interventions included sirolimus, secukinumab, bevacizumab,
acetazolamide, diclofenac, lisinopril, vitamin E, retinal antigens, echinacea and vitrectomy.
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Outcomes
Outcomes of interest were:
l visual acuity (the affected eye)
l visual acuity (both eyes)
¢ measured as the MD in BCVA according to a validated measure such as the ETDRS chart, Snellen
chart or a similar tool
¢ other measures of visual acuity would be considered if outcomes could be justified and validated in
relation to accepted relevant standard measures
l improvement in disease activity (e.g. VH grade, AC cell grade)
l uveitis-related tissue damage or complications (e.g. cataract, macular oedema, retinal vascular occlusion)
l reduction in systemic steroid use
l mortality
l adverse effects of treatment
l HRQoL, including generic measures such as the EQ-5D and functional measures such as the VFQ-25
l composite end points incorporating more than one of the above.
Study design
Data from RCTs were considered to be the most relevant for inclusion in the systematic review of the
clinical effectiveness and safety of ADA subcutaneous injection and DEX intravitreal implant.
In addition, the DEX company submission43 included efficacy and safety data from non-randomised
retrospective studies of 0.7 mg of dexamethasone (DEX 700) for non-infectious posterior segment-
involving uveitis, reported in English, which included at least 10 patients. These data are summarised here
for information, as some non-RCTs assessed DEX repeat implants (in the same eye) or implants in both
eyes, whereas the RCT of DEX assessed only one implant in one eye per patient. It was beyond the scope
of this assessment to undertake further searches or check the study selection and data extraction process
undertaken within the DEX company submission. Non-randomised studies of ADA are not included here as
they were not provided in the company submission55 and it was beyond the scope of this assessment to
undertake a de novo review of non-randomised studies of ADA.
The following publication types were excluded from the review: narrative reviews, systematic reviews,
clinical guidelines, editorials, letters, opinion pieces, abstracts with insufficient detail to assess study quality
or results and non-English-language articles. Studies of animal models and preclinical and biological studies
were not included.
Study selection process
Study selection was undertaken using a two-stage process guided by prespecified inclusion and exclusion
criteria, as presented in the previous section.
All retrieved records were exported into a reference management database (EndNote version X7; Thomson
Reuters, CA, USA). After deduplication, records were assessed for relevance by initially examining titles/
abstracts, followed by a detailed scrutiny of the related full-text versions of potentially includable studies.
At each step, studies that did not satisfy the eligibility criteria were excluded. One reviewer (EP or KC)
checked a set of records; this was followed by a 10% check of selected studies by a second reviewer
(KC or EP). Disagreements were resolved by discussion and involvement of a third researcher (HS) if needed.
Data extraction
Data were extracted by one reviewer (EP or KC) using a standardised piloted data extraction form and
checked by a second reviewer (KC or EP). Disagreements were resolved by discussion. Data relevant to the
decision problem were extracted, with no blinding to authors or journal. In relation to the interventions of
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interest, namely ADA and DEX, data extraction was limited to patients randomised to treatment arms with
doses consistent with their licensed indications. Extracted information for each study included the study
name (when reported), first author with publication year, characteristics of the study population,
interventions, comparators and outcomes. When multiple publications of the same study were identified,
data were extracted and reported as a single study.
Quality assessment
The methodological quality of each included study was assessed using an adapted Cochrane risk-of-bias
tool.56 Quality assessment was undertaken by one reviewer (EP or KC) and checked by a second reviewer
(KC or EP).
Data synthesis
It was initially anticipated that, to compare the interventions of interest with each other and with current
standard care, pairwise meta-analyses and/or NMAs may be undertaken, depending on the availability of
relevant RCTs with common comparators reporting consistent outcomes. However, conducting pairwise
meta-analyses or NMAs was not possible for the reasons presented in Indirect comparison of treatments:
rationale for not undertaking. Data from studies contributing to the review were therefore summarised
and presented using tabular and narrative syntheses. Summary statistics, for example MDs between
treatments for continuous outcomes and relative risks (RRs) for binary outcomes, were calculated if not
provided in the study reports.
Results of the clinical effectiveness review
Quantity and quality of research available
Literature searches retrieved 10,585 records (10,582 from the database searches and three from searching
reference lists). A total of 10,451 records were excluded at title and abstract stage. Of the 134 full-text
articles obtained for detailed examination, 117 were excluded because they did not meet the eligibility
criteria for the review. Details of the excluded full-text articles with reasons for exclusion are presented in
Appendix 2. Seventeen potentially relevant articles (relating to 16 studies) were retained for potential
inclusion in meta-analyses; 13 studies32,33,57–67 were related to comparators within the scope of the review
and three studies (four articles46–48,68) evaluated ADA or DEX 700. It was not possible to include any of the
13 studies of comparators within a NMA (the reasons why this was not possible, and a summary of the
13 studies, are provided in Indirect comparison of treatments: rationale for not undertaking and Table 24).
This section therefore focuses specifically on studies of DEX 700 and ADA. The selection of studies informing
the clinical effectiveness review is summarised in Figure 3. An example data extraction form is provided in
Appendix 3 and the criteria for the assessment of methodological quality are provided in Appendix 4.
Assessment of effectiveness
Study characteristics
The characteristics of the two included studies of ADA and the one included study of DEX 700 in patients
with non-infectious uveitis are summarised in Table 4.
All three included studies were international, multicentre RCTs conducted in regions including Europe,
North America and Australia.
Two trials, VISUAL I46 (n = 223 patients) and VISUAL II47 (n = 229 patients), compared ADA administered
subcutaneously as an 80-mg loading dose followed by 40 mg every other week with a corresponding
placebo treatment in patients with active (VISUAL I)46 or inactive (VISUAL II)47 non-infectious intermediate
uveitis, posterior uveitis or panuveitis. The treatment and follow-up period had a duration of up to 80 weeks
(18 months) or until treatment failure. Main study data were available for 223 patients with active uveitis
(67 study sites)46,52,55 and 229 patients with inactive uveitis (62 study sites).47,55,72 The VISUAL I and VISUAL II
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trials also included a subpopulation of patients from Japan (n = 16 and n = 32 patients respectively).55
Data for this subgroup were not included in related publications46,47 or the company submission.55
One study, HURON48 (46 study sites; n = 229 patients), a 26-week Phase III trial, evaluated the effectiveness
of two different dosages of DEX intravitreal implants, DEX 700 and DEX 350 (0.35 mg), compared with a
sham procedure in patients with active, chronic non-infectious intermediate and posterior uveitis. Only data
relating to the licensed DEX 700 arm are included in this review.
Patient characteristics
Patients included in the HURON trial48 (mean age 44.8 years) were slightly older than those included in the
VISUAL I46 and VISUAL II47 trials (mean age 42.7 and 42.5 years respectively). The proportion of women
varied from 57%46 to 63%.48
Inclusion criteria for patients with active uveitis in the VISUAL I trial46 were based on the manifestation of one or
more of the following: VH score of ≥ 2; AC cell grade of ≥ 2 and/or active inflammatory chorioretinal or retinal
vascular lesions while on high-dose oral corticosteroids (10–60mg/day) for ≥ 2 weeks. Inactive uveitis in
patients included in the VISUAL II trial47 was characterised by a VH score of ≤ 0.5 and an AC cell grade of
≤ 0.5, with no active inflammatory chorioretinal or retinal vascular lesions (i.e. uveitis inactivity), while receiving
10–35 mg/day of oral prednisone or its equivalent to maintain an inactive state of inflammation ≥ 28 days
before study entry. Patients were considered for inclusion if control of their disease was corticosteroid
dependent, that is, they had had more than one uveitic flare in the past 18 months occurring within 1 month
of tapering steroids. In the HURON trial,48 active intraocular inflammation was based on the presence of a VH
score of ≥ 1.5+ and patients unresponsive to previous treatment with corticosteroids were excluded.48
Records identified through database
searching
(n = 10,582)
Additional records identified through
other sources
(n = 3)
Records screened
(n = 10,585)
Records excluded at title/abstract
stage
(n = 10,451)
Full-text articles assessed for
eligibility
(n = 134)
Full-text articles excluded, 
with reasons
(n = 117)
• Population not relevant, n = 28
• Intervention not relevant, n = 25
• Data/outcomes not relevant, n = 15
• Not RCT, n = 33
• Other, n = 16
References for any intervention or
comparator relevant to decision
problem assessed for potential
inclusion in NMA
(n = 17)
Full-text articles included in clinical
effectiveness review
[n = 4 articles (3 studies)]
References for comparators
excluded as NMA not feasible
(n = 13)
• Intervention, n = 4
• Comparators, n = 13
FIGURE 3 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart.
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TABLE 4 Summary of the study characteristics of the included studies
Study, company, study
dates, setting
Population: sample size,
mean age, % of females,
type of uveitis Population: diagnosis
Intervention and
comparator Previous treatments Concomitant treatments Outcomes
l VISUAL I
(NCT01138657)46,55,69
l AbbVie
l August 2010–
August 2014
l 67 sites,
18 countriesa
l n= 223,b age 42.7 years,
57% female
(n= 217 analysed)
l Active uveitisc
l Intermediate 22%,
posterior 33%, pan 45%
l Bilateral 91%,
unilateral 9%
l Duration (months), mean
(SD): intervention 40.2
(51.3), comparator
51.0 (72.2)
Idiopathic 37%
(n= 81/217), sarcoidosis
8% (n= 18/217), Behçet’s
disease 7% (n= 16/217),
VKH 12% (n= 25/217),
birdshot chorioretinopathy
20% (n= 44/217),
multifocal choroiditis and
panuveitis 5% (n= 11/217),
other 10% (n= 22/217)
l Intervention: ADA
subcutaneous
injection, 80-mg
loading dose
followed by
40-mg dose every
other week
l Comparator: placebo
All patients: high-dose
oral corticosteroids
l All patients: oral
prednisone 60mg/day
tapered to 0mg by
week 15
l PRN: topical
corticosteroids,
discontinued by week 9;
immunosuppressants
(maximum one):
azathioprine 4%
(n= 8/217), ciclosporin
6% (n= 13/217),
mycophenolate mofetil or
similar 12% (n= 25/217),
methotrexate 10%
(n= 21/217)
l Primary outcome: TTF
(worsening of one or
more of AC grade,
VH grade, BCVA or
inflammatory retinal
or chorioretinal
vascular lesions)
at/after week 6,
one or more eyes
l Secondary outcomes:
BCVA (logMAR),
change in VH or AC
grade, % change in
CRT, time to MO,
change in VFQ-25
score, AEs
l VISUAL II
(NCT01124838)47,55,70
l AbbVie
l August 2010–
May 2015
l 72 sites, 22 countriesd
l n= 229,e age 42.5 years,
61% female (n= 226
analysed), 18 patients
from the UK
l Inactive uveitisf
l Intermediate 21%,
posterior 33%; pan 46%
l Bilateral 96%,
unilateral 4%
l Duration (months), mean
(SD): intervention 59.5
(64.5), comparator
62.9 (67.7)
Idiopathic 31%
(n= 69/226), sarcoidosis
14% (n= 32/226),
Behçet’s disease 7%
(n= 16/226), VKH 23%
(n= 51/226), birdshot
chorioretinopathy 13%
(n= 30/226), multifocal
choroiditis and panuveitis
3% (n= 7/226), other 9%
(n= 21/226)
l Intervention: ADA
subcutaneous
injection, 80-mg
loading dose
followed by 40-mg
dose every
other week
l Comparator:
placebo
All patients: high-dose
oral corticosteroids
l All patients: oral
prednisone 10–35mg/day
tapered to 0mg by
week 19 or earlier
l PRN: topical
corticosteroids,
discontinued by week 9;
immunosuppressants
(maximum one):
azathioprine 6%
(n= 14/226), ciclosporin
12% (n= 26/226),
mycophenolate mofetil or
similar 15% (n= 34/226),
methotrexate 15%
(n= 33/226)
l Primary outcome: TTF
(worsening of one or
more of AC grade,
VH grade, BCVA or
inflammatory retinal
or chorioretinal
vascular lesions)
at after week 2,
one or more eyes
l Secondary outcomes:
BCVA (logMAR),
change in VH or AC
grade, % change in
CRT, time to MO,
change in VFQ-25
score, AEs
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Study, company, study
dates, setting
Population: sample size,
mean age, % of females,
type of uveitis Population: diagnosis
Intervention and
comparator Previous treatments Concomitant treatments Outcomes
l HURON
(NCT003338)48,68,71
l Allergan
l May 2006–
October 2008
l 46 sites, 18 countries
l n= 229,
g
age 44.8 years,
63.3% female
(153 of analysed
sample included)
l Active uveitis
l Intermediate 81%,
posterior 19%
l Bilateral NR,
unilateral NR
l Duration (months),
mean (SD): interventionh
50.5 (54.2), comparator
61.2 (62.5)
None specified (no
patients had uncontrolled
systemic conditions)
l Intervention:
single-dose, DEX
intravitreal implant,
0.7 mg or 0.35mg
l Comparator:
sham injection
l All patients: none
specified
l Systemic
immunosuppressant
or anti-inflammatory
treatment at baseline
25% (n= 38/153)
l PRN (stable dose):
corticosteroids (topical
or systemic);
immunosuppressants;
topical NSAIDs
l Rescue medication:i
intravitreal/periocular
steroids or systemic
medication for uveitis
(new or increased)
l Primary outcome:
% of patients with
VH= 0 at week 8
l Secondary outcomes:
% of patients with
a ≥ 15-letter
improvement in
BCVA, % of patients
with a ≥ 10-point
improvement in
VFQ-25 score,
change in CRT
CRT, central retinal thickness; logMAR, logarithm of the minimum angle of resolution; MO, macular oedema; NR, not reported; NSAID, non-steroidal anti-inflammatory drug; pan, panuveitis;
PRN, pro re nata; SD, standard deviation; TTF, time to treatment failure.
a Patients included in a substudy in Japan (n= 16, seven sites) were excluded from the analyses of outcomes in this study because of regional heterogeneity.
b 217 patients analysed as an intention-to-treat population.
c Active uveitis was characterised by the presence of a VH score of ≥ 2 and/or an AC cell grade of ≥ 2 and/or active inflammatory chorioretinal or retinal vascular lesions while on oral
corticosteroids (10–60mg/day) for ≥ 2 weeks.
d Patients included in a substudy in Japan (n= 32, 10 sites) were excluded from the analyses of outcomes in this study.
e 226 patients reported in the AbbVie submission.
f Inactive uveitis was defined as an AC cell or a VH grade of ≤ 0.5+ without evidence of active inflammatory chorioretinal or retinal vascular lesions and receiving 10–35mg/day of oral
prednisone to maintain inactivity, ≥ 28 days before study entry.
g 153 patients in relevant groups, patients randomised to DEX 700 and sham procedure.
h Treatment received by patients in this study arm was DEX 700.
i Rescue medications were permitted if VH increased by ≥ 1 between week 3 and week 8 or VH was ≥ 1.5 between week 8 and week 26.
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The mean duration of uveitis was shorter in the active treatment arms than in the comparator arms across all
three studies (40.2 vs. 51.0 months for VISUAL I,46 59.5 vs. 62.9 months for VISUAL II46 and 50.5 vs. 61.2
months for HURON48). Intermediate uveitis was the most common site of inflammation in patients (81% of
patients) in the HURON trial,48 whereas panuveitis was seen more frequently in patients in the VISUAL trials46,47
(approximately 46% panuveitis vs. 22% intermediate uveitis vs. 33% posterior uveitis). Uveitis-related
systemic conditions reported for patients in the VISUAL trials46,47 included Behçet’s disease, sarcoidosis and
VKH. More patients with active uveitis had no diagnosed systemic condition (73%) than those with inactive
uveitis (56%) in the VISUAL trials.46,47 Limited information about relevant coexisting systemic conditions was
provided for the HURON trial in the journal article,48 company submission43 or clinical study report,71 only that
no patients had uncontrolled systemic conditions. Over 90% of patients in the VISUAL trials46,47 presented
with bilateral uveitis; outcomes in the left and right eyes were considered separately and were then averaged
across eyes in the analysis of the study findings. Conversely, in the HURON trial,48 the proportion of patients
with bilateral uveitis was not reported (the AG queried this and was informed by the company that these data
were not collected). In patients with bilateral uveitis, the right eye was selected for treatment; only the study
eye was analysed for relevant outcomes. Overall, 84% of patients received treatment in the worse-seeing eye.
Study treatment and follow-up
The active treatment in the HURON trial48 was a single DEX intravitreal implant. The study compared the
licensed dose of 0.7 mg (DEX 700, n = 77 patients, reported here) and a dose of 0.35 mg (DEX 350,
n = 76 patients, not reported here) with a sham procedure (n = 76 patients). One implant was received per
patient; no repeat implants were given during the 26-week follow-up period and patients had an implant
in only one eye.
The active treatment evaluated in the VISUAL trials46,47 was ADA. Patients randomised to the study arms
(n = 11146 and 11547 patients) received a loading dose of 80 mg by subcutaneous injection and then a
40-mg dose, repeated every other week.46 A corresponding placebo was administered to patients in the
comparator arms (n = 11246 and 11447 patients). For patients with active uveitis,46 visits during the study
were scheduled at baseline and weeks 1, 4, 6 and 8. Subsequently, further visits occurred every 4 weeks
until the primary end point (treatment failure) was achieved or until completion of 80 weeks of treatment.
The treatment and follow-up duration was therefore up to 80 weeks (18 months) or until treatment failure.
The median duration of treatment and follow-up in the VISUAL I trial46 was 19 weeks for ADA and 13 weeks
for placebo. In the VISUAL II trial,47 the median duration of treatment and follow-up was 35 weeks for ADA
and 22 weeks for placebo. There was a longer duration of ADA treatment in both studies because patients
in the placebo groups met the treatment failure end points earlier than patients in the ADA groups and were
taken off treatment.
Previous treatments and concomitant treatments
All patients in the VISUAL trials46,47 had previously received high-dose oral corticosteroids (> 10 mg/day of
prednisone or its equivalent) prior to study entry. Within the VISUAL I trial,46 all patients received standardised
oral prednisone (60 mg/day; hereafter referred to as a steroid burst) from randomisation, which was gradually
tapered to 0 mg by week 15 of the study. Furthermore, topical corticosteroids were permitted but were
tapered and discontinued by week 9. In the VISUAL II trial,47 all patients were already receiving oral
prednisone (10–35 mg/day); this was tapered to 0 mg by week 19 or earlier depending on the steroid dose
at baseline. During the study, patients were eligible to receive at least one immunosuppressant including
azathioprine, ciclosporin, mycophenolate mofetil or methotrexate, at the discretion of the study investigator(s).
Limited information on prior and concomitant treatments for uveitis was reported in the HURON trial,48
although one-quarter of patients in the relevant population (DEX 700 and sham groups) for this review
had received or were using systemic immunosuppressants or anti-inflammatory treatment at baseline
(n = 38/153, 25%). The company did, however, provide patient-level data, which showed that treatment
received was generally similar across arms but that more patients received immunosuppressant rescue
therapy in the sham arm (10.5%) than in the DEX 700 arm (1.3%).
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In the HURON trial,48 patients were permitted to receive different treatments at the discretion of the
investigator(s) if they were indicated. Permitted treatments before the study and at baseline as well as
during the study included the following:71
l perioperative prophylactic antibiotics (at the visit prior to implantation and 3 days postoperatively)
l IOP-lowering treatments (if IOP was > 30 mmHg in the study eye)
l topical corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) in the study eye (if doses
remained stable for ≥ 2 weeks before screening, were stable throughout the study visits and were
anticipated to remain stable up to week 8)
l intravitreal, topical or periocular corticosteroids in the non-study eye (if inflammation occurred in the
non-study eye)
l cycloplegics (indication not specified)
l cataract surgery (if reduced visual acuity had a limiting impact on the patient, the cataract interfered
with uveitis management and/or the cataract resulted in local inflammation or glaucoma; the decision
to operate was at the discretion of the investigator and patient and a delay to surgery until after week
26 was encouraged)
l systemic immunosuppressants, for example methotrexate or ciclosporin (if doses remained stable for
≥ 3 months before screening, were unchanged throughout study visits and were anticipated to remain
stable up to week 8)
l systemic corticosteroids, for example oral prednisone or equivalent (if doses remained stable and were
≤ 20 mg/day at ≥ 1 month before screening, were stable throughout study visits and were anticipated
to remain stable up to week 8)
l oral NSAIDs (indication not specified).
Within the HURON trial,48 new treatment or previous management requiring dose escalation with systemic
corticosteroids or immunosuppressants or local (intravitreal, periocular and topical) corticosteroids was
permitted only if any of these interventions was administered as rescue treatment. In general, rescue anti-
inflammatory treatments were permissible if the VH score increased by ≥ 1 unit from week 3 to the start of
week 8 and if VH = 1.5+ was recorded from week 8 to week 26.48 Other rescue medications included
anticoagulants and surgical procedures on the study eye.48,71
Study outcomes
The primary study end point varied across the studies:
l In the VISUAL I46 trial of ADA for active uveitis, the primary end point was time to treatment failure,
a composite outcome including worsening of at least one of the following in one or more eyes (from
best state achieved following the steroid burst, on or after week 6): AC cell grade, VH grade, BCVA or
new active inflammatory retinal or chorioretinal vascular lesions.
l In the VISUAL II47 trial of ADA for inactive uveitis, the primary end point was time to treatment failure,
a composite outcome including worsening of at least one of the following in one or more eyes (from
baseline, on or after week 2): AC cell grade, VH grade, BCVA or new active inflammatory retinal or
chorioretinal vascular lesions.
l In the HURON48 trial of DEX, the primary outcome was the proportion of patients with a VH score of
zero at week 8 in the study eye (outcomes were also measured up to week 26).
Outcomes reported in the included studies and grading criteria for intraocular inflammation are presented
in Tables 5 and 6 respectively.
Secondary outcomes for the VISUAL I trial46 (see Table 5) were measured from the best state prior to week 6
(following the steroid burst), whereas secondary outcomes for the VISUAL II trial47 were measured from
baseline. Secondary outcomes in the VISUAL trials were measured only up to treatment failure or the study
end and, as treatment failure occurred in more patients in the placebo arms than in the ADA arms, the
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TABLE 5 Reported efficacy outcomes in the included studies
Outcome Assessment method
VISUAL I46
Primary outcome (composite end point): time to treatment failure at or after 6 weeks – evidence of one or more of the
following in one or more eyes
AC cell grade: ≥ 0.5+ (at 6 weeks); two-step or greater increase in
AC cell grade relative to best state achieved (after 6 weeks)
DIO, graded by SUN criteria
VH grade: ≥ 0.5+ (at 6 weeks); two-step or greater increase in VH
grade relative to best state achieved (after 6 weeks)
DIO, graded by NEI/SUN criteria
New active, inflammatory chorioretinal or retinal lesions compared
with baseline
DIO
Worsening of BCVA by ≥ 15 letters compared with best score
previously observed
LogMAR units using ETDRS chart
VISUAL II47
Primary outcome (composite end point): time to treatment failure on or after 2 weeks – evidence of one or more of the
following in one or more eyes
New active, inflammatory chorioretinal or retinal lesions compared
with baseline
DIO
AC cell grade: two-step or greater increase relative to baseline DIO, graded by SUN criteria
VH grade: two-step or greater increase relative to baseline DIO, graded by NEI/SUN criteria
Worsening of BCVA by ≥ 15 letters relative to baseline LogMAR units using ETDRS chart
VISUAL I and VISUAL II46,47,73
Secondary outcomes: VISUAL I from best state achieved prior to week 6 to final or early termination visit; VISUAL II – from
baseline to final or early termination (all measured for left and right eyes separately and then treatment effects averaged
across eyes)
Change in AC cell grade in each eye DIO, graded by SUN criteria
Change in VH score in each eye DIO, graded by NEI/SUN criteria
Change in BCVA in each eye LogMAR units using ETDRS chart
Time to develop MO in at least one eye Assessed in patients without MO at baseline
% change in CRT in each eye Stratus OCT (Carl Zeiss Meditec, Inc., Dublin, CA,
USA); Cirrus HD-OCT (Carl Zeiss Meditec, Inc.,
Dublin, CA, USA) or Spectralis (Heidelberg
Engineering, Franklin, MA, USA)
Change in generic and vision-specific quality of life in each eye EQ-5D score; VFQ-25 composite score,
near vision subscore, distance vision subscore,
ocular pain subscore
Disease quiescence Absence of new active inflammatory lesions
with AC cell and VH grade of ≤ 0.5+
HURON43,48,71
Primary outcome (all in study eye only)
VH score = 0 at week 8 Scores consistent with published colour
photographic scale
Secondary outcomes (all in study eye only)
BCVA AREDS-adapted ETDRS chart
Central macular thickness OCT (at least six scans required at selected sites)
Early treatment failure VH increase of ≥ 1 unit from baseline at week 3
Late treatment failure VH ≥ 1.5+ at week 8 or after week 8
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results may have been worse in the placebo arms at the point of outcome measurement. The last observation
carried forward (LOCF) method was used for dealing with missing data.
Assessment of the methodological quality of the included studies
An overview of the methodological quality of the included studies is presented in Figure 4 and Table 7.
Generally, all three studies performed well against all of the main quality items in the Cochrane risk-of-bias
tool.56 Suitable methods for random sequence generation were reported across all studies. In the VISUAL
trials,46,47 the randomisation list was remotely generated by the statistics department of the manufacturer
(AbbVie). Patients were subsequently allocated to study arms by means of a voice-response or web-response
system. Similar methods were used in the HURON trial,48 with the manufacturer (Allergan) providing a
centrally generated randomisation schedule, which was followed by an interactive allocation procedure for
study participants that was remotely managed. In the VISUAL trials,46,47 randomisation to study arms was
stratified according to prior immunosuppressant treatment; conversely, randomisation was stratified
according to baseline VH in the HURON trial.48 Blinding of participants and investigators was assessed as
TABLE 5 Reported efficacy outcomes in the included studies (continued )
Outcome Assessment method
Use of escape medications Medications administered to patients with early
or late treatment failure
Patient-reported outcomes VFQ-25 composite score and subscores
AREDS, Age Related Eye Disease Study Research Group; CRT, central retinal thickness; DIO, dilated indirect
ophthalmoscopy; HADS, Hospital Anxiety and Depression Scale; logMAR, logarithm of the minimum angle of resolution;
OCT, optical coherence tomography; MO, macular oedema.
TABLE 6 Grading criteria for intraocular inflammation in the included studies
AC cell score VH grade
VISUAL I and II46,47 VISUAL I and II46,47 HURON48
Grade
Criteria
(number of cells)a Grade Criteria Gradeb Criteria
0 < 1 0 No evident VH 0 No inflammation
0.5+ 1–5 0.5+ Slight blurring of the optic disc margin
because of the haze; normal striations
and reflex of the nerve fibre layer
cannot be visualised
+0.5 Trace inflammation (slight
blurring of the optic disc
margins and/or loss of the
nerve fibre layer reflex)
1+ 6–15 1+ Permits a better definition of both the
optic nerve head and the retinal
vessels (compared with higher grades)
+1 Mild blurring of retinal
vessels and the optic nerve
2+ 16–25 2+ Permits better visualisation of the
retinal vessels (compared with higher
grades)
+2 Moderate blurring of the
optic nerve head
3+ 26–50 3+ Permits the observer to see the optic
nerve head, but the borders are quite
blurry
+3 Marked blurring of the optic
nerve head
4+ > 50 4+ Optic nerve head is obscured +4 Optic nerve head not visible
a Assessed according to field size of 1 mm2 of slit beam.8
b In the HURON trial, a modified grade of 1.5+ was introduced, which was assessed on the basis of optic nerve head and
posterior retina view obstruction of > +1 but < +2.
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satisfactory across studies. In the VISUAL trials,46,47 unmasking of treatment allocation was permitted only in
the event of a medical emergency. In the HURON trial,48 treatment investigators were responsible for the
implantation procedure; however, outcome assessors were masked to the treatment received by patients.
In terms of selective reporting, all studies reported prespecified primary outcomes. However, specific clinical
outcomes (e.g. visual acuity or macular oedema) were assessed and reported differently across studies.
This highlights the lack of standardisation in ophthalmic outcome reporting and makes it difficult to assess
whether or not selective reporting occurred.
In terms of other biases, as noted in Study characteristics, secondary outcomes for the VISUAL I trial46
(see Table 5) were measured from the best state prior to week 6 (following the steroid burst); this use of a
postrandomisation baseline may introduce bias. Conversely, secondary outcomes for the VISUAL II trial47
were measured from baseline. A further potential source of bias is that secondary outcomes in the VISUAL
trials were measured only up to treatment failure or the study end and, as treatment failure occurred in
more patients in the placebo arms than the ADA arms, the results may have been worse in the placebo
arms at the point of outcome measurement. The LOCF method used for dealing with missing data may
have introduced systematic bias as it assumes that data are missing at random, which is not the case here.
In terms of additional considerations for methodological and reporting quality, all studies reported
prespecified inclusion and exclusion criteria. A priori sample size calculations for detecting between-group
differences for the specified primary outcomes at a significance level of 5% indicated that 234 patients
0 20 40 60 80 100
Other biases
% of included studies
Selective reporting
Incomplete outcome assessment
Blinding of participants and assessors
Allocation concealment
Random sequence generation
Low risk of bias
Unclear risk of bias
Rating
FIGURE 4 Summary of the methodological quality of the included studies: review authors’ judgement about each
quality item across the included studies.
TABLE 7 Summary of methodological quality assessment: review authors’ judgement about each methodological
quality item for each study
Study
Quality assessment itema
1 2 3 4 5 6 7 8 9
VISUAL I46 Y Y Y N Y Y Y Y Y
VISUAL II47 Y Y Y Y Y Y Y Y Y
HURON48 Y Y Y Y Y Y Y Y Y
N, no (high risk of bias); U, unclear (insufficient details to assess the quality item); Y, yes (low risk of bias).
a (1) Were participants assigned to study groups using an acceptable random method?; (2) Was allocation concealment
adequately conducted?; (3) Were eligibility criteria specified for selecting participants?; (4) Was the study adequately
powered?; (5) Were study groups comparable for most prognostic indicators at baseline?; (6) Were patients and
investigators/outcome assessors blinded to treatment allocation?; (7) Was follow-up adequate (≥ 70% randomised
patients analysed)?; (8) Were reasons for attrition/exclusions stated?; and (9) Was an intention-to-treat analysis included?
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were needed to achieve a power of 90% in the VISUAL I trial46 (outcome time to treatment failure at or
after 6 weeks); 220 patients were needed to achieve 80% power in the VISUAL II trial47 (outcome time to
treatment failure at or after 2 weeks) and 73 patients were needed per study arm to achieve a power of
93% in the HURON trial48 (outcome proportion of patients with a VH score of 0). In the VISUAL I trial46
223 patients were randomised, slightly fewer than the 234 suggested by the power calculation; however,
given that the study showed a significant between-group difference for the primary outcome (time to
treatment failure), this was not an issue. Demographic and baseline characteristics between study arms
were comparable for all studies with the exception of the duration of uveitis, which was slightly longer in
the non-active comparator arms, as noted earlier. The impact of the non-study treatment options that
were available throughout the duration of the studies is unclear, in particular in the HURON trial,48 in
which patients with worsening of intraocular inflammation following the implantation procedure could
receive rescue (escape) medication consisting of systemic corticosteroids or immunosuppressants or topical
steroids. Indications for escape medication were early treatment failure (i.e. patients with a VH increase
of ≥ 1 unit from baseline at week 3) or late treatment failure (i.e. patients with a VH grade of ≥ 1.5+ at
week 8 or after week 8).
In the VISUAL I46 and II47 trials data for patients in the Japanese substudies were not included in the
analyses. In the HURON trial,48 100% of the patients were included in the intention-to-treat (ITT) analyses,
whereas in the VISUAL trials the analyses described as ‘ITT’ excluded 6 of 223 patients (3%)46 and 3 of
229 patients (1%)47 because of incomplete efficacy data and compliance issues at these sites.
Feasibility of meta-analysis
It was not considered appropriate to meta-analyse the findings of the VISUAL I46 and VISUAL II47 trials
because the VISUAL I trial46 enrolled patients with active uveitis and the VISUAL II trial47 enrolled patients
with inactive uveitis. Active uveitis refers to current inflammation in the eye whereas patients with inactive
uveitis have limited inflammation, usually because of treatment with corticosteroids or immunosuppressants.
In addition, the magnitude of the treatment effect is likely to be associated with the degree of disease
activity and inflammation at baseline, with patients with little inflammation or vision loss at baseline less
likely to show an improvement in outcomes. NMA was also not considered feasible or appropriate for the
reasons discussed in Indirect comparison of treatments: rationale for not undertaking.
Effectiveness results from the included studies
Treatment failure
Treatment failure: VISUAL trials The primary outcome for the VISUAL trials46,47 of ADA was a composite
treatment failure outcome, defined as worsening of at least one of the following in one or more eyes:
AC cell grade, VH grade, BCVA or new active inflammatory retinal or chorioretinal vascular lesions (see
Table 5). In the VISUAL I trial,46 outcomes were measured relative to the best state achieved following the
initial steroid burst and treatment failure was assessed from week 6. In the VISUAL II trial,47 outcomes were
measured relative to baseline and treatment failure was assessed from week 2.
In the VISUAL I trial46 (active uveitis), treatment failure was experienced by 54.5% of patients in the ADA arm
and 78.5% of patients in the placebo arm (Table 8). The median time to treatment failure was 5.6 months
for ADA and 3 months for placebo, giving a hazard ratio (HR) of 0.50 (95% CI 0.36 to 0.70; p < 0.001).
Treatment failure related to each of the four individual criteria (worsening of AC cell grade, VH grade or
BCVA or new lesions) was also significantly greater in the placebo arm than in the ADA arm (p = 0.04 to
p < 0.001).
In the VISUAL II trial47 (inactive uveitis), treatment failure was experienced by 39% of patients in the ADA
arm and 55% of patients in the placebo arm (see Table 8). The median time to treatment failure was not
estimable for the ADA arm (> 18 months), because fewer than half of the patients had experienced
treatment failure, and was 8.3 months for the placebo arm (HR 0.57, 95% CI 0.39 to 0.84; p = 0.004).
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Treatment failure because of a reduction in BCVA was significantly greater in the placebo arm than in the
ADA arm (p = 0.002), although failure related to the other three criteria (worsening of AC cell grade or VH
grade or new lesions) was not statistically significant (p = 0.105 to p = 0.589).
Treatment failure: HURON trial Treatment failure in the HURON trial48 was defined as a VH grade
increase of ≥ 1 unit at weeks 3–8 or a VH of ≥ +1.5 at weeks 8–26. No data were reported in the journal
article,48 company submission43 or clinical study report,71 but a statistically significant difference between
the DEX 700 arm and the sham arm (p < 0.001) was noted.
TABLE 8 Summary of treatment failure outcomes reported in the VISUAL I, VISUAL II and HURON studies
Outcome
Study
VISUAL I46,55
(active uveitis) VISUAL II47,55 (inactive uveitis)
HURON48,71
(active uveitis)
ADA Placebo ADA Placebo DEX 700 Sham
TF, n/N (%) 60/110 (54.5)a 84/107
(78.5)a
45/115 (39)b 61/111 (55)b NRc NRc
Comparison between
groups
NR NR p< 0.001d
Time to TF in one or more
eyes (months), median (IQR)
5.6 (3.0 to not
estimable)
3.0
(1.5–5.6)
Not estimable
(4.7 to not estimable)
8.3 (3.0 to not
estimable)
NR NR
Comparison between
groups, HR (95% CI)
0.50 (0.36 to 0.70);
p< 0.001
0.57 (0.39 to 0.84); p = 0.004 NR
TF because of new lesions,
n/N (%)
17/110 (15.5) 29/107
(27.1)
NR NR NR NR
Comparison between
groups, HR (95% CI)
0.38 (0.21 to 0.69);
p= 0.001
0.55 (0.26 to 1.15); p = 0.105 NR
TF because of AC cell
grade, n/N (%)
24/110 (21.8) 34/107
(31.8)
NR NR NR NR
Comparison between
groups, HR (95% CI)
0.51 (0.30 to 0.86);
p= 0.01
0.70 (0.42 to 1.18); p = 0.180 NR
TF because of VH grade,
n/N (%)
16/110 (14.5) 39/107
(36.4)
NR NR NR NR
Comparison between
groups, HR (95% CI)
0.32 (0.18 to 0.58);
p< 0.001
0.79 (0.34 to 1.81); p = 0.589 NR
TF because of reduction in
BCVA, n/N (%)
23/110 (20.9) 27/107
(25.2)
10/115 (9) 23/111 (21) NR NR
Comparison between
groups, HR (95% CI)
0.56 (0.32 to 0.98);
p= 0.04
0.33 (0.16 to 0.70); p = 0.002 NR
IQR, interquartile range; NR, not reported; TF, treatment failure.
a Treatment failure= at least one of AC cell grade of ≥ 0.5+ (at week 6) or increase of ≥ 2 (after week 6), VH grade of
≥ 0.5+ (at week 6) or increase of ≥ 2 (after week 6), BCVA worsening by ≥ 15 letters and new active inflammatory
retinal or chorioretinal vascular lesions. Outcomes were measured relative to the best state achieved following the initial
steroid burst.46
b Treatment failure= uveitis recurrence, defined as at least one of AC cell grade increase of ≥ 2, VH grade increase of ≥ 2,
BCVA worsening of ≥ 15 letters and new active inflammatory retinal or chorioretinal vascular lesions on or after week 2
(relative to baseline).47
c Treatment failure= VH increase of ≥ 1 unit at weeks 3–8 or VH of ≥+1.5 at weeks 8–26.71
d From Kaplan–Meier curve.
Note
In the VISUAL I46 and II47 trials, dropouts for reasons other than treatment failure were censored at the time of dropping
out. Within the analyses of cause-specific treatment failure, failures from other causes were censored at the time of failure.
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Best corrected visual acuity
Best corrected visual acuity: VISUAL trials The studies of ADA reported change in BCVA in units of
logMAR (logarithm of the minimum angle of resolution) (Table 9). In the VISUAL I trial,46,52 change was
measured from the best state reached prior to week 6 after the initial steroid burst rather than from
baseline to the final value (week 80 or at the time of treatment failure). BCVA improved in both the ADA
arm and the placebo arm following the initial steroid burst but worsened as time progressed, with greater
worsening in the placebo arm. The change in BCVA (logMAR) from the best state prior to week 6 to final
or early termination was 0.07 and 0.04 in the left and right eyes, respectively, in the ADA arm and 0.12
and 0.13 in the left and right eyes, respectively, in the placebo arm. The MD between groups in BCVA
change, pooled across left and right eyes, was –0.07 (95% CI –0.11 to –0.02; p = 0.003).
In the VISUAL II trial,47,72 change was measured from baseline to the final value (week 80 or at the time
of treatment failure). BCVA stayed fairly constant from baseline to the final value in the ADA arm and
worsened in the placebo arm (see Table 9). The change in BCVA (logMAR) from baseline to final or early
termination was 0.01 and –0.01 in left and right eyes, respectively, in the ADA arm and 0.06 and 0.02 in
left and right eyes, respectively, in the placebo arm. The MD between groups in BCVA change, pooled
across left and right eyes, was reported as –0.04 (95% CI –0.08 to 0.01; p = 0.096).
Best corrected visual acuity: HURON trial In the HURON trial,43,48 BCVA was measured as the
proportion of patients with a change of two or more or three or more ETDRS lines over the 26 weeks
(Table 10). The proportion with an improvement of three or more lines was 43% in the DEX 700 arm and
7% in the sham arm at week 8 (p < 0.001) and 38% in the DEX 700 arm and 13% in the sham arm at
week 26 (p < 0.001). Improvement of two or more lines followed a similar pattern (see Table 10). In the
DEX 700 arm, there was a significant improvement in mean BCVA over weeks 3–26 (no values reported,
p ≤ 0.002).71
Patient-reported outcome measures
Data on patient-reported outcome measures (PROMs) derived from the publications and submissions
related to the VISUAL and HURON studies are reported here. These data are presented in this report
before additional clinical outcomes because of their importance for the cost-effectiveness modelling.
Patient-reported outcome measures: VISUAL trials The main PROM reported in the journal articles for
the VISUAL trials46,47 was the VFQ-25. Additional PROMS reported in the company’s submission55 and
clinical study reports52,72 for the VISUAL trials included the EQ-5D, Hospital Anxiety and Depression Scale
(HADS),74 Work Productivity and Activity Impairment (WPAI) questionnaire75 and Healthcare Resource
Utilisation questionnaire.76
Visual Function Questionnaire scores: VISUAL trials The VFQ-25 is made up of 25 questions that
cover 11 vision-specific quality-of-life subscales and one general health item.28 Condition-specific subscales
in the tool include those for general vision, ocular pain, distance activities, near activities, vision-specific
dependency, vision-specific role difficulties, vision-specific social functioning, vision-specific mental health,
driving, peripheral vision and colour vision. Responses to items in each subscale are coded and scored from
0 to 100. Summary scores for each subscale are derived from an average of scores for items within the
subscale. A composite score is obtained by calculating the average of all of the scores from the 11 vision-
specific subscales. The general health item score and blank items within the instrument are excluded when
calculating the composite score. Higher scores indicate better visual functioning.
In the VISUAL I trial,46 ADA produced a statistically significant and clinically meaningful improvement in the
VFQ-25 composite score for patients with active uveitis relative to patients in the placebo arm (MD 4.20,
95% CI 1.02 to 7.38; p = 0.01), from the best state achieved following the initial steroid burst to time of
treatment failure (early termination) or study end (80 weeks), as shown in Table 11. Of the three subscales
predefined as secondary outcomes in the VISUAL trials, statistically significant and clinically meaningful
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TABLE 9 Visual acuity outcomes [logMAR (SD)] reported in the VISUAL I and VISUAL II studies: LOCF analysis
Outcome
Study
VISUAL I46,52 (active uveitis) VISUAL II47,72 (inactive uveitis)
ADA Placebo ADA Placebo
Left eye
(n= 101)
Right eye
(n= 101)
Left eye
(n= 103)
Right eye
(n= 103)
Left eye
(n= 115)
Right eye
(n= 115)
Left eye
(n= 110)
Right eye
(n= 110)
Mean VA, baseline (for VA change in VISUAL II47
only)
0.22 (0.344) 0.23 (0.277) 0.24 (0.291) 0.25 (0.307) 0.14 (0.255) 0.12 (0.222) 0.16 (0.287) 0.15 (0.274)
Mean VA, best value prior to week 6 following
steroid burst (used as ‘baseline’ for changes in
VISUAL I46)
0.13 (0.290) 0.14 (0.243) 0.12 (0.262) 0.14 (0.271) NA NA NA NA
Mean VA, final (week 80 or early termination) 0.20 (0.370) 0.18 (0.294) 0.24 (0.319) 0.27 (0.442) 0.15 (0.338) 0.11 (0.282) 0.22 (0.388) 0.16 (0.293)
Mean change in VA
VISUAL I:46 from best state reached prior to
6 weeks to final or early termination
0.07 (0.160) 0.04 (0.143) 0.12 (0.169) 0.13 (0.320) NA NA NA NA
VISUAL II:47 from baseline to final or early
termination
NA NA NA NA 0.01 (0.251) –0.01 (0.165) 0.06 (0.239) 0.02 (0.198)
Difference in mean VA change between
groups (pooled across left and right eyes),
mean (95% CI)
–0.07 (–0.11 to –0.02); p= 0.003 –0.04 (–0.08 to 0.01); p = 0.096
NA, not applicable; SD, standard deviation; VA, visual acuity.
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differences favouring ADA over placebo were observed for changes in the near vision subscale (MD 5.12,
95% CI 0.34 to 9.90; p = 0.036) and the ocular pain subscale (MD 10.02, 95% CI 4.86 to 15.19;
p < 0.001); differences in the distance vision subscale were not statistically significant (MD 1.86, 95% CI
–2.03 to 5.75; p = 0.346).
In the VISUAL II trial,47 differences between the ADA arm and the placebo arm were not statistically
significant for change in VFQ-25 composite score (MD 2.12, 95% CI –0.84 to 5.08; p = 0.16) or for the
distance vision, near vision or ocular pain subscales (p = 0.40 to p = 0.97; see Table 11).
Other patient-reported outcome measures: VISUAL trials In the VISUAL I trial, EQ-5D estimates were
higher in ADA-treated patients than in the placebo group (Table 12). Reported EQ-5D predicted values,
assessed from change from the best state achieved before week 6 to the final visit or early termination,
demonstrated statistical significance, favouring ADA over placebo (MD 0.04, 95% CI 0.00 to 0.07;
p = 0.044).52,55 According to estimates based on the WPAI, compared with patients treated with placebo,
those receiving ADA had less time off work (MD –10.61 days, p = 0.011). There were no significant
differences between treatment groups for the remaining outcomes.52,55
There was no significant improvement in patients’ EQ-5D scores in the VISUAL II trial (MD 0.00, 95% CI
–0.03 to 0.04; p = 0.836).72 No other significant differences were reported for the other outcomes.
TABLE 11 Changes in VFQ-25 scores in the VISUAL I and VISUAL II studies
Outcome
Study
VISUAL I46 (active uveitis) VISUAL II47 (inactive uveitis)
Treatment, mean (SD)
MD (95% CI),
p-value
Treatment, mean (SD)
MD (95% CI),
p-value
Placebo
(n= 102)
ADA
(n= 101)
Placebo
(n= 109)
ADA
(n= 115)
Composite score –5.50
(11.97)
–1.30
(10.98)
4.20 (1.02 to 7.38),
p= 0.010
1.24
(10.7)
3.36
(11.7)
2.12 (–0.84 to 5.08),
p= 0.16
Distance vision
subscale
–5.64
(14.65)
–3.77
(13.41)
1.86 (–2.03 to 5.75),
p= 0.346
0.76
(16.3)
2.64
(17.2)
1.88 (–2.53 to 6.29),
p= 0.40
Near vision
subscale
–8.09
(17.75)
–2.97
(16.78)
5.12 (0.34 to 9.90),
p= 0.036
3.98
(17.4)
3.88
(18.3)
–0.10 (–4.81 to 4.61),
p= 0.97
Ocular pain
subscale
–12.62
(21.44)
–2.6
(15.34)
10.02 (4.86 to 15.19),
p< 0.001
2.87
(17.2)
3.42
(21.3)
0.56 (–4.56 to 5.68),
p= 0.83
SD, standard deviation.
TABLE 10 Visual acuity outcomes reported in the HURON trial: percentage of patients with BCVA improvement
according to ETDRS lines
Outcome
Treatment, n/N (%)
MD (95% CI) (%); p-value RR (95% CI); p-valueDEX 700 Sham
Patients with BCVA improvement of three or more ETDRS lines (≥ 15 letters)
Week 8 33/77 (43) 5/76 (7) 36.3 (24 to 49); p< 0.001 6.5 (2.7 to 15.8); p< 0.001
Week 26 29/77 (38) 10/76 (13) 24.5 (11 to 38); p< 0.001 2.9 (1.5 to 5.5); p< 0.001
Patients with BCVA improvement of two or more ETDRS lines (≥ 10 letters)
Week 8 46/77 (60)a 13/76 (17)a 43 (29 to 56); p< 0.001 3.5 (2.1 to 5.9); p< 0.001
Week 26 42/77 (55)a 19/76 (25)a 30 (15 to 44); p< 0.001 2.2 (1.4 to 3.4); p< 0.001
a Read off Figure 4 in the company’s submission.43
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Visual Function Questionnaire scores: HURON trial
Change from baseline in Visual Function Questionnaire score Table 13 provides a summary of the
VFQ-25 composite scores at baseline and weeks 8 and 26 in the HURON trial.43,68,71 At baseline, the mean
composite VFQ-25 score was 63.7 in the DEX 700 group and 71.3 in the sham group.43
By week 8 (based on analyses using raw scores for patients available at each time point), the change from
baseline in composite VFQ-25 score in the DEX 700 group was 11.6 points and in the sham group was
3.4 points (p < 0.001).71 Change at week 8 using LOCF analyses was 9.6 for the DEX 700 group and 4.2
for the sham group (p = 0.007).68 Change at week 26 using LOCF analyses was 10.1 and 2.8 for patients
in the DEX 700 and sham groups respectively (p = 0.001).
TABLE 12 EuroQol-5 Dimensions outcomes reported in the VISUAL I and VISUAL II studies
Outcome
Study, mean (SD)
VISUAL I52,55 (active uveitis) VISUAL II72 (inactive uveitis)
ADA (n= 101) Placebo (n= 100) ADA (n= 115) Placebo (n= 108)
EQ-5D score, baseline 0.83 (0.15) 0.82 (0.164) 0.86 (0.160) 0.85 (0.138)
EQ-5D score, best value prior
to week 6
0.89 (0.128) 0.88 (0.142) NA NA
EQ-5D score, final or early
termination
0.86 (0.153) 0.80 (0.187) 0.85 (0.165) 0.84 (0.177)
Mean change in EQ-5D score
VISUAL I:46 from best state
prior to week 6 to final or
early termination
–0.04 (0.129) –0.07 (0.135) NA NA
VISUAL II:47 from baseline to
final or early termination
NA NA –0.01 (0.134) –0.01 (0.161)
MD (95% CI) 0.04 (0.00 to 0.07); p= 0.044 0.00 (–0.03 to 0.04); p = 0.836
NA, not applicable; SD, standard deviation.
Predicted values based on LOCF in the ITT population.
TABLE 13 Change in VFQ-25 composite scores in the HURON trial: LOCF and PP populations
Time point
Absolute values Change from baseline
MD (95% CI);
p-value
DEX 700 Sham DEX 700 Sham
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Baselinea 73 63.7 (20.74) 73 71.3 (19.0) NR NA NR NA
Week 8 LOCFa 73 75.1 (NR) 74 74.2 (NR) 73 9.6 (NR) 74 4.2 (NR) 5.4 (NR); p= 0.007
Week 8 PP 69 74.4 (17.3) 70 74.5 (18.1) 69 11.6 (14.7) 69 3.4 (11.2) 8.2 (NR); p< 0.001
Week 16 LOCFa 73 75.9 (NR) 74 75.3 (NR) NR NR NR NR NR
Week 16 PP 69 75.3 (18.12) 70 75.6 (19.1) 69 10.5 (14.3) 69 4.5 (12.7) 6.0 (NR); p= NR
Week 26 LOCFa 73 76.2 (NR) 74 73.2 (NR) 73 10.1 (NR) 74 2.8 (NR) 7.3 (NR); p= 0.001
Week 26 or
early exit (CSR71)
72 74.6 (19.32) 73 74.3 (20.4) 72 10.3 (16.7) 72 2.8 (13.9) 7.5 (NR); p= NR
CSR, clinical study report; NA, not applicable; NR, not reported; PP, per protocol; SD, standard deviation.
a Estimated from graph for absolute values.68
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Statistically significant differences between the DEX 700 group and the sham group for changes in
distance vision (p = 0.023), near vision (p = 0.031), peripheral vision (p = 0.045) and vision-specific social
functioning (p = 0.019) were reported at the primary time point (week 8).46,71
Percentage of patients with a ≥ 5-point or ≥ 10-point improvement in Visual Function
Questionnaire composite score More patients in the DEX 700 group than the sham group had a
≥ 5-point improvement in VFQ-25 composite score (week 8: 54.8% vs. 27.0%, p < 0.001; week 26:
57.5% vs. 32.4%, p < 0.05; Table 14). More patients in the DEX 700 group than the sham group
also had a ≥ 10-point improvement in VFQ-25 composite score (week 8: 45.2% vs. 14.9%, p < 0.001;
week 26: p-value reported as significant but no value given; see Table 14).43,71 Additionally, statistically
significant differences between the groups were reported for the percentage of patients with ≥ 5-point
and ≥ 10-point improvements in distance vision, general vision, peripheral vision, colour vision, ocular pain,
vision-specific social functioning and vision-specific mental health (all p < 0.05).
Other patient-reported outcome measures: HURON trial EuroQol-5 Dimensions (US tariff), Short
Form questionnaire-6 Dimensions (SF-6D)77 and Short Form questionnaire-36 items (SF-36)78 estimates were
presented at baseline in the HURON trial but not beyond this and no other outcomes were reported.43,71
Vitreous haze grade
Vitreous haze was measured by dilated indirect ophthalmoscopy in the VISUAL46,47 and HURON48 studies.
In both cases grading was based on the original scale proposed by Nussenblatt et al.37 and later adopted
by SUN8 (with the minor modification of ‘trace’ being replaced by 0.5+ in the ordinal scale). An important
difference between the VISUAL trials and the HURON trial, however, was that the HURON trial48 proposed
an additional 1.5+ grade for cases that were deemed to lie between the 1+ and 2+ grades (see Table 6).
Vitreous grade scores are presented in Study outcomes.
Vitreous haze grade: VISUAL trials In the VISUAL trials,46,47 VH outcomes were considered as criteria
contributing to the primary composite end points of treatment failure. In the VISUAL I trial,46 VH was
assessed as the change from the best achieved score following a mandatory steroid burst until the final or
early termination visit. In the VISUAL II trial,47 VH was assessed as the change from baseline to the final or
early termination visit. Higher scores are correlated with increased severity of uveitis.
A statistically significant difference in change in VH score was reported for patients in the ADA group
compared with patients in the placebo group in the VISUAL I trial46 (–0.27, 95% CI –0.43 to –0.11;
p < 0.001; Table 15). Lower mean VH scores were also noted for the ADA group compared with the
TABLE 14 Visual Function Questionnaire composite scores in the HURON trial: percentage of patients with a
≥ 5-point or ≥ 10-point improvement
VFQ-25 scores DEX 700, n/N (%) Sham, n/N (%) MD (95% CI) (%); p-value
Patients with a ≥ 5-point improvement
Week 8 40/73 (54.8) 20/74 (27.0) 27.8 (13 to 43); p< 0.001
Week 16 NR NR NR (NR); p = significant (NR)
Week 26 42/73 (57.5) 24/74 (32.4) 25.1 (10 to 41); p< 0.05
Patients with a ≥ 10-point improvement
Week 8 33/73 (45.2) 11/74 (14.9) 30.3 (16 to 44); p< 0.001
Week 16 NR NR NR (NR); p = significant (NR)
Week 26 NR NR NR (NR); p = significant (NR)
NR, not reported.
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placebo group in the VISUAL II trial,47 but the difference between the groups was not statistically significant
(–0.13, 95% CI –0.28 to 0.01; p = 0.070). In the VISUAL I trial,46 VH worsening was the least common
cause of treatment failure in the ADA group (15% of events) and the most common reason for treatment
failure in the placebo group (36% of events; HR 0.32, 95% CI 0.18 to 0.58; p < 0.001). Conversely,
increases in VH grade in the VISUAL II trial47 were not significantly different between the treatment groups
and did not affect the time to treatment failure (HR 0.79, 95% CI 0.34 to 1.81; p = 0.569).
Vitreous haze grade: HURON trial Study entry eligibility criteria included, among others, a VH score of
≥ +1.5.48 At baseline, more patients had a VH score of +1.5 to +2 (DEX 700: 84%, n = 65/77; sham:
87%, n = 66/76) than a score of +3 to +4 (DEX 700: 16%, n = 12/77; sham: 13%, n = 10/76). Patients
were stratified using these two VH cut-off points. The primary efficacy outcome was the proportion of
patients with a VH score of zero. The analysis was based on an ITT population and the primary time point
was week 8 following implantation; outcomes were also measured up to week 26.
Proportion of eyes achieving a vitreous haze score of zero: HURON trial Compared with patients
receiving a sham procedure, a statistically significantly higher proportion of patients in the DEX 700 arm
achieved a VH score of zero at week 8 (MD 34.9%, 95% CI 22% to 48%; p < 0.001) and week 26
(MD 16.7%, 95% CI 4% to 30%; p = 0.014)48 (Table 16). Subgroup analyses by baseline VH score and
previous systemic therapy are also shown in Table 16.
Time to vitreous haze score of zero: HURON trial Time to a VH score of zero was measured from day
0 (day of implantation) to the first event of VH of zero. Time points considered included weeks 3, 6 and
8 and any unplanned visit or early exit from study before week 8. A decrease in VH score to zero occurred
earlier and was of a greater magnitude in effect in patients in the DEX 700 group than in those in the
sham arm (p < 0.001; see Table 16).48
TABLE 15 Vitreous haze in the VISUAL trials
Outcome
Study
VISUAL I46 (active uveitis) VISUAL II47 (inactive uveitis)
ADA Placebo ADA Placebo
Left eye
(n= 101)
Right eye
(n= 101)
Left eye
(n= 103)
Right eye
(n= 103)
Left eye
(n= 115)
Right eye
(n= 115)
Left eye
(n= 110)
Right eye
(n= 110)
Mean (SD) VH score,
final (week 80 or
early termination)
0.44
(0.736)
0.47
(0.636)
0.73
(0.795)
0.78
(0.865)
0.32
(0.594)
0.32
(0.601)
0.48
(0.728)
0.42
(0.630)
Mean (SD) change in VH score
VISUAL I:46
from best state
reached prior to
week 6 to final or
early termination
0.11
(0.559)
0.13
(0.648)
0.33
(0.666)
0.45
(0.781)
NA NA NA NA
VISUAL II:47
from baseline to
final or early
termination
NA NA NA NA 0.16
(0.601)
0.18
(0.604)
0.33
(0.733)
0.27
(0.605)
Difference in mean
change in VH score
between groups
(pooled across
left and right eyes)
(95% CI)
–0.27 (–0.43 to –0.11); p< 0.001 –0.13 (–0.28 to 0.01); p = 0.070
SD, standard deviation.
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Mean vitreous haze score and change in vitreous haze score: HURON trial The VH score for each
study eye was assessed at each study visit.48 Mean VH scores were significantly lower in the DEX 700
group than in the sham group at week 8 (–0.97; p < 0.001) and week 26 (–0.58; p < 0.001). The
proportion of patients with an improvement in VH score of ≥ 1 unit was significantly greater in the DEX
700 group than in the sham group (p < 0.001 throughout the study), as was the proportion with an
improvement of ≥ 2 units (DEX 700 vs. sham: week 3, p = 0.023; weeks 6–26, p ≤ 0.002).
Anterior chamber cell grade
Anterior chamber cell grade: VISUAL trials In the VISUAL I trial,46,52,55 AC cell grade (see Table 6 for
criteria) worsened to a greater extent in the placebo group than in the ADA group (MD –0.29; 95% CI
–0.51 to –0.07; p = 0.011). In the VISUAL II trial,47,55,72 no significant difference in worsening of AC cell
grade was noted between patients in the ADA group and patients in the placebo arm (MD –0.14; 95% CI
–0.37 to 0.08; p = 0.218; Table 17).
TABLE 16 Vitreous haze outcomes in the HURON trial: ITT population
Outcome DEX 700 Sham
MD (95% CI) (%);
p-value RR (95% CI); p-value
VH score = 0, % (n)
Week 8: all patients 46.8 (36/77) 11.8 (9/76) 34.9 (22 to 48); p< 0.001 4.0 (2.0 to 7.6); p < 0.001
Week 26: all patients 31.2 (24/77) 14.5 (11/76) 16.7 (4 to 30); p= 0.014 2.2 (1.1 to 4.1); p = 0.02
Week 8a
Baseline VH +1.5 or +2 48.4 (31/64) 12.1 (8/66) 36 (22 to 51); p < 0.001 4.0 (2.0 to 8.0); p < 0.001
Baseline VH +3 or +4 41.7 (5/12) 10.0 (1/10) 32 (–2 to 65); p= 0.06 4.2 (0.6 to 30.1); p= 0.16
Week 26a
Previous systemic therapy 28.6 (4/14) 7.1 (1/14) 21 (–6 to 49); p= 0.12 4.0 (0.5 to 31.5); p= 0.19
No previous systemic therapy 31.7 (20/63) 16.1 (10/62) 16 (1 to 30); p= 0.04 2.0 (1.0 to 3.9); p = 0.05
Improvement of ≥ 1 in VH score, % (n)
Week 8 94.8 (73/77) 44.7 (34/76) 50.1 (38 to 62); p< 0.001 2.1 (1.6 to 2.7); p < 0.001
Week 26 81.8 (63/77) 51.3 (39/76) 30.5 (16 to 45); p< 0.001 1.6 (1.3 to 2.0); p < 0.001
Improvement of ≥ 2 in VH score, % (n)
Week 8 44.2 (34/77) 13b (10/76) Approximately 31;
p< 0.001
Approximately 3.4;
p< 0.001
Week 26 33.8 (26/77) 14b (11/76) Approximately 19;
p= 0.001
Approximately 2.3;
p= 0.008
Mean (SD) VH score
Week 8 0.47 (NR) 1.44 (NR) –0.97; p < 0.001
Week 26 0.72 (NR) 1.30 (NR) –0.58; p < 0.001
Time to VH score = 0
Cumulative response rate NR NR NR; p< 0.001
NR, not reported; SD, standard deviation.
a Reported according to subgroup.
b Estimated from a graph in the study by Lowder et al.48
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Anterior chamber cell grade: HURON trial In the HURON trial,48 the difference in the percentage of
patients with ≥ 1 cell in the AC was statistically significant between the DEX 700 group and the sham
group (14.5% vs. 38.7%; p = 0.002 between all three groups).
Disease quiescence: VISUAL trials In the VISUAL trials,46,47 intraocular inflammation (assessed by VH
grade and AC cell grade) was used to define disease quiescence and steroid-free quiescence as follows:73
l disease quiescence:
¢ no new active inflammatory lesions
¢ AC cell grade of ≤ 0.5
¢ VH grade of ≤ 0.5+
l steroid-free quiescence (when not receiving steroid therapy):
¢ no active inflammatory lesions
¢ AC cell grade of zero
¢ VH grade of zero.
In both studies, a statistically significant higher proportion (p-values not available) of patients in the ADA
group were reported to have experienced disease quiescence and steroid-free quiescence at all assessment
time points except for weeks 6 and 12 in the VISUAL I trial46 and week 16 in the VISUAL II trial.47
Macular oedema
Measures of macular oedema were reported in terms of change in central macular thickness for patients
with macular oedema at baseline and time to optical coherence tomography evidence of macular oedema
for patients who developed the condition during the studies.
TABLE 17 Anterior chamber cell grade in the VISUAL trials
Outcome
Study
VISUAL I46,52,55 (active uveitis) VISUAL II47,55,72 (inactive uveitis)
ADA Placebo ADA Placebo
Left eye
(n= 101)
Right eye
(n= 101)
Left eye
(n= 102)
Right eye
(n= 102)
Left eye
(n= 115)
Right eye
(n= 115)
Left eye
(n= 110)
Right eye
(n= 110)
Mean (SD) change in AC cell grade
VISUAL I:
from best state
reached prior to
week 6 to final or
early termination
0.35 (NR) 0.36 (NR) 0.59 (NR) 0.69 (NR) NA NA NA NA
VISUAL II:
from baseline
to final or early
termination
NA NA NA NA 0.41 (NR) 0.40 (NR) 0.57 (NR) 0.53 (NR)
MD (95% CI) in
change in AC cell
grade between
groups (pooled
across left and right
eyes)
–0.29 (–0.51 to –0.07); p= 0.011 –0.14 (–0.37 to 0.08); p = 0.218
NA, not applicable; NR, not reported; SD, standard deviation.
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Macular oedema: VISUAL trials In the VISUAL trials,46,47 ADA did not significantly reduce the time to
optical coherence tomography evidence of macular oedema in patients with active uveitis (HR 0.70, 95% CI
0.39 to 1.26; p = 0.231) or in patients with inactive uveitis (HR 0.75, 95% CI 0.34 to 1.69; p = 0.491).
Additional post hoc analyses presented by the company for patients without a macular hole and/or retinal
detachment in the VISUAL I trial showed that ADA resulted in statistically significant reductions in time to
optical coherence tomography evidence of macular oedema in at least one eye at or after week 6 (HR 0.33,
95% CI 0.12 to 0.90; p = 0.023).
There was a significant difference between the groups in the percentage change in central macular
thickness for patients with active uveitis (MD –11.4%, 95% CI –20.9% to –1.8%; p = 0.020)46 but not for
those with inactive uveitis (MD –2.3%, 95% CI –8.5% to 3.8%; p = 0.451)47 (Table 18).
Macular oedema: HURON trial Central macular thickness was assessed by optical coherence tomography
at a number of study sites in the HURON trial.48 The MD in decrease in central macular thickness between
patients in the DEX 700 group and patients in the sham group was statistically significant at week 8
(MD –87.0 µm, 95% CI –147 to –27 µm; p = 0.004) but not at week 26 (MD –14.7 µm, 95% CI –66 to
37 µm; p = 0.58) (see Table 18).
The incidence of macular oedema is discussed further in Safety of the included interventions.
TABLE 18 Macular oedema outcomes in the VISUAL I, VISUAL II and HURON studies
Outcome
Study
VISUAL I46 (active uveitis)a VISUAL II47 (inactive uveitis)
ADA (n= 101) Placebo (n= 102) ADA (n= 114) Placebo (n= 107)
Left
eye
Right
eye
Left
eye
Right
eye
Left
eye
Right
eye
Left
eye
Right
eye
Percentage change in macular
thickness, mean (SD)
9.6
(29.8)
8.2
(25.8)
20.2
(52.0)
22.0
(62.5)
4.5
(29.8)
5.4
(34.8)
6.4
(20.7)
7.7
(28.9)
MD (95% CI) (pooled across left
and right eyes)
–11.4 (–20.9 to –1.8); p= 0.02 –2.3 (–8.5 to 3.8); p = 0.451
Outcome ADA (n= 55) Placebo (n= 45) ADA (n= 90) Placebo (n= 95)
Median time to macular oedema in one or more eyes, months (IQR)
Time frame: at or after week 6 11.1 (2.6–15.9) 6.2 (1.4 to not
estimable)
NA NA
Time frame: at or after week 2 NA NA Not estimableb Not estimableb
MD (95% CI) 0.70 (0.39 to 1.26); p= 0.23 0.75 (0.34 to 1.69); p= 0.49
Outcome
HURON48
DEX 700 (n= 39) Sham (n= 43)
Decrease in macular thickness (µm), mean (SD)
Week 8 –99.4 (151.8) –12.4 (123.7)
Week 26 –50.2 (102.9) –35.5 (134.9)
Week 8: MD (95% CI) (µm) –87.0 (–147 to –27); p= 0.004
Week 26: MD (95% CI) (µm) –14.7 (–66 to 37); p= 0.58
IQR, interquartile range; MD, mean difference; NA, not applicable; SD, standard deviation.
a Comparison: change from best state reached prior to week 6 to final or early termination.55
b Not estimable because of the low number of events.
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Effectiveness data from non-randomised studies of dexamethasone and adalimumab
Dexamethasone studies
A summary of effectiveness data from 11 non-randomised, non-comparative studies of the DEX 700
implant is shown in Appendix 5.18,50,51,79–86 This is based on data from the company submission for DEX;43
the original study publications have not been examined because of time constraints. These data are
included here as they provide some data on repeat implants, implants in both eyes and corticosteroid
reduction, which were not assessed in the HURON trial.48 Non-randomised study data for ADA are not
included here as they were not provided in the company submission and it was beyond the scope of this
assessment to undertake a de novo review of such data.
Following a single implant, two studies reported significant improvements in BCVA at 2–3 months, with a
return to baseline values by 6 months,18,82 and significant improvements in VH up to 6 months,18,82 with a
return to baseline by 12 months in the study with a longer follow-up.18 Significant improvements in central
retinal thickness were reported in one study up to 6 months after a single implant82 and in another study
up to 3 months, with a return to baseline by 6 months.83
Studies in which patients received between one and four implants reported improvements in BCVA at
12 months,50,83,86 with the improvements reported to be significant in one study.50 Among studies with
patients having a mix of single or multiple implants and macular oedema, significant improvements in
central retinal thickness were reported up to 12 months in one study,50 with another study reporting
significant improvements at 3 months but not at 6 months.85
In terms of repeat implants, one study reported that after the second implant BCVA improved significantly
by 1 month but then decreased, with a similar trend following up to six implants (not significant but small
patient numbers).18 Central retinal thickness and VH also showed a significant temporary improvement
after the second implant, with similar (non-significant) improvements after the third and fourth implants.18
Another study reported that the improvements in BCVA and central retinal thickness at 1 month were
similar (not significantly different) following the first and second implants.84
In a study of uveitis patients the median time from first to second implant was 10 months50 whereas in
four studies of uveitic macular oedema the mean/median time from first to second implant was 4.7,81
5.0,51 7.183 and 1086 months. The mean time from second to third implant was 3.4 months in one study of
uveitic macular oedema.81
Implants in both eyes were assessed in one study, with 3 out of 11 patients (27%) receiving implants in
both eyes having a response (reduced central retinal thickness and improved BCVA) in the second eye.18
In terms of reduction in other therapies following a single implant, one study reported that 21 out of
27 patients (78%) reduced or stopped systemic or local treatment,18 whereas in another study 3 out of
12 patients (25%) reduced their corticosteroid dose79 and in another study systemic corticosteroids were
reduced or discontinued in 14 out of 32 patients (44%) and discontinued in 8 out of 32 patients (25%) at
6 months.82 Among studies using a mix of single or multiple implants, in one study systemic corticosteroids
or immunosuppressants were reduced in 62% of patients and steroids were discontinued in 36% of patients
at 12 months50 and in another study systemic corticosteroids were reduced or discontinued in 78% of
patients and discontinued in 32% of patients at 12 months.51
Adalimumab studies
Non-RCT data were presented in the company submission72 and these were based on a retrospective audit
presented in the Clinical Commissioning Policy for anti-TNF treatment options for adult patients with
severe refractory uveitis.87 The study evaluated data for patients aged > 18 years with different clinical
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forms of uveitis receiving ADA (40 mg every other week) or infliximab (3–5 mg/kg every other week).
The main findings of the audit were as follows:
l Clinical remission of uveitis was observed in all patients (n = 41) on biologics [mean ± standard
deviation (SD) follow-up of 1.36 ± 0.88 person-years].
l In total, 48.78% of patients experienced visual acuity improvement (mean ± SD follow-up of
2.51 ± 2.01 person-years).
l Fewer patients (17.07%) had worsening of visual acuity (mean ± SD follow-up of 4.38± 3.50 person-years).
l Patients receiving biologics, in due course, required fewer or reduced concomitant treatments:
¢ 88.89% of patients showed a reduction in steroid dose to ≤ 10 mg (mean ± SD follow-up of
3.06 ± 2.32 person-years)
¢ 75.85% of patients showed a reduction in steroid dose to ≤ 5 mg (mean ± SD follow-up of
3.15 ± 1.76 person-years)
¢ 45.16% of patients discontinued steroid treatment (mean ± SD follow-up of 3.49± 1.59
person-years)
¢ 83.33% of patients showed a reduction in the number and/or frequency of immunomodulatory
therapy (mean ± SD follow-up of 1.54 ± 0.99 person-years).
l Patient-reported outcomes reported in the audit87 are summarised as follows:
¢ A significant decrease in vision-related quality of life [Vision Core Measure (VCM) scale88] was
directly associated with a decrease in visual acuity in the worse eye within 1 year of starting
biologics (p = 0.0064).
¢ Median vision-related VCM scores decreased with increasing follow-up time from the time of
starting treatment with biologics.
¢ Mean SF-36 physical component summary scores (< 47) were lower than estimates for the general
population. However, the SF-36 mental component summary scores (> 47) were higher than
estimates for the general population, with the exception of scores obtained at year 3 (duration of
audit period not reported).
Safety of the included interventions
Safety information from Summaries of Product Characteristics
The SmPC for the DEX implant45 states that the most commonly reported AEs are those frequently observed
with ophthalmic steroid treatment or intravitreal injections, including elevated IOP, cataract and conjunctival
or vitreal haemorrhage. Less frequently reported but more serious adverse reactions include endophthalmitis
(severe eye infection), necrotising retinitis (viral infection of the retina), retinal detachment and retinal tear.45
The SmPC for ADA44 summarises AEs from studies of 9506 patients across a range of conditions. The SmPC
states that the most commonly reported AEs are infections (such as nasopharyngitis, upper respiratory tract
infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), headache
and musculoskeletal pain. TNF antagonists such as ADA affect the immune system and their use may affect
the body’s defence against infection and cancer. Fatal and life-threatening infections (including sepsis,
opportunistic infections and tuberculosis), hepatitis B virus reactivation and various malignancies (including
leukaemia, lymphoma and hepatosplenic T-cell lymphoma) have also been reported with use of ADA. Serious
haematological, neurological and autoimmune reactions have also been reported, including rare reports of
pancytopenia, aplastic anaemia, central and peripheral demyelinating events and lupus, lupus-related
conditions and Stevens–Johnson syndrome.44
Safety data from pivotal randomised controlled trials
Safety data from the RCTs are based on the published journal articles for the HURON trial48 and VISUAL I46
and II47 trials, the company submissions43,55 and the clinical study reports.52,71,72 In the case of the HURON
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trial the safety data are based on all patients who were randomised to a group and received treatment
[n = 76/77 (99%) for the DEX 700 group and n = 75/76 (99%) for the sham group]. Within the 26-week
trial, the mean exposure to the intervention was 25.9 weeks in both groups. For the two RCTs of ADA
compared with placebo, safety data are based on all randomised patients in both trials [n = 111 (100%, ADA)
and 112 (100%, placebo) in VISUAL I and n = 115 (100%, ADA) and 114 (100%, placebo) in VISUAL II].
It should be noted that, in these trials, exposure to ADA was longer than exposure to placebo because
treatment failure (and cessation of study treatment) occurred earlier in the placebo groups (median exposure:
VISUAL I – 19 weeks ADA vs. 13 weeks placebo; VISUAL II – 35 weeks ADA vs. 22 weeks placebo). Therefore,
one might expect more events in the ADA groups than in the placebo groups.
A summary of AEs is provided in Table 19. An AE of any type occurred in 80% of patients in the DEX 700
group compared with 68% in the sham group in the HURON trial48 and in 85–91% of patients in the ADA
group compared with 79–84% of patients in the placebo group in the two VISUAL trials.46,47 Serious AEs
(SAEs) occurred in 9% of patients in the DEX 700 group compared with 6.7% of the sham group in
the HURON trial48 and in 6–14% of patients in the ADA group compared with 5–8% of patients in the
placebo group in the VISUAL trials.46,70 There were no deaths in the HURON trial48 and one death in the
ADA arm in each of the VISUAL trials;46,70 neither death was considered to be treatment related.
Systemic adverse events
Serious systemic AEs are shown in Table 20. Table 21 lists other systemic AEs that (1) occurred in ≥ 5% of
patients in any treatment group in the HURON trial,48 (2) occurred in ≥ 5% of patients in the ADA groups
in the VISUAL trials46,89 and (3) were noted as potentially important within uveitis treatments by clinical
advisors to the AG. No reported systemic AEs (serious or non-serious) had a substantially higher rate in the
DEX 700 arm than in the sham arm. The rate of serious infections was higher in the ADA group than the
placebo group in the VISUAL I trial46 (4.5% vs. 1.8%) but not the VISUAL II trial47 (1.7% vs. 1.8%).
Malignancies and chronic renal failure each occurred in a total of three patients across the ADA arms of
both VISUAL trials but in no patients in the placebo arms. The majority of the listed systemic AEs had a
somewhat higher rate in the ADA arms than the placebo arms.
TABLE 19 Summary of AEs in the included RCTs
AE summary
Study
HURON48 (active uveitis) VISUAL I46 (active uveitis) VISUAL II47 (inactive uveitis)
DEX 700 Sham ADA Placebo ADA Placebo
Time over which
AEs were
measured (weeks)
26
(mean 25.9)
26
(mean 25.9)
≤ 80
(median 19)
≤ 80
(median 13)
≤ 80
(median 35)
≤ 80
(median 22)
AEs (all), n/N (%) 61/76
(80.3)
51/75
(68.0)
94/111 (84.7) 88/112 (78.6) 105/115 (91.3) 96/114 (84.2)
AEs considered
possibly treatment
related, n/N (%)
46/76
(60.5)
21/75
(28.0)
ADA related:
45/111 (40.5)
ADA related:
35/112 (31.3)
ADA related:
64/115 (55.7)
ADA related:
52/114 (45.6)
Steroid related:
57/111 (51.4)
Steroid related:
53/112 (47.3)
Steroid related:
50/115 (43.5)
Steroid related:
48/114 (42.1)
SAEs, n/N (%) 7/76 (9.2) 6/75 (8.0) 15/111 (13.5) 5/112 (4.5) 7/115 (6.1) 9/114 (7.9)
SAEs considered
possibly treatment
related, n/N (%)
NR NR ADA related:
6/111 (5.4)
ADA related:
2/112 (1.8)
ADA related:
2/115 (1.7)
ADA related:
2/114 (1.8)
Steroid related:
2/111 (1.8)
Steroid related:
2/112 (1.8)
Steroid related:
0/115 (0)
Steroid related:
3/114 (2.6)
Discontinuation
because of AEs,
n/N (%)
2/76 (2.6) 0/75 (0) 11/111 (9.9) 4/112 (3.6) 10/115 (8.7) 7/114 (6.1)
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TABLE 20 Serious systemic AEs (all those reported in RCTs)
AE
Study, n/N (%)
HURON48 (active uveitis) VISUAL I46 (active uveitis) VISUAL II47 (inactive uveitis)
DEX 700 Sham ADA Placebo ADA Placebo
Deaths 0/76 (0) 0/75 (0) 1/111 (0.9)
(not treatment
related)
0/112 (0) 1/115 (0.9)
(not treatment
related)
0/114 (0)
Hospitalisation NR NR NR NR NR NR
Infections (serious) NR NR 5/111 (4.5) 2/112 (1.8) 2/115 (1.7) 2/114 (1.8)
Tumours/malignancy NR NR 2/111 (1.8) 0/112 (0) 1/115 (0.9) 0/114 (0)
Anaphylactic reaction NR NR 1/111 (0.9) 0/112 (0) NR NR
Demyelinating disease NR NR 1/111 (0.9) 0/112 (0) 0/115 (0) 0/114 (0)
Renal failure, chronic NR NR 1/111 (0.9) 0/112 (0) 2/115 (1.7) 0/114 (0)
Accidental overdose NR NR 1/111 (0.9) 0/112 (0) NR NR
Ligament/tendon rupture NR NR 1/111 (0.9) 0/112 (0) NR NR
Fracture NR NR 0/111 (0) 1/112 (0.9) 1/115 (0.9) 1/114 (0.9)
Hepatitis, acute NR NR 0/111 (0) 1/112 (0.9) NR NR
Abortion, induced NR NR 0/111 (0) 1/112 (0.9) NR NR
Neutropenia NR NR NR NR 1/115 (0.9) 0/114 (0)
Dysphagia (difficulty
swallowing)
NR NR NR NR 1/115 (0.9) 0/114 (0)
Dysarthria (unclear speech) NR NR NR NR 1/115 (0.9) 0/114 (0)
Status migrainosus NR NR NR NR 1/115 (0.9) 0/114 (0)
Epistaxis (nosebleed) NR NR NR NR 1/115 (0.9) 0/114 (0)
Pleurisy NR NR NR NR 1/115 (0.9) 0/114 (0)
Cardiac tamponade NR NR NR NR 1/115 (0.9) 0/114 (0)
Aortic dissection NR NR NR NR 1/115 (0.9) 0/114 (0)
Deep-vein thrombosis NR NR NR NR 0/115 (0) 2/114 (1.8)
Hypertensive crisis NR NR NR NR 0/115 (0) 1/114 (0.9)
Arthritis NR NR NR NR 0/115 (0) 1/114 (0.9)
Cerebrovascular accident 1/76 (1.3) 0/75 (0) NR NR NR NR
Pelvic inflammatory disease 1/76 (1.3) 0/75 (0) NR NR NR NR
Cerebellar infarction 1/76 (1.3) 0/75 (0) NR NR NR NR
Pyelonephritis 0/76 (0) 1/75 (1.3) NR NR NR NR
Ankylosing spondylitis 0/76 (0) 1/75 (1.3) NR NR NR NR
NR, not reported.
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TABLE 21 Other systemic AEs in RCTs
AE
Study, n/N (%)
HURON48 (active uveitis) VISUAL I46 (active uveitis) VISUAL II47 (inactive uveitis)
DEX 700 Sham ADA Placebo ADA Placebo
Systemic AEs (≥ 5% in any group for the HURON trial or ≥ 5% in the treatment group in the VISUAL trials)
Nasopharyngitis NR NR 21/111 (18.9) 8/112 (7.1) 18/115 (15.7) 19/114 (16.7)
Headache 5/76 (6.6) 5/75 (6.7) 12/111 (10.8) 15/112 (13.4) 17/115 (14.8) 17/114 (14.9)
Fatigue 0/76 (0) 2/75 (2.7) 12/111 (10.8) 7/112 (6.3) 14/115 (12.2) 9/114 (7.9)
Arthralgia (joint pain) 0/76 (0) 2/75 (2.7) 10/111 (9.0) 11/112 (9.8) 27/115 (23.5) 12/114 (10.5)
Back pain NR NR 9/111 (8.1) 2/112 (1.8) 9/115 (7.8) 7/114 (6.1)
Injection site reactions NR NR 7/111 (6.3) 7/112 (6.3) 23/115 (20.0) 15/114 (13.2)
Urinary tract infection NR NR 7/111 (6.3) 0/112 (0) 13/115 (11.3) 10/114 (8.8)
Cough NR NR 7/111 (6.3) 4/112 (3.6) 11/115 (9.6) 6/114 (5.3)
Bronchitis NR NR 7/111 (6.3) 4/112 (3.6) NR NR
Hyperhidrosis
(increased sweating)
NR NR 7/111 (6.3) 3/112 (2.7) NR NR
Muscle spasms NR NR 7/111 (6.3) 4/112 (3.6) NR NR
Nausea 0/76 (0) 4/75 (5.3) 6/111 (5.4) 7/112 (6.3) 2/115 (1.7) 3/114 (2.6)
Paraesthesia
(‘pins+ needles’)
NR NR 6/111 (5.4) 0/112 (0) NR NR
Insomnia NR NR 5/111 (4.5) 8/112 (7.1) 8/115 (7.0) 3/114 (2.6)
Myalgia (muscle pain) NR NR 5/111 (4.5) 2/112 (1.8) 6/115 (5.2) 2/114 (1.8)
Hypertension 2/76 (2.6) 3/75 (4.0) 4/111 (3.6) 1/112 (0.9) 7/115 (6.1) 5/114 (4.4)
Liver changes:
elevated alanine
aminotransferase
NR NR 1/111 (0.9) 2/112 (1.8) 8/115 (7.0) 1/114 (0.9)
Liver changes:
elevated aspartate
aminotransferase levels
NR NR 1/111 (0.9) 1/112 (0.9) 6/115 (5.2) 1/114 (0.9)
Pain in extremity NR NR NR NR 10/115 (8.7) 3/114 (2.6)
Upper respiratory tract
infection
NR NR NR NR 10/115 (8.7) 3/114 (2.6)
Injection site pain NR NR NR NR 8/115 (7.0) 9/114 (7.9)
Sinusitis NR NR NR NR 8/115 (7.0) 4/114 (3.5)
Additional systemic AEs (noted as potentially important by clinical advisors)
Anxiety NR NR 5/111 (4.5) 0/112 (0) 5/115 (4.3) 2/114 (1.8)
Renal: elevated
creatinine
NR NR 4/111 (3.6) 2/112 (1.8) 2/115 (1.7) 3/114 (2.6)
Weight gain NR NR 3/111 (2.7) 2/112 (1.8) 2/115 (1.7) 0/114 (0)
Anaemia NR NR 3/111 (2.7) 0/112 (0) 0/115 (0) 2/114 (1.8)
Muscle weakness
(myasthenia)
NR NR 3/111 (2.7) 0/112 (0) NR NR
Cushing syndrome NR NR 2/111 (1.8) 1/112 (0.9) 1/115 (0.9) 0/114 (0)
Depression NR NR 1/111 (0.9) 1/112 (0.9) 2/115 (1.7) 3/114 (2.6)
Diabetes NR NR 1/111 (0.9) 2/112 (1.8) 2/115 (1.7) 0/114 (0)
Osteoporosis NR NR 1/111 (0.9) 1/112 (0.9) 0/115 (0) 2/114 (1.8)
AE, adverse event; NR, not reported.
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Immunogenicity
In the VISUAL I trial,46 anti-ADA antibodies were detected in 3 out of 110 patients (2.7%) in the ADA
group. These three patients had treatment failure at 16, 44 and 48 weeks (compared with a median time
to treatment failure of 24 weeks among the remaining 107 patients). In the VISUAL II trial,47 anti-ADA
antibodies were detected in 6 out of 115 patients (5.2%) in the ADA group. Five of these six patients had
treatment failure at weeks 13, 16, 16, 24 and 31 (not estimable for the remaining patient).
Ocular adverse events
Ocular AEs are shown in Table 22. In terms of serious ocular AEs, endophthalmitis (severe eye infection)
and severe uveitis worsening occurred in one patient each in the DEX 700 group and in no patients in the
sham group in the HURON trial.48 Conjunctival haemorrhage occurred in 30% of patients in the DEX 700
group and 21% of patients in the sham group in the HURON trial,48 whereas rates for this AE were low in
the VISUAL trials.46,47
Raised IOP occurred in 25% of the DEX 700 group compared with 7% of the sham group in the HURON
trial,48 whereas there was little difference between the ADA group and the placebo group in the VISUAL
trials.46,47 In the DEX 700 group, IOP of ≥ 25 mmHg peaked at week 3 (7.1% vs. 1.4% in the sham group),
whereas IOP of ≥ 35 mmHg peaked at week 12 (4.1% vs. 0% in the sham group). By week 26, no
patients in the DEX 700 group had an IOP of ≥ 25 mmHg whereas 4.2% of patients in the sham group
had an IOP of ≥ 25 mmHg.
Glaucoma rates showed little difference between the DEX 700 group (0%) and the sham group (2.7%) in
the HURON trial48 or between the ADA group (0.9%) and the placebo group (0%) in the VISUAL I trial.46
In the HURON trial48 no patients required incisional surgery for glaucoma, whereas two patients (2.6%) in
the DEX 700 group required laser iridotomy in the study eye for iris bombe and raised IOP. At any single
time point across the 26 weeks, up to 23% of patients in the DEX 700 group required IOP-lowering
medication (the percentage requiring this at any point in the study is not reported).
In the HURON trial,48 9 out of 62 eyes (15%) in the DEX 700 group and 4 out of 55 eyes (7%) in the sham
group had cataracts in eyes that were phakic (had a natural lens) at baseline. Among phakic eyes with no
cataract at baseline, 9 out of 42 eyes (21%) in the DEX 700 group and 4 out of 28 eyes (14%) in the sham
group had cataracts. For the ADA group, no data were reported on whether eyes were phakic or had
cataract at baseline; among all patients there were more cataracts in the ADA group than in the placebo
group in the VISUAL I trial46 (3.6% vs. 1.8%) but more in the placebo group than in the ADA group in the
VISUAL II trial47 (1.7% vs. 5.3%). Cataract surgery among phakic eyes occurred in 1 out of 62 patients
(1.6%) in the DEX 700 group and 2 out of 55 patients (3.6%) in the sham group; in the VISUAL II trial47
cataract surgery occurred in one patient in the ADA group and two patients in the placebo group.
Safety data from non-randomised studies of dexamethasone
A summary of safety data from 11 non-randomised, non-comparative studies of the DEX implant is shown
in Appendix 6.18,50,51,79–86 This is based on data presented within the company submission for DEX.43 The
proportion of patients with an increased IOP is typically higher in real-world studies than in a RCT, which
may reflect the inclusion of patients with a prior need for IOP-lowering medications, who were excluded
from the HURON trial.43 Implant migration to the AC has been reported in a few patients and occurred in
eyes that were aphakic (no lens) or pseudophakic (artificial lens).43 A few cases of endophthalmitis or
retinal detachment were reported after administration of DEX 700.43 Non-randomised studies of ADA are
not included here as they were not included in the company submission and it was beyond the scope of
this assessment to undertake a de novo review of these data.
Ongoing studies
Ongoing studies relevant to the decision problem are shown in Table 23. These were identified through a
search of the ClinicalTrials.gov database (using terms for uveitis plus ADA or DEX) and from the DEX
company submission.43
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TABLE 22 Ocular AEs in RCTs
AE
Study, n/N (%)
HURON48 (active uveitis) VISUAL I46 (active uveitis)
VISUAL II47
(inactive uveitis)
DEX 700 Sham ADA Placebo ADA Placebo
Serious ocular AEs in the study eyea (all reported in trials)
Retinal detachment 2/76 (2.6) 2/75 (2.7) 1/111 (0.9) 1/112 (0.9) 0/115 (0) 1/114 (0.9)
Endophthalmitis
(severe eye infection)
1/76 (1.3) 0/75 (0) NR NR NR NR
Uveitis worsening (as SAE) 1/76 (1.3) 0/75 (0) NR NR NR NR
Cataract (as SAE) 0/76 (0) 1/75 (1.3) NR NR NR NR
Choroidal
neovascularisation
NR NR 1/111 (0.9) 0/112 (0) 0/115 (0) 1/114 (0.9)
Transient blindness NR NR NR NR 1/115 (0.9) 0/114 (0)
Subretinal fluid NR NR NR NR 0/115 (0) 1/114 (0.9)
Ocular AEs in the study eyea (≥ 5% in any group for the HURON trial and ≥ 5% in the treatment group for the VISUAL trials)
Raised IOP 19/76 (25.0) 5/75 (6.7) 3/111 (2.7) 2/112 (1.8) 3/115 (2.6) 2/114 (1.8)
≥ 25mmHg Week 3:
5/70 (7.1)
Week 3:
1/70 (1.4)
NR NR NR NR
Week 8:
3/73 (4.1)
Week 8:
0/71 (0)
Week 26:
0/74 (0)
Week 26:
3/72 (4.2)
≥ 35mmHg Week 3:
1/70 (1.4)
Week 3:
0/70 (0)
NR NR NR NR
Week 8:
2/73 (2.7)
Week 8:
0/71 (0)
Week 26:
0/74 (0)
Week 26:
0/72 (0)
Conjunctival haemorrhage 23/76 (30.3) 16/75 (21.3) 0/111 (0) 1/112 (0.9) 3/115 (2.6) 2/114 (1.8)
Vitreous haemorrhage NR NR Eye
haemorrhage:
1/111 (0.9)
Eye
haemorrhage:
0/112 (0)
1/115 (0.9) 0/114 (0)
Retinal
haemorrhage:
1/111 (0.9)
Retinal
haemorrhage:
2/112 (1.8)
Ocular discomfort 10/76 (13.2) 6/75 (8.0) NR NR NR NR
Eye pain 9/76 (11.8) 10/75 (13.3) 9/111 (8.1) 2/112 (1.8) 9/115 (7.8) 6/114 (5.3)
Cataract
All patients 9/76 (11.8) 4/75 (5.3) 4/111 (3.6) 2/112 (1.8) 2/115 (1.7) 6/114 (5.3)
Phakic eyes at baseline 9/62 (14.5) 4/55 (7.3) NR NR NR NR
Phakic eyes with no
cataract at baseline
9/42 (21.4) 4/28 (14.3) NR NR NR NR
Iridocyclitis 7/76 (9.2) 4/75 (5.3) 1/111 (0.9) 0/112 (0) 3/115 (2.6) 2/114 (1.8)
Ocular hypertension 6/76 (7.9) 0/75 (0) 3/111 (2.7) 1/112 (0.9) 0/115 (0) 2/114 (1.8)
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Ongoing studies of dexamethasone
Two ongoing RCTs of DEX 700 were identified, both in patients with macular oedema as a result of
uveitis. Both compared DEX 700 against other local treatments. The POINT trial [PeriOcular and INTravitreal
Corticosteroids for Uveitic Macular Edema Trial (NCT02374060), due to complete in 2018] compares DEX
700 with intravitreal triamcinolone or periocular triamcinolone, whereas the MERIT trial [Macular Edema
Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (NCT02623426), due to complete in 2019]
compares DEX 700 with intravitreal methotrexate or intravitreal ranibizumab. In addition, a long-term
safety cohort study of DEX 700 (NCT01539577) in 875 patients with posterior segment-involving uveitis or
central or branch retinal vein occlusion was due to complete in March 2016, but no published results
were identified.
TABLE 22 Ocular AEs in RCTs (continued )
AE
Study, n/N (%)
HURON48 (active uveitis) VISUAL I46 (active uveitis)
VISUAL II47
(inactive uveitis)
DEX 700 Sham ADA Placebo ADA Placebo
Myodesopsia (floaters or
vitreal cells)
6/76 (7.9) 5/75 (6.7) NR NR NR NR
Uveitis/uveitis worsening 6/76 (7.9) 7/75 (9.3) 11/111 (9.9) 8/112 (7.1) 6/115 (5.2) 9/114 (7.9)
Conjunctival hyperaemia
(red eye)
5/76 (6.6) 7/75 (9.3) NR NR NR NR
Vision blurred 5/76 (6.6) 3/75 (4.0) 8/111 (7.2) 2/112 (1.8) NR NR
Macular oedema 3/76 (3.9) 6/75 (8.0) NR NR 7/115 (6.1) 7/114 (6.1)
Eye pruritus (itching) 3/76 (3.9) 5/75 (6.7) NR NR NR NR
Visual acuity reduced 1/76 (1.3) 4/75 (5.3%) NR NR 6/115 (5.2) 10/114
(8.8)
Eye swelling 1/76 (1.3) 4/75 (5.3) NR NR NR NR
Conjunctivitis 0/76 (0) 4/75 (5.3) NR NR NR NR
Additional ocular AEs in the study eyea (noted as potentially important by clinical advisors)
Cataract surgery
All patients 1/76 (1.3) 2/75 (2.7) NR NR 1/115 (0.9) 2/114 (1.8)
Phakic eyes at baseline 1/62 (1.6) 2/55 (3.6) NR NR NR NR
Phakic eyes with no
cataract at baseline
1/42 (2.4) 2/28 (7.1) NR NR NR NR
IOP-lowering medications Up to 16/71
(23) at any
single time
point
NR, presumed
0%
NR NR NR NR
IOP-lowering surgery
Incisional surgery,
laser trabeculoplasty,
cryotherapy
0/76 (0) 0/75 (0) NR NR NR NR
Laser iridotomy 2/76 (2.6) 0/75 (0) NR NR NR NR
Glaucoma 0/76 (0) 2/75 (2.7) 1/111 (0.9) 0/112 (0) NR NR
Low IOP (hypotony) 1/76 (1.3) 0/75 (0) NR NR NR NR
NR, not reported.
a Study eye relates to the HURON trial,48 in which one eye was designated the study eye.
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TABLE 23 Ongoing studies as of June 2016
Study name/company
Type and
estimated
number of
participants Population Interventions Key outcomes Follow-up
Start and end
dates Reference
DEX 700
PeriOcular and INTravitreal
Corticosteroids for Uveitic
Macular Edema Trial (POINT);
Johns Hopkins Bloomberg
School of Public Health
(JHSPH) Center for Clinical
Trials/NEI
RCT,
n= 267
l Non-infectious anterior
uveitis, intermediate
uveitis posterior uveitis
or panuveitis
l Active or inactive
l Macular oedema
l DEX 700
l 4mg of intravitreal
triamcinolone
l 40mg of periocular
triamcinolone
l Change in CRT
l IOP elevation
l Change in BCVA
8 and
24 weeks
March 2015–
July 2018
ClinicalTrials.gov
(NCT02374060)
Macular Edema
Ranibizumab v. Intravitreal
Anti-inflammatory Therapy
Trial (MERIT); JHSPH Center
for Clinical Trials/NEI
RCT,
n= 240
l Non-infectious anterior
uveitis, intermediate
uveitis, posterior uveitis
or panuveitis
l Inactive or minimally
active
l Macular oedema
l DEX 700
l 400 µg of intravitreal
methotrexate
l 0.5 mg of intravitreal
ranibizumab
l Change in CRT 8 weeks and
6 months
November 2016–
March 2019
ClinicalTrials.gov
(NCT02623426)
A Long-Term Safety Study of
Ozurdex in Clinical Practice;
Allergan
Cohort,
n= 875
l Central or branch retinal
vein occlusion or
non-infectious posterior
segment-involving
uveitis
l Macular oedema
l DEX 700 l AEs 2 years March 2012–
March 2016
(CSR available
September 2016a)
ClinicalTrials.gov
(NCT01539577)
ADA
Adalimumab in Uveitis
Refractory to Conventional
Therapy (ADUR); Heidelberg
University/Abbott
RCT, n= 25 l Non-infectious uveitis
l Active despite
≥ 7.5 mg/day
of corticosteroids
l 40mg of ADA every
other week +
corticosteroids +
immunosuppressants
l Corticosteroids
+ immunosuppressants
l % BCVA improved
by three or more
lines on the
ETDRS chart
l Inflammatory
activity
l Cystoid macula
oedema
l Cumulative steroid
dosage
Up to
24 weeks
August 2006–
March 2013
ClinicalTrials.gov
(NCT00348153);
Mackensen
201290 (abstract)
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Study name/company
Type and
estimated
number of
participants Population Interventions Key outcomes Follow-up
Start and end
dates Reference
Randomized Trial Comparing
Efficacy of Adalimumab,
Anakinra and Tocilizumab in
Non-infectious Refractory
Uveitis (RUBI); Assistance
Publique – Hôpitaux de Paris
RCT,
n= 120
l Non-infectious
intermediate uveitis,
posterior uveitis
or panuveitis
l Active
l 40mg of ADA every
other week
l 100mg/day of anakinra
l 162mg/week of
tocilizumab
l % with at least a
two-step reduction
in VH or AC score
l Change in VH
l Change in BCVA
l Change in CRT
l Change in steroid
dose
16 weeks October 2016–
May 2019
ClinicalTrials.gov
(NCT02929251)
Intravitreal Adalimumab
Versus Subcutaneous
Adalimumab in Non-
infectious Uveitis (IVAS)
RCT, n= 32 l Non-infectious
intermediate uveitis,
posterior uveitis
or panuveitis
l Active
l 40mg of ADA
(subcutaneous) every
other week
l ADA (intravitreal)
1.5 mg/0.03 ml every
4 weeks
l Change in VH
l Change in AC score
l Change in BCVA
(ETDRS, logMAR)
l Change in CRT
l Success in steroid
tapering
26 weeks February 2016–
June 2019
ClinicalTrials.gov
(NCT02706704)
A Study of the Long-term
Safety and Efficacy of
Adalimumab in Subjects with
Intermediate-, Posterior-, or
Panuveitis (VISUAL III);
AbbVie (previously Abbott)
Non-RCT,
n= 400
l Non-infectious
intermediate uveitis,
posterior uveitis
or panuveitis
l Active or inactive
patients from the
VISUAL I and VISUAL II
studies (completed
or experienced
treatment failure)
l 40mg of ADA every
other week
l AEs
l BCVA
l New lesions
l VH
l AC cells
l CRT
l VFQ-25
l Reduction in
immunosuppression
(active and inactive
patients separately)
Up to
330 weeks
(6.3 years)
November 2010–
March 2018
ClinicalTrials.gov
(NCT01148225);
Suhler 201691
(abstract)
CRT, central retinal thickness; CSR, clinical study report.
a Allergan submission.
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Ongoing studies of adalimumab
Three ongoing RCTs of ADA were identified. One small RCT [Adalimumab in Uveitis Refractory to
Conventional Therapy (ADUR) (NCT00348153)]90 compared ADA plus corticosteroids and immunosuppressants
with corticosteroids in combination with immunosuppressants and was due to be completed in March 2013.
This study is potentially of interest because of its active comparator arm. However, no published results were
identified other than an abstract reporting intermediate results for 20 of 25 patients;90 this was not included
in the clinical effectiveness review because of the limited results presented. The two other RCTs of ADA are
due to complete in 2019. The RUBI trial [Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and
Tocilizumab in Non-infectious Refractory Uveitis (NCT02929251)] aims to compare ADA against two further
biological therapies: anakinra (an interleukin-1 receptor antagonist) and tocilizumab (an antibody against
the interleukin-6 receptor). The IVAS trial [Intravitreal Adalimumab Versus Subcutaneous Adalimumab in
Non-infectious Uveitis (NCT02706704)] aims to compare subcutaneous ADA against intravitreal ADA.
In addition, a non-randomised extension study of ADA [A Study of the Long-term Safety and Efficacy of
Adalimumab in Subjects with Intermediate-, Posterior-, or Panuveitis (VISUAL III) (M11-327, NCT01148225)]
enrolled patients from the VISUAL I and VISUAL II studies (ADA or placebo arms) who either completed
these trials or experienced treatment failure. Patients who discontinued the VISUAL I or II study because of
treatment failure were defined as having active disease on entry to the VISUAL III study, whereas patients
who completed the VISUAL I or II study were defined as having inactive disease. Patients received open-label
ADA (40 mg every other week) and were followed up for 78 weeks (active uveitis patients) or 54 weeks
(inactive uveitis patients). The study is due to be completed in 2018. Preliminary data are available from a
conference abstract.91 This states that, of 243 patients with active uveitis after 78 weeks, 96.3% had no new
inflammatory lesions relative to week 8, 91.0% had an AC cell grade of ≤ 0.5+ and 87.8% had a VH grade
of ≤ 0.5+. Of 128 patients with inactive uveitis after 54 weeks, 98.5% had no new inflammatory lesions
relative to baseline, 98.5% had an AC cell grade of ≤ 0.5+ and 92.6% had a VH grade of ≤ 0.5+. The mean
systemic corticosteroid daily dose decreased from 12.7 to 3.68 prednisone equivalents by year 1 for patients
with active uveitis and remained stable from 1.48 to 1.21 prednisone equivalents for inactive patients. AE
rates were stated to be comparable to those in the VISUAL I and VISUAL II trials but no data were presented
in terms of numbers of patients with events. No data were presented for visual acuity or the VFQ-25.
Indirect comparison of treatments: rationale for not undertaking
The decision problem states that relevant comparators include periocular or intravitreal corticosteroid
injections, intravitreal corticosteroid implants, systemic corticosteroids, systemic immunosuppressants,
TNF-alpha inhibitors and intravitreal methotrexate (see Chapter 2). The trials of DEX 700 and ADA compared
these interventions only with placebo/sham procedure. In the absence of direct evidence comparing ADA and
DEX 700 and the absence of direct evidence comparing either of these treatments with a comparator reflective
of current UK practice, an indirect comparison using a NMA was considered. A NMA allows a simultaneous
comparison between interventions based on a synthesis of any direct and indirect evidence about treatment
effects across RCTs that share at least one treatment in common with at least one other study.
Consideration of indirect comparisons for all studies of clinically relevant comparators
Randomised controlled trials that included any of the treatments in the comparator decision set for
posterior segment-involving uveitis were sought. In addition to the trials of DEX 700 (HURON48) and ADA
(VISUAL I46 and II47), 13 additional trials of relevant comparators were identified.32,33,57–67
Unfortunately, it was considered infeasible and inappropriate to conduct a NMA for the reasons outlined in
Table 24. However, a brief summary of all identified trials of relevant comparators is provided in this section
for information: study characteristics are provided in Table 25 and a summary of reported outcomes is
provided in Table 26. The reasons for not including the additional identified trials in a NMA were:
l No link to the network containing ADA and DEX 700, that is, no common comparator. This applied to
studies of fluocinolone implant,57,58 periocular steroids,60 methotrexate32,67 and mycophenolate mofetil.32
The use of elicitation of experts’ beliefs to inform the parameters required to link disconnected
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TABLE 24 Studies considered for NMA: rationale for non-inclusion
Study Intervention Comparator Reasons for non-inclusion in NMA
HURON48,68 DEX 700 implant
(local steroid)
Placebo (sham) l Outcomes measured from baseline
(different from in the VISUAL trials)
VISUAL I46 ADA (anti-TNF) Placebo l Outcomes measured from peak after
steroid burst to treatment failure
(not from randomisation as in the
HURON trial)
VISUAL II47 ADA (anti-TNF) Placebo l Inactive uveitis
l Outcomes measured from baseline
Multicenter Uveitis
Steroid Treatment
Trial Research
Group57
Fluocinolone implant
(local steroid)
Steroids and
immunosuppressants
l Not connected to network
Pavesio 201058 Fluocinolone implant
(local steroid)
Steroids and
immunosuppressants
l Not connected to network
Shin 201559 Triamcinolone
intravitreal injection
(local steroid)
Placebo (sham) l 100% uveitic macular oedema
l No data on VA, VH, VFQ-25
Ferrante 200060 Triamcinolone
periocular injection
(local steroid)
Methylprednisolone
periocular injection
l Not connected to network
Foster 200361 Etanercept (anti-TNF) Placebo l Inactive uveitis
l No comparable VA outcomes
l No data on VH or VFQ-25
Yazici 199062 Azathioprine
(immunosuppressant)
Placebo l 100% Behçet’s disease
l No clear data on VA, VH, VFQ-25
Murphy 200533 Ciclosporin
(immunosuppressant)
Tacrolimus l Only connected via study of
ciclosporin vs. sham,63 which has no
data on VA, VH, VFQ-25
de Vries 199063 Ciclosporin
(immunosuppressant)
Placebo l No data on VA, VH, VFQ-25
Nussenblatt 199164 Ciclosporin
(immunosuppressant)
Prednisolone l Only connected via study of
ciclosporin vs. sham,63 which has no
data on VA, VH, VFQ-25
Bodaghi 2012
(active)65,66
Voclosporin
(immunosuppressant)
Placebo l No data on VA, VH, VFQ-25
Bodaghi 2012
(maintenance)65,66
Voclosporin
(immunosuppressant)
Placebo l Inactive uveitis
l No data on VA, VH, VFQ
Mackensen 201367 Methotrexate
(immunosuppressant)
Interferon-beta l Not connected to network
Rathinam 200432 Methotrexate
(immunosuppressant)
Mycophenolate
mofetil
l Not connected to network
VA, visual acuity.
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TABLE 25 Studies considered for NMA: study characteristics
Study Intervention Comparator
Patients
randomised,
n
Age
(years);
mean
(range)
Location of
uveitis
Duration of
uveitis
(months)
Bilateral
uveitis
(%)
% with
MO
Systemic
conditions
HURON
48,68
DEX 700 Placebo (sham) 153 (DEX
700+ sham)
≥ 18; 45
(18–82)
Int/post DEX 700 51,
sham 61
NR NR No uncontrolled
systemic condition
VISUAL I
46
ADA (40mg
every 2 weeks)
Placebo 223 ≥ 18; 43
(18–81)
Int/post/pan ADA 40,
placebo 51
91 Left 36,
right 37
None 73%,
sarcoid 8%,
Behçet’s disease
7%, VKH 12%
VISUAL II
47
ADA (40mg
every 2 weeks)
Placebo 229 ≥ 18; 43
(NR)
Int/post/pan 61 96 NR None 56%,
sarcoid 16%,
Behçet’s disease
6%, other 8%
Multicenter Uveitis
Steroid Treatment
Trial Research
Group
57
Fluocinolone
implant
(0.59mg)
Systemic steroids and
immunosuppressants
255 ≥ 13; 46
(NR)
Int/post/pan Fluocinolone
47, control
43
88 41 None 73%,
systemic 27%;
none requiring
systemic therapy
Pavesio 2010
58
Fluocinolone
implant
(0.59mg)
Systemic steroids and
immunosuppressants
140 ≥ 6; 42
(12–75)
Int/post/pan NR NR NR None requiring
systemic therapy
Shin 2015
59
Triamcinolone
intravitreal
injection
Placebo (sham) 50 ≥ 20; 52
(NR)
NR NR NR 100 None 48%,
systemic 52%
(sarcoid, Behçet’s
disease, VKH)
Ferrante 2000
60
Triamcinolone
periocular
injection
Methylprednisolone
periocular injection
36 NR; NR
(NR)
Int/post NR NR NR NR
Foster 2003
61
Etanercept
(25mg SC
twice a week)
Placebo 20 ≥ 18; 47
(NR)
NR NR
(6 months
MTX)
NR NR None 60%, SLE
15%, HLA-B27
15%, arthritis
10%
Yazici 1990
62
Azathioprine
(2.5mg/kg
daily)
Placebo 48 Any age,
32 (NR)
NR Azathioprine
103, placebo
83
71 NR Behçet’s disease
100%
Murphy 2005
33
Ciclosporin
(2.5–5.0
mg/kg/day)
Tacrolimus (0.03–0.08
mg/kg daily)
37 NR;
median
43 (NR)
Int/post/pan 12–24 76 NR None 70%,
Behçet’s disease
11%, sarcoidosis
8%
de Vries 1990
63
Ciclosporin
(10mg/kg/day)
Placebo 27 ≥ 18; 45
(22–75)
Int/post/pan Ciclosporin
67, placebo
78
NR NR None 74%,
Behçet’s disease
15%, sarcoidosis
11%
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Study
Current
inflammation
(active,
non-active)
Inclusion criteria:
VA and
inflammation
% prior HD steroids/
immunosuppressants
Concomitant
treatment
Eyes
treated
Eyes
analysed
Duration:
treatment and
follow-up
HURON
48,68
Active VH ≥ 1.5, BCVA
10–75 letters
26% steroids or
immunosuppressants
26% stable dose
steroids or
immunosuppressants;
rescue: local steroids,
systemic medications
(new or increased)
One (right
if bilateral)
Study eye only Single implant,
follow-up 6 months
(26 weeks)
VISUAL I
46
Active At least one of VH
≥ 2, AC cell grade
≥ 2, inflammatory
lesions
100% HD steroids All: prednisone
60mg/day, tapered
by week 15; some:
immunosuppressants,
maximum 1
NA
(systemic)
Left and right
separately
Up to 80 weeks
(1.5 years); ADA
19 weeks (median),
placebo 13 weeks
(median)
VISUAL II
47
Inactive
(≥ 28 days)
VH ≤ 0.5, AC cell
grade ≤ 0.5, no
inflammatory
lesions, steroid
dependent
100% HD
steroids, some
immunosuppressants
All: prednisone
10–35mg/day,
tapered by
week 19; some:
immunosuppressants,
maximum 1
NA
(systemic)
Left and right
separately
Up to 80 weeks
(1.5 years); ADA
35 weeks (median),
placebo 22 weeks
(median)
Multicenter Uveitis
Steroid Treatment
Trial Research
Group
57
Active (or
recently active)
No VH criteria
(some had VH= 0),
BCVA= hand
motions or better
Some steroids, some
immunosuppressants
(% NR)
Fluocinolone arm:
steroids and
immunosuppressants
discontinued; control
arm: steroids
(tapered),
immunosuppressants
(86%)
Both if
bilateral
All uveitic eyes Repeat if recurs,
follow-up 2 years
Pavesio 2010
58
Inactive
(‘clinically quiet’)
VH ≤ 2, AC cells
≤ 10, visual acuity
≥ 1.4 logMAR
(6/150)
100% HD
steroids, some
immunosuppressants
Fluocinolone arm:
steroids and
immunosuppressants
discontinued; control
arm: HD steroids±
immunosuppressants;
rescue: steroids
One (worse
if bilateral)
Study eye only Single implant,
follow-up 2 years
Shin 2015
59
NR UMO, BCVA
25–80 ETDRS
letters
100% HD
steroids, some
immunosuppressants
All: systemic
steroids or
immunosuppressants
and topical steroids
One (worse
if bilateral)
Study eye only Repeat if MO recurs,
follow-up 6 months
Ferrante 2000
60
Active (vitritis or
UMO)
UMO or vitritis NR NR NR
(assume
one)
NR Repeat at 6 weeks if
needed, follow up
3 months
Foster 2003
61
Inactive,
VH ≥ 1.5, BCVA
10–75 letters
NR 100% MTX
(immunosuppressant)
All: MTX (tapered);
steroid eye drops if
needed
NA
(systemic)
Both eyes,
all patients
6 months
(24 weeks)
Yazici 1990
62
NR NR No steroids or
immunosuppressants
(past month)
Rescue: systemic
steroids if required
NA
(systemic)
Unclear 2 years
Murphy 2005
33
NR NR 100% HD steroids
(or as required)
Some: oral steroids
only
NA
(systemic)
Per patient 3 months
de Vries 1990
63
Active BCVA ≤ 0.5 in best
eye (or Behçet’s or
trauma)
100% HD steroids All: oral steroids
(tapered)
NA
(systemic)
Unclear Up to 1 year
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TABLE 25 Studies considered for NMA: study characteristics (continued )
Study Intervention Comparator
Patients
randomised,
n
Age
(years);
mean
(range)
Location of
uveitis
Duration of
uveitis
(months)
Bilateral
uveitis
(%)
% with
MO
Systemic
conditions
Nussenblatt 1991
64
Ciclosporin
(10mg/kg/day
orally)
Prednisolone
(42–64mg/day orally)
56 ≥ 10; 38
(10–61)
Int/post NR 100 55 None 82%,
sarcoidosis
13%, VKH 5%
Bodaghi 2012
(active)
65,66
Voclosporin
(0.2, 0.4,
0.6mg/kg
b.i.d.)
Placebo 218 ≥ 13;
median
42 (NR)
Int/post/pan 52 NR NR NR
Bodaghi 2012
(maintenance)
65,66
Voclosporin
(0.2, 0.4,
0.6mg/kg
b.i.d.)
Placebo 232 ≥ 13;
median
43 (NR)
Int/post/pan 52 NR NR NR
Mackensen 2013
67
MTX (20mg
SC weekly)
Interferon-beta
(44 µg SC three times
weekly)
19 ≥ 18;
median
42 (NR)
Intermediate ≥ 1 year NR 100 None 74%,
multiple sclerosis
26%
Rathinam 2004
32
MTX (25mg
orally weekly)
Mycophenolate
mofetil (1 g twice/day)
80 ≥ 16; 39
(NR)
Int/post/pan NR 81 41 None 35.5%,
VKH 54%,
Behçet’s disease
8%, sarcoidosis
2.5%
b.i.d., twice a day; HD, high-dose; HLA-B27, human leucocyte antigen B27; int, intermediate; MO, macular oedema;
MTX, methotrexate; NA, not applicable; NR, not reported; pan, panuveitis; post, posterior; SC, subcutaneously;
sep, separately; SLE, systemic lupus erythematosus; UMO, uveitic macular oedema; VA, visual acuity.
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Study
Current
inflammation
(active,
non-active)
Inclusion criteria:
VA and
inflammation
% prior HD steroids/
immunosuppressants
Concomitant
treatment
Eyes
treated
Eyes
analysed
Duration:
treatment and
follow-up
Nussenblatt 1991
64
Active VA 20/40 or
worse, both eyes;
inflammation
(VH, VA decrease,
retinal lesions)
No steroids or
immunosuppressants
(past month)
No systemic
treatments; topical
medications
permitted
NA
(systemic)
Per patient 3 months
Bodaghi 2012
(active)
65,66
Active VH ≥ 2 100% HD steroids
(or contraindicated
refused)
Some: oral steroids NA
(systemic)
Study eye or
either
6 months
(24 weeks)
Bodaghi 2012
(maintenance)
65,66
Inactive NR 100% HD steroids Some: oral steroids NA
(systemic)
Study eye or
either
6 months
(26 weeks)
Mackensen 2013
67
Active Uveitic macular
oedema
(≥ 250 um); visual
acuity ≤ 20/30
(0.2 logMAR)
100% HD steroids and
acetazolamide
NR NA
(systemic)
Study eye
(worse)
3 months
Rathinam 2004
32
Active At least one of: VH
≥ 1, AC cell grade
≥ 1, Vitreous cells
≥ 1, Active lesions
100% HD steroids All: oral steroids
(tapered); some:
topical steroid
NA
(systemic)
All uveitic eyes 6 months
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TABLE 26 Studies considered for NMA: outcomes reported
Study Intervention Comparator
VA
Final value Change
% improved
three or more
lines
HURON48
,68 DEX 700 Placebo (sham) Y (ETDRS) (6 months) Y (2, 6 months)
VISUAL I46 ADA Placebo Y (logMAR) Y (logMAR)
VISUAL II47 AD Placebo Y (logMAR) Y (logMAR)
Multicenter Uveitis
Steroid Treatment Trial
Research Group57
Fluocinolone implant Systemic steroids and
immunosuppressants
Y (ETDRS)
(2, 6, 24 months)
Y (ETDRS)
(6, 12, 24 months)
Y (24 months)
Pavesio 201058 Fluocinolone implant Systemic steroids and
immunosuppressants
Y (24 months)
Shin 201559 Triamcinolone
intravitreal injection
Placebo (sham) (No data just
p=NS)
Ferrante 200060 Triamcinolone
periocular injection
Methylprednisolone
periocular injection
Foster 200361 Etanercept Placebo
Yazici 199062 Azathioprine Placebo Unclear data
Murphy 200533 Ciclosporin Tacrolimus
de Vries 199063 Ciclosporin Placebo Y (Landolt C,
p-value only)
Nussenblatt 199164 Ciclosporin Prednisolone Y
Bodaghi 2012 (active)65
,66 Voclosporin Placebo
Bodaghi 2012
(maintenance)65
,66
Voclosporin Placebo
Mackensen 201367 MTX Interferon-beta Y (Snellen,
logMAR)
Y (ETDRS, logMAR)
Rathinam 200432 MTX Mycophenolate mofetil Y (logMAR)
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Inflammatory activity Complications
% improved two
or more lines VH: final % VH= 0
% VH
improved
≥ 1
% VH
improved
≥ 2
AC cell grade:
change
Cataract:
incidence
Cataract:
% surgery
Y (2, 6 months) Y (final, no SD) Y Y Y Y Y
Y (final and change) Y Y Y
Y (change) Y Y Y
Y HR only Y Y
Y Y
Y Y
Y
Y
Y
Y Y
Unclear data
Y Y (final) Y
Y
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Study
Complications
MO
incidence
Time
to MO
Macular
thickness:
change
% eyes MO
improved
Steroid
reduction
% reduced
steroids
% rescue
steroids
HURON48
,68 Y Y Y (intravitreal/
systemic)
VISUAL I46 Y Y Y
VISUAL II47 Y Y
Multicenter Uveitis
Steroid Treatment Trial
Research Group57
Y
Pavesio 201058 Y (improved)
Shin 201559 No data,
p-value
Y (% reduced)
Ferrante 200060 Y (intravitreal)
Foster 200361
Yazici 199062 Y (intravenous)
Murphy 200533
de Vries 199063 Y (% stopped)
Nussenblatt 199164 Y (resolved)
Bodaghi 2012 (active)65
,66
Bodaghi 2012
(maintenance)65
,66
Mackensen 201367 Y Y (improved/
resolved)
Rathinam 200432 Y (resolved)
MO, macular oedema; MTX, methotrexate; NS, not significant; SE, standard error; SF-36, Short Form-36; VA, visual acuity;
Y, yes (reported).
a Worsening of AC cell grade, VH grade or VA or new inflammatory lesions.
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Composite outcomes HRQoL AEs
Time to treatment
failure (active
uveitis)
Uveitis
recurrence
Composite
(positive)
Generic
HRQoL
VFQ-25
composite:
final
VFQ-25
composite:
change
Systemic
AEs Ocular AEs
Y (2, 4,
6 months)
Y (no SD/SE)
(2, 6 months)
Y Y
Y (worse AC cells,
VH, VA, lesions)a
Y (EQ-5D,
HADS, WPAI)
Y Y Y Y
Y (AC, VH,
VA, lesions)
Y Y Y
Y (EQ-5D,
SF-36)
Y (6, 12,
24 months)
Y (6, 12,
24 months)
Y Y
Y (AC, VH,
VA)
Y Y
Y
Y
Y (uveitis
flare-ups)
Y
Y
Y (previous
responders)
Y (VA two or more
lines or
ophthalmoscopy= 0)
Y
No data, p-values Y
Y (VA three or
more lines or VH
improvement ≥ 2)
Y
Y (recurrence)
SF-36, no
data
Y Y Y
Y (% with minimal
inflammation while
on low or no steroid
treatment)
Y Y
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networks was considered in depth but was not implemented for two reasons. It was deemed to be
infeasible in the time frame and, moreover, would be of questionable benefit given the concerns
related to the comparability of the two main trials (see Consideration of indirect comparisons for trials
of adalimumab and dexamethasone) and hence the validity of the resulting connected network.
l Heterogeneity in patient populations in terms of active/inactive uveitis. It was not considered
appropriate to pool studies of patients with active and inactive uveitis. Active uveitis refers to current
inflammation in the eye, whereas patients with inactive uveitis have limited inflammation, usually
because they have received treatment with corticosteroids or immunosuppressants. The treatment
effect is likely to be related to the degree of activity/inflammation at baseline. The trial of etanercept,61
one trial of ADA (VISUAL II)47 and one trial of voclosporin65,66 could not be analysed with the HURON48
and VISUAL I46 studies for this reason. In terms of trials in patients with inactive uveitis, the trials of
etanercept61 and voclosporin65,66 had no comparable outcome data to enable a NMA to be conducted
with the VISUAL II trial.47
l Heterogeneity in patient populations for other reasons. The trial of intravitreal triamcinolone59 was
carried out in patients who all had uveitic macular oedema, whereas in most trials only a subset of
patients had uveitic macular oedema. The treatment effect is likely to be associated with the proportion
of patients with uveitic macular oedema at baseline because this condition causes vision loss.
Therefore, treating uveitic macular oedema is likely to lead to greater gains in vision than treating
patients with uveitis but no uveitic macular oedema. The trial of azathioprine62 was carried out in
patients who all had Behçet’s disease, whereas most trials were carried out in a mixed population with
only a small percentage of patients having Behçet’s disease and other systemic diseases; again, these
are clinically very different populations. In addition, as noted in Consideration of indirect comparisons
for trials of adalimumab and dexamethasone, there are many differences in the populations and the
prior and concomitant treatments used between the DEX 700 (HURON7) and the ADA (VISUAL I46)
studies for active uveitis.
l Lack of comparable outcomes. Within the trials that had a common comparator to DEX 700 or ADA
(i.e. a placebo arm),59,61–63,65,66 none reported outcomes that were consistent with those in the DEX 700
and ADA trials (see Table 26). Change in VFQ-25 score was reported for both the HURON trial48 and
the VISUAL I trial46 but a NMA was not considered appropriate for the reasons listed in Indirect
comparison of treatments: rationale for not undertaking.
Consideration of indirect comparisons for trials of adalimumab and dexamethasone
The outcomes reported for the ADA and DEX 700 trials varied from trial to trial (see Study characteristics)
and so the potential networks of evidence were considered separately for each outcome of interest.
Outcomes considered for the NMA were VFQ-25, visual acuity, VH and AEs. This was driven by the
potential to undertake a NMA for these outcomes.
Two networks of evidence were considered. A diagram of network 1 is provided in Figure 5. Network 1
consists of two trials (HURON48 and VISUAL I46) and allows pairwise comparisons to be made between ADA
and DEX 700 and placebo/sham procedure (the common comparator of the two trials). The trials share
common assessment time points of 8, 16 and 26/27 weeks (26 weeks for the HURON trial48 and 27 weeks
for the VISUAL I trial46). Given that the HURON trial48 was a 26-week trial, comparison beyond this time
point is not possible based on the observed data.
A diagram of network 2 is provided in Figure 6. Network 2 is an extension of network 1 including the
Multicenter Uveitis Steroid Treatment (MUST) trial of fluocinolone corticosteroid implant compared with
systemic corticosteroids and immunosuppressants,57 under the assumption that the efficacy of the
fluocinolone implant is the same as that of DEX 700. This allows an indirect comparison with treatment
with systemic corticosteroids and immunosuppressants, which may be considered more reflective of
current UK practice than treatment with placebo/sham procedure. An indirect comparison using this
network is possible only at 26 weeks (the first follow-up time point in the MUST trial).
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The AG began with a question about the best way to compare the treatment options within a network,
with the prior belief that such an analysis could be undertaken. However, after substantial deliberation
between all members of the AG and discussion with the clinical advisors, it was reluctantly decided that a
NMA was inappropriate and may provide misleading results. The main issues were as follows.
l Baseline systemic therapy: in the HURON trial48 only 26% of patients were receiving systemic therapy at
baseline, whereas in the VISUAL I trial46 all patients were receiving systemic high-dose corticosteroids.
Therefore, patients in these studies may have been on different ‘lines’ of treatment. In addition, in the
VISUAL I trial46 91% of patients had bilateral uveitis, whereas the corresponding proportion was not
reported in the HURON trial;48 this may be a further difference between the patient populations in
these studies.
l Rescue therapy: a greater proportion of patients in the sham arm than in the DEX 700 arm in the
HURON trial48 received rescue therapy (38.2% vs. 22.1%). In the VISUAL I trial46 there was no reported
difference in concomitant therapy between the two arms. It may be misleading to attribute an indirect
effect of ADA compared with DEX 700 to these interventions alone.
l Comparability of the baseline treatments in the HURON48 and VISUAL I46 studies: the VISUAL I trial46
included an initial steroid burst; this was not included in the HURON trial.48 Thus, the baseline interventions
were different and it would be meaningful to combine the treatment effects across studies only if the
initial steroid burst did not affect the treatment effect. However, clinical advice suggests that the treatment
effect will depend on the initial steroid burst. Patients experience an initial improvement from the steroid
burst and there is less scope during this period for patients to demonstrate further improvement (i.e. the
effect of ADA is not additive to the effect of the steroids). In the analyses undertaken by AbbVie this issue
HURON48
MUST57
VISUAL I46
ADA
Placebo/sham Immunosuppressants
DEX/fluocinolone
FIGURE 6 Network 2 for the VFQ-25 outcome: indirect comparison of ADA, DEX, placebo/sham and
immunosuppressants.
HURON48
VISUAL I46
DEX
ADA
Placebo/sham
FIGURE 5 Network 1 for the VFQ-25 outcome: indirect comparison of ADA, DEX and placebo/sham.
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was addressed by considering the change from the peak within the first 6 weeks to the final/termination
visit for each individual. This approach was not considered appropriate for estimating the treatment effect
because patients are comparable only at baseline and treatment effects should be estimated relative
to baseline.
l Validity of the comparable efficacy assumption for dexamethasone and fluocinolone (network 2 only):
although DEX 700 and fluocinolone are both corticosteroid intravitreal implants, they cannot be
considered clinically equivalent because the fluocinolone implant has a higher potency (median
duration of effect 30 months)92 than the DEX 700 implant (median duration of effect 6 months).43
There are no head-to-head trials comparing DEX 700 and fluocinolone implants.
l Issues with the reported data: patients in the VISUAL I trial46 were followed up to the time of treatment
failure only and missing data beyond this point were imputed using LOCF. No other methods for
dealing with missing data were considered and it is possible that the use of LOCF may provide a biased
estimate of the treatment effect as it assumes that the data are missing at random, which is not true in
this case. Although LOCF was also used in the HURON trial48 the issue is less problematic in this case
because most patients were followed up for 26 weeks and treatment could not be discontinued
(because the implants are not removed). Estimates of the treatment effect for secondary outcomes
(including VFQ-25 score, EQ-5D score, visual acuity and VH) may be biased because data were
collected only until treatment failure. Evidence about key outcome measures could be synthesised using
either absolute values at each time point or change from baseline. The use of absolute values was
ruled out because of differences in response at baseline between the sham arm and the treatment arm
in the HURON trial48 for the VFQ-25. The sham arm had a higher mean VFQ-25 score at baseline,
whereas clinical advice suggests that the lower mean VFQ-25 score associated with the treatment arm
is likely to be more representative of the population. It was not possible to account appropriately for
baseline differences.
l Treatment with adalimumab and dexamethasone is generally appropriate for different patient groups:
as discussed in Description of the technologies under assessment, there is only a small patient group in
which it would be appropriate to compare DEX 700 and ADA, with the most likely group being
patients with bilateral uveitis with a temporary flare-up. Consequently, an analysis that assumes that
clinicians would be prepared to treat any patient in the population with any of the treatments
is inappropriate.
Summary of clinical effectiveness and safety (randomised controlled trials)
Three RCTs were included in the review of clinical effectiveness; a summary of the results is provided in
Table 27. Two RCTs compared ADA with placebo, for up to 80 weeks or until treatment failure, in patients
with intermediate uveitis, posterior uveitis or panuveitis on high-dose oral corticosteroids: VISUAL I46 (active
uveitis) and VISUAL II47 (inactive uveitis). Oral corticosteroids were tapered from baseline and patients could
receive up to one systemic immunosuppressant. One RCT (HURON48) compared DEX 700 (a single 0.7-mg
implant) with a sham procedure over 26 weeks’ follow-up in patients with intermediate or posterior
uveitis. At baseline, 25% of participants were on systemic therapies, which could be continued at a stable
dose.48 Thirteen additional studies of clinically relevant comparator treatments (vs. placebo or one another)
were identified. However, because of clinical heterogeneity, differences in outcomes and a lack of
common comparators, it was not feasible to undertake a NMA. Therefore, the summary of clinical efficacy
evidence presented here is restricted to the VISUAL I,46 VISUAL II47 and HURON48 studies.
Treatment failure in the VISUAL trials of ADA was defined as worsening of any of the following in either
eye: AC cell grade, VH grade, BCVA or new inflammatory lesions. In the VISUAL I trial46 (active uveitis), the
median time to treatment failure was 5.6 months for ADA compared with 3 months for placebo (HR 0.50,
95% CI 0.36 to 0.70; p < 0.001). Treatment failure was experienced by 54.5% of participants on ADA
compared with 78.5% of participants on placebo. In the VISUAL II trial47 (inactive uveitis), the median time
to treatment failure was not estimable for ADA and was 8.3 months for placebo (HR 0.57, 95% CI 0.39 to
0.84; p = 0.004). Treatment failure was experienced by 39% of participants on ADA compared with 55%
of participants on placebo. In the VISUAL I trial46,52 there were significant benefits of ADA compared with
placebo for changes in the following (averaged across both eyes): visual acuity (p = 0.003), inflammation
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TABLE 27 Summary of clinical effectiveness
Outcome
Difference between groups: treatment effect (95% CI), p-value
ADA: VISUAL I
(active uveitis)
ADA: VISUAL II
(inactive uveitis)
DEX 700: HURON –
8 weeks
DEX 700: HURON –
26 weeks
Time to treatment failure
(worsening of AC, VH or
BCVA or new lesions)
HR 0.50
(0.36 to 0.70),
p < 0.001
HR 0.57
(0.39 to 0.84),
p = 0.004
NR NR
BCVA (change) (logMAR) MD –0.07
(–0.11 to –0.02),
p = 0.003
–0.04
(–0.08 to 0.01),
p = 0.096
NR MD NR, p= 0.002
BCVA improvement of three
of more lines (15 letters)
NR NR MD 36.3% (24 to 49),
p< 0.001; RR 6.5
(2.7 to 15.8), p< 0.001
MD 24.5 (11 to 38),
p< 0.001; RR 2.9
(1.5 to 5.5), p = 0.001
BCVA improvement of two
or more lines (10 letters)
NR NR MD 43 (29 to 56),
p< 0.001; RR 3.5
(2.1 to 5.9), p< 0.001
MD 30 (15 to 44),
p< 0.001; RR 2.2
(1.4 to 3.4), p < 0.001
VH grade (change) MD –0.27
(–0.43 to –0.11),
p < 0.001
MD –0.13
(–0.28 to 0.01),
p = 0.070
NR NR
VH grade (final) NR NR MD –0.97 (NR),
p< 0.001
MD –0.58 (NR),
p< 0.001
% with VH = 0 NR NR MD 34.9 (22 to 48),
p< 0.001; RR 4.0
(2.0 to 7.6), p< 0.001
MD 16.7 (4 to 30),
p= 0.014; RR 2.2
(1.1 to 4.1), p = 0.02
% with VH improvement of
≥ 2
NR NR MD NR, p< 0.001 MD NR, p= 0.001
AC cell grade (change) MD –0.29
(–0.51 to –0.07),
p = 0.011
MD –0.14
(–0.37 to 0.08),
p = 0.218
NR NR
Macular oedema (change
in macular thickness) (µm)
NR NR MD –87.0 (–147 to –27),
p= 0.004
MD –14.7 (–66 to 37),
p= 0.58
Macular oedema (change
in macular thickness)
(% change)
MD –11.4
(–20.9 to –1.8),
p = 0.020)
MD –2.3
(–8.5 to 3.8),
p = 0.451
NR NR
VFQ-25 composite score
(change)
MD 4.20
(1.02 to 7.38),
p = 0.010
MD 2.12
(–0.84 to 5.08),
p = 0.160
MD NR, p= 0.007 MD NR, p= 0.001
% with ≥ 5-point
improvement in VFQ-25
score
NR NR MD NR, p< 0.001 MD NR, p< 0.05
EQ-5D score (change) MD 0.04
(0.00 to 0.07),
p = 0.044
MD 0.00
(–0.03 to 0.04),
p = 0.836
NR NR
% requiring rescue
medication
NR NR NR MD 16, p= 0.030
NR, not reported.
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[VH (p < 0.001) and AC cell grade (p = 0.011)], macular oedema [change in central retinal thickness
(p = 0.020)], VFQ-25 composite score (p = 0.010) and EQ-5D score (p = 0.044). In the VISUAL II trial,47,72
differences were not significant for ADA compared with placebo for changes in any of the following
(averaged across both eyes): visual acuity (p = 0.096), inflammation [VH (p < 0.070) and AC cell grade
(p = 0.218)], macular oedema [change in central retinal thickness (p = 0.451)], VFQ-25 composite score
(p = 0.160) or EQ-5D score (p = 0.836).
In the HURON trial48 there were significant benefits of DEX 700 compared with the sham procedure for the
following (measured in the study eye only): percentage of patients with a VH score of zero at 8 weeks
(p < 0.001) and 26 weeks (p = 0.014), percentage of patients with a VH improvement of ≥ 2 units at
8 weeks (p < 0.001) and 26 weeks (p = 0.001), percentage of patients with a BCVA improvement of three
or more lines over weeks 3–26 (p < 0.001), mean BCVA improvement over weeks 3–26 (p ≤ 0.002),
central retinal thickness at 8 weeks (p ≤ 0.004) although not 26 weeks (p ≥ 0.227), change in VFQ-25
composite score (per patient as opposed to study eye) at 8 weeks (p = 0.007) and 26 weeks (p = 0.001)
and percentage of patients with a ≥ 5-point improvement in VFQ-25 score at 8 weeks (p < 0.001) and
26 weeks (p < 0.05). Rescue medication (corticosteroid injections in the study eye or new/increased use of
systemic corticosteroids or immunosuppressants) were required in 22% of participants in the DEX 700 arm
and 38% of participants in the sham arm (p = 0.030).
As ADA affects the immune system, the potential risks of treatment with ADA include infections and
malignancy.44 The rate of serious infections was higher in the ADA group than in the placebo group in the
VISUAL I trial46 (4.5% vs. 1.8%) but not the VISUAL II trial47 (1.7% vs. 1.8%). Malignancies and chronic
renal failure each occurred in a total of three patients across both trials in the ADA group, with no cases
in the placebo group. Systemic AEs that had a higher rate of occurrence in the ADA group than in the
placebo group in at least one of the VISUAL trials46,47 included infections, injection site reactions, fatigue,
arthralgia, myalgia, paraesthesia, hypertension and elevations of liver enzymes. Anti-ADA antibodies in
patients receiving ADA occurred in 2.7% in the VISUAL I trial46 and 5% in the VISUAL II trial.47 There was
little difference between ADA and placebo in the rates of ocular AEs.
In terms of safety, the risks of DEX 700 include those associated with intraocular steroids, that is, increased
IOP, cataract and glaucoma, as well as infection and bleeding.45 In the HURON trial,48 raised IOP occurred
in 25% of participants in the DEX 700 group compared with 7% of participants in the sham group,
whereas IOP of ≥ 25 mmHg occurred in 7.1% of participants in the DEX 700 group compared with 1.4%
of participants in the sham group. Glaucoma rates were lower in the DEX 700 group (0%) than in the
sham group (2.7%); no patients required incisional surgery for glaucoma, whereas 2.6% of participants
in the DEX 700 group required a laser iridotomy and, at any single time point, up to 23% of participants
in the DEX 700 group required IOP-lowering medication (not reported for the sham group). Cataracts in
eyes that were phakic (had a natural lens) at baseline occurred in 15% of participants in the DEX 700
group compared with 7% of participants in the sham group and cataract surgery was carried out in 1.6%
and 3.6% of the DEX 700 and sham groups respectively. Endophthalmitis (severe eye infection) and severe
uveitis worsening occurred in one patient each in the DEX 700 group; there were no cases in the sham
group. Conjunctival haemorrhage occurred in 30% of participants in the DEX 700 group compared with
21% of participants in the sham group. No systemic AEs had a substantially higher rate in the DEX 700
group than in the sham group.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
Chapter 4 Assessment of cost-effectiveness
This chapter first presents a systematic review of existing cost-effectiveness evidence for treatments givento mainly adult patients with non-infectious uveitis. This is followed by a description of the de novo
model developed by the AG to assess the cost-effectiveness of DEX in patients with active uveitis, ADA in
patients with active uveitis and ADA in patients with inactive uveitis, all compared with current practice,
and the results of the model and discussion of the analysis. Finally, a summary of the key model results
is presented.
Systematic review of existing cost-effectiveness evidence
Methods
A comprehensive search was undertaken to systematically identify economic evaluations and quality-of-life
studies in patients with active non-infectious intermediate uveitis, posterior uveitis and/or panuveitis.
The following electronic databases and clinical trials registries were searched from inception:
l MEDLINE (via Ovid) (1946–2016)
l MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
(1946–2016)
l EMBASE (via Ovid) (1980–2016)
l The Cochrane Library (via Wiley Online Library)
¢ HTA database (1995–2016)
¢ NHS EED (1995–2015)
l CINAHL (via EBSCOhost) (1982–2016)
l Web of Science Citation Index (Thomson Reuters) (1899–2016)
l CPCI (Thomson Reuters) (1990–2016)
The search strategy consisted of MeSH or EMTREE Thesauri terms and free-text synonyms for ‘uveitis’.
Searches were translated across databases and were limited by neither language nor publication date.
The search strategies are presented in Appendix 1. Search filters designed to identify economic evaluations
and quality-of-life studies were used on MEDLINE and other databases when appropriate. Reference and
citation searching of included papers was undertaken.
The inclusion criterion was economic evaluations of treatments given to mainly adult patients for
non-infectious uveitis. This took a deliberately broad perspective and was not limited to treatment with
ADA or DEX. Studies that reported only costs were excluded, although these were marked as being
potentially useful for informing the model parameters. Study selection was undertaken by one reviewer (IB)
and checked by a second reviewer (HS). Critical appraisal of the included studies was undertaken using a
combination of key components of the BMJ checklist for economic evaluations93 together with the Eddy
checklist for mathematical models94 (see Table 28).
Results
The electronic literature searches identified 1177 potentially relevant economic analyses of treatment for
non-infectious uveitis. Of these, only seven studies appeared to relate to the economic evaluation of
non-infectious uveitis and full texts of these papers were obtained.95–101 Two of these studies met the
inclusion criteria,100,101 one of which was published only as a conference abstract.100 The numbers of studies
screened and included within the review are shown in Figure 7.
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Justification for excluding studies at the full paper screening stage
The review by the Health Technology Inquiry Service95 was excluded following full paper screening as it did
not identify any cost-effectiveness studies. The study reported by Ang et al.96 was excluded because it
related to an analysis of interventions for tuberculous uveitis rather than non-infectious uveitis and
compared diagnostic testing strategies rather than treatments for diagnosed disease. The studies by
Ramanan et al.97 and Ramanan et al.98 were excluded because they were limited to children and they did
not include an economic analysis. The study reported by Nguyen et al.99 was excluded because it was not
an economic evaluation.
Included economic evaluations
The key characteristics of the two studies100,101 identified for inclusion within the review are shown in
Table 28 and are discussed briefly below. Neither of these studies included ADA or DEX as interventions or
comparators. One of the economic analyses was based on a semi-Markov model100 whereas the other101
extrapolated cost and HRQoL data collected during the MUST trial.57,102 The two economic evaluations
compared a different set of treatments.
Padula et al.:100 a cost-effectiveness analysis of off-label biologics to treat sarcoid
posterior uveitis versus standard of care: comparing infliximab to methotrexate and
systemic steroids
The study by Padula et al.100 was reported only as a conference abstract. The authors presented the
methods and results of a cost-effectiveness analysis of infliximab compared with methotrexate and systemic
steroids over a lifetime horizon. The economic evaluation used a semi-Markov approach to estimate health
outcomes and costs. Patients entered the model following the onset of sarcoid posterior uveitis. No further
information was provided about the population reflected in the model. Cost-effectiveness was evaluated in
terms of the incremental cost per quality-adjusted life-year (QALY) gained from a societal perspective.
Probabilities, health utilities and costs used in the model were reported to be taken from the literature,
although parameter values were not reported in the abstract. It was not specified whether or not a
systematic review was conducted. Costs and health outcomes were discounted at a rate of 3% per
annum. Costs were expressed in 2010 US dollars. The authors conducted univariate sensitivity analyses,
threshold analyses and probabilistic sensitivity analysis (PSA) using 10,000 simulations.
Potentially relevant articles
identified and screened for retrieval
(n = 1177)
(Broad search looking for
any economic evaluation of 
non-infectious uveitis treatments)
Full papers screened
(n = 7)
Papers rejected at the abstract stage
(n = 1170)
Full papers excluded
(n = 5)
Full papers accepted
(n = 2)
FIGURE 7 Summary of selection and exclusion of economic evaluation studies.
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The incremental cost-effectiveness ratio (ICER) for methotrexate compared with systemic steroids was
estimated to be US$10,053 per QALY gained. Methotrexate dominated infliximab in the base case.
However, if a patient’s health utility after successful recovery was < 0.750 (base-case value of 0.84),
then infliximab produced a greater net benefit than methotrexate, assuming a willingness-to-pay (WTP)
threshold of US$50,000 per QALY gained. The PSA suggested that the probability of methotrexate
dominating infliximab was 0.60.
It is not possible to assess the validity of the model as only limited information is provided within the
conference abstract. The AG notes that this analysis does not include either of the interventions being
assessed within this appraisal (DEX and ADA) and the model does not appear to differentiate between
unilateral and bilateral uveitis, which may be associated with different cost-effectiveness results. There is
insufficient information provided within the abstract for this analysis to be useful in the current appraisal.
Sugar et al.:101 cost-effectiveness of fluocinolone acetonide implant versus systemic
therapy for noninfectious intermediate, posterior, and panuveitis
Sugar et al.101 presented a cost-effectiveness analysis of fluocinolone acetonide intraocular implant
compared with oral corticosteroids and immunosuppressive agents. Costs and health benefits were
estimated from data collected during the MUST trial.57 The economic analysis used a time horizon of
3 years and costs and benefits were discounted at a rate of 3% per annum. Costs were expressed in US
dollars (year unclear). The authors used a payer’s perspective for costs and the patient’s perspective for
outcomes. The authors estimated the cost to a payer to maximise health benefits by using the more
effective, but more expensive, treatment.
The within-trial data (differences in costs and utilities), reported at 2 years’ follow-up, were extrapolated
by a further year for a 3-year time horizon. The difference in the mean total costs of the treatments was
determined with a linear regression with a saturated means model. The history of the disease was
modelled through a sequence of utility values measured during the trial at different points in time.
No health states were used. Uncertainty was assessed using bootstrapping and was represented using
cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs).
TABLE 28 Characteristics of studies included in the cost-effectiveness review
Characteristics
Study
Padula et al.100 Sugar et al.101
Country and year of publication USA, 2011 USA, 2014
Type of economic analysis Cost–utility analysis Cost–utility analysis
Health economic perspective Societal Payer’s perspective for costs and the patient’s perspective
for outcomes
Health economic comparisons
(listed interventions)
Infliximab, systemic
steroids, methotrexate
Fluocinolone acetonide intraocular implant, oral
corticosteroid with immunosuppressive agents as needed
Population Patients with sarcoid
posterior uveitis
Patients aged ≥ 13 years with non-infectious intermediate
uveitis, posterior uveitis or panuveitis in one or both
eyes (active within ≤ 60 days) for which systemic
corticosteroids were indicated (excluding those requiring
systemic therapy for non-ocular indications)
Time horizon Lifetime 3 years
Health economic outcomes Incremental cost per
QALY gained
Incremental cost per QALY gained
Modelling approach Semi-Markov model Extrapolation of trial data
QALY, quality-adjusted life-year.
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For bilateral uveitis, the fluocinolone acetonide implant for both eyes was estimated to generate 0.057
additional QALYs at an additional cost of US$16,900; the ICER was reported to be US$297,800 per QALY
gained. The probabilities of the fluocinolone acetonide implant being cost-effective compared with
systemic therapy at WTP thresholds of US$50,000 and US$100,000 per QALY gained were 0.003 and
0.04 respectively. For unilateral uveitis, the implant resulted in 0.130 additional QALYs at an additional cost
of US$5300; the ICER was reported to be US$41,200 per QALY. The probabilities of the implant being
cost-effective compared with systemic therapy at WTP thresholds of US$50,000 and US$100,000 per
QALY gained were 0.53 and 0.74 respectively.
The study highlights the importance of considering unilateral and bilateral uveitis separately within future
economic evaluations in terms of (1) the cost difference between types of treatments, (2) quality-of-life
impacts and (3) the greater risk to vision of an operative procedure on both eyes compared with one eye.
However, this study does not consider the cost-effectiveness of the implant in one eye for patients with
bilateral uveitis as all patients with bilateral uveitis within the MUST trial were given an implant in both
eyes.57 The model has several additional key limitations:
l All relevant comparators were not included in the model. Systemic steroids and immunosuppressants
were assumed to be the gold standard as they were the only included comparators of the fluocinolone
acetonide implant, with no discussion about whether or not this was appropriate.
l AEs were not taken into consideration.
l It is not clear how the 2 years of data from the MUST trial were extrapolated to the 3-year time horizon.
l It is not clear whether or not the implant would have benefits after this 3-year period.
l No model validation was reported.
l The analysis of uncertainty was not well described.
Company submissions
Neither AbbVie55 (ADA) nor Allergan43 (DEX) submitted a health economic model. Within its submission,
AbbVie provided no discussion of cost-effectiveness and presented a budget impact estimate based on the
acquisition costs of ADA only.55
Within its submission, Allergan argued that DEX has been recommended by NICE for the treatment of
macular oedema secondary to retinal vein occlusion103 and that the costs per patient associated with DEX
are comparable for posterior segment uveitis and patients with macular oedema secondary to retinal vein
occlusion, whereas the incremental gains in visual acuity are greater in posterior segment uveitis based on
the trial data from the individual trials. This argument fails to consider the incremental (rather than
absolute) cost of DEX treatment compared with current treatment. Allergan also submitted a budget
impact model, which takes into account the costs of treatment and monitoring but not the costs of
treating events associated with uveitis or AEs associated with treatment.
Summary of the review of existing cost-effectiveness studies
No existing studies have assessed the cost-effectiveness of either DEX or ADA within this patient
population. Only one published health economic model of non-infectious uveitis exists. This study was
subject to several limitations, including poor reporting of some of the methods, validation and uncertainty
analysis, not taking into account AEs and the use of a 3-year time horizon, which may not fully capture all
impacts of the treatments.
Independent economic assessment
Methods
This section provides details of the Markov model developed by the AG, which was used to evaluate the
cost-effectiveness of ADA and DEX within their licensed indications for non-infectious posterior segment-
involving uveitis compared with current practice, from a NHS and PSS perspective. A cohort of patients with
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a mean age of 44.8 years was followed over a lifetime. All costs and QALYs were discounted at a rate of
3.5% per year. ADA and DEX were not compared against each other. This is because of their different use
in clinical practice (see Chapter 1, Description of the technologies under assessment) and because, for the
limited indications for which the clinician has a choice regarding which treatment to use, there is a lack of
evidence, as detailed in Chapter 3 (see Indirect comparison of treatments: rationale for not undertaking).
Table 29 describes the key features of the model for both ADA and DEX.
Because of the substantial uncertainties associated with the above assumptions because of the limited
evidence base, most of the assumptions were altered within exploratory analyses to test their impact on
the model results.
Model description
Patient population
The model population consists of people with non-infectious intermediate uveitis, posterior uveitis or
panuveitis. Patients receiving DEX were assumed to have active disease, whereas the model assessed the
TABLE 29 Model summary (base-case analysis)
Characteristic
Intervention
ADA DEX
Population People with non-infectious intermediate uveitis,
posterior uveitis or panuveitis with (1) active disease
(VISUAL I46) and (2) inactive disease (VISUAL II47)
People with non-infectious intermediate
uveitis, posterior uveitis or panuveitis
with active disease (HURON48)
Intervention ADA until treatment failure + LCP(VI), ADA until
treatment failure+ LCP(VII)
One DEX implant + LCP(H)
Comparator LCP(VI), LCP(VII) LCP(H)
Outcome used from trial EQ-5D VFQ-25
Time horizon Lifetime Lifetime
Discounting 3.5% per year for costs and QALYs 3.5% per year for costs and QALYs
Treatment
discontinuation
Parametric survival curve of time to treatment failure
fitted to VISUAL I and II trial data
Patients are given only one DEX implant
Method for estimating
QALYs during the trial
period
Use directly measured EQ-5D scores at each time
point until treatment failure, when patients revert to
baseline utility, adjusted for age
Use VFQ-25 data captured at each time
point in the trial mapped onto EQ-5D
scores
Method for estimating
QALYs following the
trial period
Patients who have not failed treatment retain the
averaged utility from months 12–18 of the trial
(because of small patient numbers), adjusted for
age. Patients who fail treatment revert to baseline
utility, adjusted for age
Assumes that utility remains the same
for 4 weeks following the trial and then
returns to baseline by week 30,
adjusted for age
AEs (except blindness) Cataract, raised IOP, glaucoma, serious infections, hypertension, fractures, diabetes. Impact on
HRQoL associated with these AEs was assumed to be captured within the VFQ-25/EQ-5D scores
Permanent blindness
(comparator)
No blindness prior to treatment failure. Constant
rate of blindness after treatment failure based on
Dick et al.19
Constant rate of blindness based on
Dick et al.19
Permanent blindness
(intervention)
No blindness prior to treatment failure. Constant
rate of blindness after treatment failure based on
Dick et al.19
RR for blindness of 0.5 for 30 weeks
following implantation
Treatment following
remission
For all patients, treatment will continue until
treatment failure
For all patients, treatment will continue
until treatment failure
LCP(H), limited current practice based on the HURON trial; LCP(VI), limited current practice based on the VISUAL I trial;
LCP(VII), limited current practice based on the VISUAL II trial.
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cost-effectiveness of ADA separately for patients with active and inactive disease. An analysis was
undertaken to explore the cost-effectiveness of DEX use in one eye in patients with unilateral disease as a
separate subgroup; the trial did not provide data separately for this group and hence this analysis is
considered to be exploratory. Because of a lack of evidence, it was not possible to explore additional
subgroups. A cohort of uveitis patients was assumed to enter the model with a mean age of 44.8 years,
based on the mean age within the HURON trial,48 and was followed over a lifetime. The model population
was limited to adults aged ≥ 18 years because the marketing authorisations for the technologies being
considered relate only to this group.
Interventions
The two technologies considered were ADA (40 mg every 2 weeks until treatment failure) and the DEX
implant (0.7 mg, once only in the base case).
Within the clinical trials of ADA (VISUAL I46 and II47), patients were already receiving high-dose corticosteroids at
randomisation, with a corticosteroid burst given to all patients at the start of the VISUAL I trial; corticosteroids
were tapered to zero by week 15 (VISUAL I) or week 19 (VISUAL II). Clinical advisors to the AG suggested that
this is also likely to reflect clinical practice, although the SmPC suggests that ADA may be given alongside
corticosteroids or alone.44 Given the evidence available, for patients with active disease, the model considers
the cost-effectiveness of ADA plus an initial oral corticosteroid burst, rather than ADA alone.
The DEX implant can be administered in the affected eye to unilateral patients, in one eye for patients with
bilateral disease or in both eyes at staggered intervals for patients with bilateral disease. Patients could also
receive more than one consecutive implant. Clinical advisors to the AG suggested that the DEX implant would
most probably be used when disease affects only one eye (or is more severe in one eye in the case of asymmetric
disease), or to treat a temporary flare-up in one or both eyes, when systemic disease is not present or is well
controlled. The base-case model assumed that patients would receive one DEX implant in one affected eye,
as in the HURON trial.48 There are no RCTs that assess the use of more than one consecutive implant or the use
of implants in two affected eyes. However, there are several non-randomised trials, with 12–24 months of
follow-up, that allow the use of repeat implants.18,50,51 These studies consistently report that, after around
6 months, patients’ outcomes return to those at baseline and that up to three repeat implants are each likely to
have a similar treatment effect. Given the limited evidence around repeat implants, this was explored within
sensitivity analysis. In one of the studies that assessed implants in both eyes, 3 out of 11 patients (27%) receiving
implants had a response (reduced central retinal thickness and improved BCVA) in the second eye.18 Clinical
advisors to the AG suggested that it is more likely that systemic treatment would be used if both eyes required
treatment; however, the direction of the ICER for treatment in both eyes compared with one eye is considered in
Chapter 6.
Comparators
The two technologies were compared independently with current practice, which includes a range of
immunosuppressants (such as methotrexate, mycophenolate mofetil, ciclosporin and azathioprine) and
corticosteroids. Given the concerns regarding the robustness of undertaking a NMA (see Chapter 3,
Indirect comparison of treatments: rationale for not undertaking), within the base-case analysis, current
practice was assumed to be equivalent to practice in the control arm (sham or placebo) of the clinical trials
of the interventions. In the VISUAL trials of ADA,46,47 patients received initial corticosteroids, which were
tapered by 15 weeks (VISUAL I46) and 19 weeks (VISUAL II47), and 32% in the VISUAL I trial46 and 48% in
the VISUAL II47 study were receiving one immunosuppressant at baseline (across arms), which they were
able to maintain according to the study protocol. Given that a greater proportion of patients in practice are
likely to receive systemic corticosteroids, these comparators are denoted throughout as limited current
practice based on the VISUAL I trial [LCP(VI)] or the VISUAL II trial [LCP(VII)]. In the HURON trial of DEX,48
patients were allowed to receive rescue therapy with corticosteroids or immunosuppressants and 25%
were using systemic immunosuppressants or anti-inflammatory treatment at baseline, which they were
able to maintain according to the study protocol. This comparator is denoted throughout as limited current
practice based on the HURON trial [LCP(H)]. Apart from rescue therapy with immunosuppressants within
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the HURON trial, the proportions receiving immunosuppressants and corticosteroids were similar across the
arms of the HURON48 and VISUAL I46 and II47 trials. In current practice, a greater proportion of patients
would receive systemic immunosuppressants or anti-inflammatory treatment than in the control arms of
the pivotal studies; consequently, the base-case analysis is likely to underestimate both the effectiveness
and the AE profile of current practice, as well as the costs associated with treatment. Within exploratory
analyses, the AG assessed the impact on the results of increasing the value of these parameters within the
model. However, it should also be noted that in clinical practice a greater proportion of patients being
treated with ADA and DEX are also likely to receive concomitant treatment.
Outcomes
The model was used to estimate the incremental cost per QALY gained for each intervention compared
with current practice.
The VISUAL trials and the HURON trial48 each reported VFQ-25 HRQoL data at baseline and at each
follow-up visit. The VISUAL trials46,47 also reported EQ-5D data at baseline and at each follow-up visit. The
model used the EQ-5D data directly for modelling the effectiveness of ADA. The HURON trial48 reported
EQ-5D data at baseline but not at subsequent time points. It was therefore not possible to use the EQ-5D
data directly; however, Allergan shared patient-level data from the HURON trial with the AG, which
allowed an analysis of the relationship between the VFQ-25 and the EQ-5D using the baseline data (see
Model structure). It was necessary to convert VFQ-25 data to EQ-5D utilities to estimate QALYs associated
with treatment with DEX and LCP(H).104
The use of the outcomes from the HURON trial48 representing vision and inflammation (visual acuity, VH)
was considered by the AG as an alternative to the use of the VFQ-25 for estimating QALYs; however, the
VFQ-25 outcome was preferred because of the difficulties associated with using vision as an outcome in
uveitis and capturing all impacts of the interventions (see Chapter 1, Description of the health problem).
Clinical advisors to the AG suggested that clinicians measure ocular outcomes based on multiple factors,
including visual acuity, VH and macular oedema. The VFQ-25 captures multiple components of vision, as
well as broader considerations such as general health and the vision-related impact on the ability to drive
and undertake normal activities. It is also essential to capture the AEs associated with the treatments and it
is difficult to determine the utility decrements associated with the multiple interacting AEs associated with
these treatments. The AG considered that the VFQ-25 should largely capture the impact of AEs, as well as
treatment effects, on HRQoL.
The presence of unilateral or bilateral uveitis is important in terms of estimating outcomes for several
reasons. The BCVA in the better-seeing eye is more representative of quality of life than the BCVA in the
worst-seeing eye.105 In addition, a patient with bilateral disease is expected to have a lower quality of life
on average than a patient with unilateral disease. Thus, a person with bilateral disease has more scope to
benefit from treatment. However, in patients with bilateral disease receiving local treatment, the choice of
study eye is important in determining the extent to which quality of life can increase.
In the VISUAL I46 and VISUAL II47 trials, 91% and 96% of patients had bilateral disease respectively. Clinical
advice received by the AG suggests that this is representative of patients who would be given ADA in
practice because it is a systemic treatment. Within the HURON trial48 it was not recorded whether patients
had unilateral or bilateral disease. Based on the patient-level data provided by Allergan, the proportion of
patients with VH that was greater than zero in the non-study eye was 51%; clinical advisors to the AG
stated that this suggests that ≥ 51% of patients had bilateral disease. Within the HURON trial,48 when
patients had bilateral uveitis, the right eye was chosen for treatment. This resulted in the better-seeing eye
being treated in 10.7% and 17.1% of cases for DEX 700 and the sham procedure respectively.
Given that the presence of unilateral or bilateral uveitis was not reported in the HURON trial,48 it was not
possible for the AG to undertake robust subgroup analysis around this factor. The base-case model is
therefore dependent on the assumption that the patients included within the HURON trial and the way in
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which DEX was used within the trial would be representative of current practice. It was not possible to draw
robust conclusions about the subgroups separately in terms of cost-effectiveness; however, an exploratory
subgroup analysis was undertaken (see Model evaluation methods). As described within Chapter 1 (see
Description of the health problem), it is expected that around 70–80% of this patient population would
have bilateral disease. However, it may be that, because DEX is a local treatment, patients with unilateral
disease would be more likely to be selected for DEX treatment, both within the trial and in practice. Given
that patients with bilateral disease have a greater capacity to benefit from treatment because of the BCVA
of the better-seeing eye being the best predictor of quality of life, and that treatment of one eye would cost
the same whether given to a person with unilateral or bilateral disease, if the trial had a lower proportion of
bilateral cases than in practice, the effectiveness of DEX may be underestimated. Conversely, if the trial had
a higher proportion of bilateral cases than in practice, the effectiveness of DEX may be overestimated.
Time horizon
The time horizon of the model was the lifetime of patients (up to age 100 years) and a starting age of 44.8
years was used, representing the average age of patients with non-infectious posterior segment-involving uveitis
within the HURON trial.48 A cycle length of 2 weeks was chosen as this is the time between administration of
ADA doses and assessment of patients for disease progression. This is also a sufficiently short cycle length to
capture all relevant clinical events associated with DEX and current practice.
Discounting
All costs and QALYs were discounted at a rate of 3.5% per year.
Model structure
The structure of the AG model is presented in Figure 8. The model includes five health states: (1) treatment:
no permanent blindness, (2) treatment failure: no permanent blindness, (3) permanent blindness, (4) remission
(no treatment) and (5) death. For DEX, treatment was one implant, which was assumed to be effective for
6 months, at which time patients move to the treatment failure health state if they have remained in the
treatment state until this time. Patients in the LCP(H) group begin in the treatment failure health state.
Patients may discontinue ADA because of treatment failure, defined by the VISUAL trial criteria,46,47 at which
time they will move to the treatment failure health state if they have remained in the treatment state until this
time. Patients in the LCP(VI) and LCP(VII) groups also begin in the treatment health state and move to the
treatment failure health state once they have met criteria for treatment failure. Within the treatment health
state, HRQoL (defined using the VFQ-25 or EQ-5D) can be improved as a result of the treatment effect or as a
result of a reduction in AEs. The HRQoL estimates should capture any impacts of the interventions on visual
loss while treatment is provided. However, treatment may also reduce the risk of experiencing permanent
damage to the eye, resulting in a decreased risk of permanent legal blindness. Once a patient experiences
legal blindness in the model, they can either remain in this health state or progress to death.
On treatment
Remission
Death
Permanent
blindness
Treatment failure/
end of treatment effect
FIGURE 8 State transition diagram of the decision model.
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Patients may also enter remission, whereby they do not receive further treatment but they continue
to receive the benefits of the previous treatment. Within the base case, the proportion of patients
experiencing remission was assumed to be zero; the impact of increasing this proportion was considered
within the exploratory analyses.
Estimation of model parameters
Treatment discontinuation
In the base-case analysis, the DEX implant was assumed to be administered only once to one eye and to
have an efficacy of 30 weeks, based on data from the HURON trial.48
Patients could discontinue ADA as a consequence of any of the four criteria for treatment failure used
within the VISUAL trials,46,47 including (1) the development of new inflammatory lesions, (2) worsening of
AC cell grade, (3) worsening of VH grade or (4) worsening of visual acuity. Treatment discontinuation was
modelled using parametric curves fitted to Kaplan–Meier curves for time to treatment failure from the
trials. The Kaplan–Meier curves for time to treatment failure included in the VISUAL I52 and II72 clinical
study reports were digitised and individual patient data were reconstructed using the methods described
by Guyot et al.106 A number of parametric curves were fitted to the data using the flexsurv R package
(R version 3.3.2, flexsurv version 1.0.0; The R Foundation for Statistical Computing, Vienna, Austria).
Tables 30 and 31 present the Akaike information criterion (AIC) and Bayesian information criterion (BIC)
scores for statistical goodness of fit.
It should be noted that these are relative measures of goodness of fit and it is possible that other models
not tested here could provide a better fit to the data. Figures 9–12 show the Kaplan–Meier data and the
fitted parametric distributions for the VISUAL I46 and II47 trials for the ADA and comparator groups.
The statistical analysis suggested that, of those tested, the parametric distributions with the best fit to the
data were the Gompertz and the log-normal distributions for both the ADA group and the placebo group
in the VISUAL I46 and II47 trials. Clinical advisors to the AG suggested that it is clinically plausible that some
patients would remain on ADA for years; hence, the plateauing of these curves seems potentially
TABLE 30 Akaike information criterion and BIC scores for parametric curves fitted to the Kaplan–Meier curves for
time to treatment failure in the ADA arm in the VISUAL I trial46
Criterion Arm Log-normal Gamma Weibull Gompertz Exponential Log-logistic
AIC ADA 374.7 388.5 384.7 370.3 403.4 377.5
Placebo 435.9 465.7 456.5 438.4 486.7 438.9
BIC ADA 377.4 391.2 387.4 373.0 407.1 380.2
Placebo 438.5 468.4 459.2 441.1 490.3 441.5
TABLE 31 Akaike information criterion and BIC scores for parametric curves fitted to the Kaplan–Meier curves for
time to treatment failure in the ADA arm in the VISUAL II trial47
Criterion Arm Log-normal Gamma Weibull Gompertz Exponential Log-logistic
AIC ADA 370.6 378.9 377.3 364.9 382.2 373.1
Placebo 403.5 408.4 406.1 403.7 428.5 403.2
BIC ADA 373.3 381.6 380.0 367.7 385.9 375.8
Placebo 406.2 411.2 408.8 406.4 432.3 406.0
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reasonable. However, the Gompertz curve seems clinically implausible as observational studies of ADA in
similar patient populations have suggested that patients are likely to continue to fail treatment in the
longer term.107,108 The log-normal distribution appears to be the most plausible for the placebo arm so
that patients do fail on treatment relatively quickly. The log-normal distribution also appears clinically
reasonable for the ADA group. It should be noted that, although based on these predictions alone some
patients would continue to receive treatment for an implausibly long period of time, within the model
patients may die of other causes, which negates the need for a cure model to be employed.
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FIGURE 9 Observed and fitted curves for time to treatment discontinuation in the ADA arm in the VISUAL I trial.
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FIGURE 10 Observed and fitted curves for time to treatment discontinuation in the placebo arm in the VISUAL I
trial.
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It was assumed that after patients fail and discontinue treatment with ADA, or 6 months after the DEX
implant is injected, patients receive limited current practice, which includes a range of immunosuppressants
(such as methotrexate, mycophenolate mofetil, ciclosporin and azathioprine) and corticosteroids for a
proportion of patients. It was also assumed that ADA and DEX are effective only while they are being given.
Therefore, patients who are no longer being treated with ADA, and patients who received the DEX implant
> 6 months ago, accrue no additional health gains.
Permanent legal blindness
The VISUAL46,47 and HURON48 trials did not report any occurrence of blindness, which is likely to be
because of the short duration of these trials. However, it may be that the use of ADA or DEX could
prevent damage to the eye, which may in turn prevent future blindness. Conversely, it is possible that the
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FIGURE 11 Observed and fitted curves for time to treatment discontinuation in the ADA arm in the VISUAL II trial.
0
0.0
0.2
0.4
Pr
o
b
ab
ili
ty
 o
f 
su
rv
iv
al
0.6
0.8
1.0
5 10 15 20 25
Time (months)
Gamma
Log-normal
Weibull
Gompertz
Exponential
Log-logistic
FIGURE 12 Observed and fitted curves for time to treatment discontinuation in the placebo arm in the VISUAL II
trial.
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AEs associated with treatment (such as raised IOP) could lead to an increased risk of blindness via
glaucoma. There is no evidence about any longer-term (positive or negative) impacts of the interventions
on vision loss beyond the treatment duration. As such, it was not possible to include a complex model of
long-term outcomes associated with the interventions. However, as these interventions ultimately aim to
reduce permanent damage to the eye, a state for becoming permanently legally blind was included as this
has the largest impact on quality of life and costs.
We defined blindness as a BCVA of ≤ 20/200 in the better-seeing eye, according to the UK definition of
legal blindness.109 The AG considered two approaches for modelling permanent blindness based on the
evidence from the key RCTs. The first was to extrapolate the decrease in BCVA over time using the mean
change and distribution from the trials and estimate the proportion of patients who would go below the
legal blindness threshold in each group. The AG considered that this approach had three weaknesses:
(1) the follow-up period of the clinical trials was not long enough to capture the total impact on visual
acuity because damage to the eye does not always immediately impact on visual acuity; (2) there are
different trajectories according to the cause of the damage to the eye, which could not be appropriately
captured by a single parametric distribution; and (3) for patients with unilateral disease, additional
assumptions about the probability of blindness in both eyes would need to be made.
The second approach considered by the AG was to use outcomes from the trials such as glaucoma and
macular oedema as surrogate outcomes for blindness in the future. In principle, this would allow a more
accurate estimate of blindness over time to be made, and could exclude outcomes such as cataract, for
which blindness is reversible through surgery. However, the AG did not identify any evidence that could
provide a link between these shorter-term outcomes and blindness. The only evidence of blindness caused
by uveitis identified by the AG was cross-sectional and did not specify time to blindness.18,27 This means
that populating the model would have required elicitation or an assumed distribution for how long it
would take patients to become blind and for this to be extended beyond the period of the cross-sectional
study data. In addition, the key long-term outcome to include in the model is blindness in both eyes, given
that the BCVA in the better eye is the best predictor of quality of life and blindness in both eyes would
incur the greatest costs. The cross-sectional studies do not provide sufficient information to estimate the
probability of blindness in both eyes; hence, numerous assumptions would be required. The identified
studies also include patients with anterior uveitis. The AG requested the patient-level data from the
authors of one of the cross-sectional studies18 to be able to predict blindness over time from the outcomes
reported within the clinical trials; however, these data were not provided. Given the number of
assumptions that would be required to undertake this analysis in the absence of patient-level data, and the
low proportions of patients reported to have glaucoma (< 3% in any arm) and new cases of macular
oedema (< 8% in any arm) in the clinical trials,46–48 the AG decided that adopting such a complex analysis
within the model may produce potentially misleading results.
Therefore, a simpler approach was taken and the assumptions were tested within exploratory analyses.
For the base-case analysis, clinical experts to the AG helped to identify sources that could be used to
estimate a constant blindness rate associated with (limited) current practice. All studies identified were
cross-sectional rather than longitudinal. The best source of evidence was considered to be a study by Dick
et al.,19 a retrospective analysis of insurance claims data, because all patients (n = 1769) had posterior
segment, non-infectious uveitis. A constant rate of blindness and uncertainty around this parameter was
estimated by the AG based on the proportion of patients going blind within the study by Dick et al.19 and
the mean follow-up time. By 10 years, this study predicted that 6.6% of patients would go legally blind,
in the absence of death from other causes. The proportions of patients who had unilateral and bilateral
disease are not reported within the study. Two alternative similar sources were also identified as being
potentially relevant, studies by Tomkins-Netzer et al.18 and Durrani et al.11 The constant blindness rate
derived from the study by Tomkins-Netzer et al.18 was deemed to be an underestimate by one of the
clinicians consulted by the AG (Alastair Denniston, personal communication) and the study included a
wider population than the target population of the current appraisal (including patients with infectious and
anterior uveitis). The rate derived from the study by Durrani et al.11 was substantially higher than the rate
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derived from Dick et al.19 but this study also included a wider population. As the authors warned, ‘being a
tertiary referral centre, more patients are likely to suffer from severe, often bilateral uveitis’ and they
acknowledged that the results of their study ‘could not be applied to the general population because of
the tertiary nature of the patient population’.11 The AG explored the impact of using blindness rates based
on these other two sources in exploratory analyses (see Exploratory sensitivity analyses and Results).
As discussed earlier, there is no evidence on the treatment effect of ADA or DEX on legal blindness.
To model the impact of treatment with ADA on the rate of blindness, given the strict criteria for treatment
failure within the VISUAL trials,46,47 it was assumed that patients could not go blind before treatment
failure. This was assumed for both the intervention and the comparator. The rate of blindness following
treatment failure was then approximated so that the rate of blindness at each cycle in the placebo group
was equivalent to the estimate from Dick et al.19 It was not considered clinically reasonable that a DEX
implant would prevent all cases of blindness during treatment, but it was deemed equally unreasonable to
assume that it would prevent no cases of blindness. In light of the absence of evidence around this
parameter, the AG sampled from a uniform distribution between 0 and 1 within the PSA and used the
mean of this distribution (0.5) for the deterministic analysis. Therefore, the AG assumed that half of the
cases of blindness in this group would be avoided for the period in which the treatment effect was applied
(30 weeks in the base case). It was assumed that patients in the comparator group would have the same
blindness rate as in the general population.
The AG heard from clinicians that around 20–30% of patients with uveitis remain unilateral and that
patients treated with DEX are more likely to be unilateral. The AG assumed that patients who remained
unilateral would not go blind and therefore the rate of blindness in the DEX target population would be
lower than that in the general population and this is turn would be lower than that in the ADA target
population. For the base case, the AG assumed that, in the general population, 25% of patients would
remain unilateral whereas in the DEX target population 30% of patients would remain unilateral. For ADA,
the proportions of patients with unilateral uveitis as reported in the VISUAL I46 (9.2%) and VISUAL II47
(4.4%) trials were used for active and inactive patients respectively. The blindness rate for bilateral patients
was determined by dividing the blindness rate estimated from Dick et al.19 by the proportion of bilateral
patients in the general population. The incidence of blindness in each analysis was adjusted by multiplying
the rate of blindness for bilateral patients by the proportion of bilateral patients in each population.
Adverse events
One of the key drivers for new treatment options is the substantial AE profile of existing treatments, which
reduce HRQoL and incur treatment costs. In addition, treatment with ADA and DEX is associated with AEs.
Given that the main outcome measures being used from the clinical trials were the VFQ-25 and EQ-5D,
it was assumed that these will capture the quality-of-life impacts associated with AEs during the period
in which the treatments are provided. The incidence of AEs from the trials was therefore used only to
calculate the additional costs associated with their management. As such, AEs included within the model
are limited to those for which the cost of treatment is substantial. Based on advice from the clinical experts
to the AG, the AEs associated with substantial costs of treatment are cataract, raised IOP, glaucoma,
serious infections, hypertension, fractures and diabetes.
There are no longer-term safety data for ADA and DEX for uveitis beyond the data reported within the key
clinical trials.46–48 However, Burmester et al.110 reported the results of a study on the long-term safety of
ADA in 23,458 patients with other indications compared with the general population in terms of the
incidence of disease. The study found that overall malignancy and lymphoma rates were not increased as a
result of ADA use. Although the incidence of non-melanoma skin cancer was greater for patients receiving
ADA for some of the indications included, for all indications death rates were equivalent to or lower than
those expected in the general population. Given the findings of this study, the model does not include any
longer-term cumulative impacts of ADA on patient outcomes. For DEX, the model assumed that patients
will receive only one implant. The application of more than one implant is considered later in the
discussion section.
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There is no clinical rationale for the AEs associated with corticosteroid use to differ between study arms
because usage is similar between the arms within the trials. Therefore, although diabetes and osteoporosis
are associated with substantial costs, there are no real differences in incidence between the arms of the trials.
Within the exploratory analysis assessing the impact of greater corticosteroid use in the comparator groups,
the proportion of patients with these AEs was increased according to their incidence in the MUST trial.57
The probabilities of AEs per cycle used in the model (Table 32) were calculated based on their incidence in
the trials and the mean follow-up time of each trial.
Quality of life
Estimating the relationship between the Visual Function Questionnaire and the EuroQol-5
Dimensions The AG considered the published studies for mapping the VFQ-25 to the EQ-5D included
in the database of mapping studies by Dakin.111 However, none of the published mapping studies was
based on a population with uveitis and, considering that the AG had access to the VFQ-25 and EQ-5D
patient-level data at baseline from the HURON trial,48 the AG decided to fit a new mapping model. The
AG used the approach that produced the best fit according to Browne et al.112 (ordinary least squares) and
noticed that the mapping resulted in similar coefficient values to those presented by Payakachat et al.,113
who used an alternative modelling method (censored least absolute deviation). The mapping was used for
all of the analyses involving DEX, within the exploratory analyses comparing the interventions with current
practice, as provided in the MUST trial,57 and within a sensitivity analysis for ADA.
The patient-level data from the HURON trial48 were used to test for a correlation between the VFQ-25
and the EQ-5D at baseline. The scatterplot is presented in Figure 13. A linear regression model was fitted
to the data to predict EQ-5D utilities from VFQ-25 scores. One regression model was fitted to all three
arms of the HURON trial (sham, DEX 350 implant and DEX 700 implant) to maximise the sample size for
the regression analysis. The underlying assumption was that the relationship between VFQ-25 scores and
EQ-5D utilities would be independent of treatment. The fitted regression used in the economic model was:
EQ-5D utility = 0:4454059 + VFQ-25 score × 0:0051322. (1)
It is recognised that a linear model is not bounded and is likely to have poor performance for utility values
at the extremes. However, given that the mapping was only used for means, no extreme values were used.
Alternative non-linear models (e.g. quadratic regression) were also tested but did not significantly improve
the fit to the data. The variance–covariance matrix of the slope and the intercept of the regression model is
presented in Table 33. To represent the uncertainty in the regression model, the matrix was used to
TABLE 32 Probability of AEs per cycle
AE DEX 700 LCP(H)
Active uveitis Inactive uveitis
SSIADA LCP(VI) ADA LCP(VII)
Raised IOP 0.019 0.005 0.002 0.002 0.001 0.001 0.001
Cataract 0.016 0.011 0.002 0.002 0.001 0.003 0.008
Glaucoma 0.000 0.002 0.001 0.000 0.000 0.000 0.001
Hypertension 0.002 0.003 0.002 0.001 0.003 0.003 0.002
Serious infections 0.000 0.000 0.003 0.003 0.001 0.001 0.000
Fracture 0.000 0.000 0.000 0.000 0.000 0.000 0.002
Diabetes 0.000 0.000 0.000 0.000 0.000 0.000 0.001
SSI, systemic steroids and immunosuppressants.
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sample the two coefficients of the regression model in the PSA. The baseline utilities, that is, the utilities
for patients at week 0, were estimated based on the patient-level data from each trial: the HURON trial48
for DEX and its comparator [LCP(H)], the VISUAL I trial46 for ADA and its comparator in active patients
[LCP(VI)] and the VISUAL II trial for ADA and its comparator in inactive patients [LCP(VII)]. In the HURON
trial,48 the baseline utility and visual acuity were substantially different between the sham arm and the
DEX arm (visual acuity was 71.3 for the sham arm and 63.7 for the DEX 700 arm). Clinical advisors to the
AG were asked to consider whether or not the baseline difference in both utility and visual acuity were
reasonably due to random variation. All three experts agreed that a difference in visual acuity of ≥ 10 letters
is considered to be clinically significant and a difference below this level could be owing to random variation
and therefore it is plausible that the difference between the arms at baseline in the HURON trial was due to
random variation. The baseline utilities were not varied to represent any population subgroups because
these data were not available from the trials. The impact of changing the baseline utility has been assessed
within the univariate sensitivity analysis; however, this analysis assumes that the relative treatment effect
remains the same. This is unlikely to be the case for subgroups with differing baseline utilities such as
patients with unilateral or bilateral uveitis. However, there is no evidence from the trials around outcomes
for these subgroups that would enable a robust subgroup analysis.
Estimating utility over time The VFQ-25 data from each follow-up point within the HURON trial48
(weeks 0, 8, 16 and 26) and the EQ-5D data from each follow-up point of the VISUAL trials46,47 (weeks 0,
1, 4, 6, 8, 12, 16, 20, 24, 27 and 32 and then every 4 weeks until week 80) were used to estimate the
change in utility for each treatment group over the time period of the trials. These were adjusted
according to the average baseline utilities but maintaining the change from baseline in each arm.
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FIGURE 13 The relationship between the VFQ-25 and the EQ-5D based on patient-level data from the
HURON trial.48
TABLE 33 Variance–covariance matrix of the intercept and the covariate of the regression model
Intercept VFQ-25
Intercept 1.75E-03
VFQ-25 –2.42E-05 3.63E-07
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When comparing DEX with its comparator, the AG assumed that the utility of patients who received DEX
would drop to that of patients in the comparator arm after the duration of the treatment effect. Within
the base-case analysis, the treatment effect was assumed to last for 30 weeks (4 weeks longer than the
trial period). Within the sensitivity analyses the utility was assumed to decrease to the baseline utility over
varying time periods. When comparing ADA with its comparator, for patients who fail and hence
discontinue treatment it was assumed that utility returns to the baseline utility score, adjusted for any
reduction in utility associated with age. For patients who receive ADA beyond the duration of the trial
(80 weeks), it was assumed that their utility remains constant after the last follow-up point until treatment
discontinuation. This utility is based on the mean of the last 6 months of data. Figures 14–16 present the
predicted mean utility values over time, excluding any adjustments for blindness, for DEX compared with
LCP(H) for active patients, ADA compared with LCP(VI) for active patients and ADA compared with LCP(VII)
for inactive patients respectively.
Age adjustments to utility were based on the regression equation reported by Ara and Brazier.114
Age-related utility was calculated using the following formula:
Utility = A × (Male) + B × (Age) + C × (Age × Age) + D, (2)
where A = 0.0212126, B = –0.0002587, C = –0.0000332 and D = 0.9508566.
The ratio between the utility for the general population at the starting age and that of the mean cohort
age at each cycle was applied within the model.
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FIGURE 14 Mean utilities for DEX compared with LCP(H) for active patients over time.
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FIGURE 15 Mean utilities for ADA compared with LCP(VI) for active patients over time.
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Adverse events Given that the main outcome measures being used from the clinical trials are the
VFQ-25 and EQ-5D, it was assumed that these will capture the quality-of-life impacts associated with AEs
during the period in which the treatments are provided.
Utilities associated with blindness Two UK-based studies report utilities associated with blindness,109,115
which the AG thought to be the best sources of evidence. Both studies have been used within previous
NICE appraisals.116–120 Czoski-Murray et al.109 used contact lenses to simulate blindness associated with
macular degeneration, whereas Brown115 estimated utilities according to valuations by patients with a range
of conditions associated with blindness. The AG used the time trade-off values reported in these studies. Each
study provided utilities for different levels of blindness and the AG calculated a weighted average based on
the number of patients within the studies falling into each category. This assumed that patients with uveitis
would have a similar distribution for the severity of blindness. The study by Czoski-Murray et al.109 was used in
the base-case analysis as it was based on public valuations of utility; however, it does not provide utilities for
the worst states of blindness and may therefore overestimate the overall utility associated with blindness. This
resulted in a utility associated with blindness of 0.38. Uncertainty around this parameter was modelled using
the variance–covariance matrix provided within the study. The utility estimated from the study by Brown115
(0.57) was employed within sensitivity analysis.
Resource use and costs
Treatment costs The costs of ADA, DEX, immunosuppressants and corticosteroids were based on the
latest drug tariff.49 Drug acquisition costs included within the model are presented in Table 34.
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FIGURE 16 Mean utilities for ADA compared with LCP(VII) for inactive patients over time.
TABLE 34 Drug acquisition costs
Drug Dose Brand name 6-monthly cost (£)
ADA 40mg every 2 weeks Humira 4578
DEX One 0.7-mg implant Ozurdex 870
Mycophenolate mofetil 1 g twice daily NA 136
Methotrexate 15 mg weekly NA 16
Ciclosporin 2 mg/kg twice daily NA 985
Azathioprine 1 mg/kg daily NA 27
Systemic prednisolone 7.5 mg daily NA 12
NA, not applicable.
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The cost of treatment with immunosuppressants was calculated separately for each comparison [DEX vs.
LCP(H), ADA vs. LCP(VI) and ADA vs. LCP(VII)] as a weighted average of mycophenolate mofetil,
methotrexate, ciclosporin and azathioprine, based on their usage in the relevant trials (HURON,48 VISUAL I46
and VISUAL II47).
The two arms of each clinical trial were similar in terms of the use of corticosteroids and other
medications, when reported. There was, however, an imbalance in the use of rescue therapy within the
HURON trial.48 The clinical study report states that the proportions of patients who received rescue therapy,
which involved systemic and local corticosteroid use and immunosuppressants, in the DEX arm and the
sham arm were 22.1% and 38.2% respectively.71 Based on the patient-level data from the HURON trial,48
the largest imbalance is in the provision of immunosuppressants as rescue therapy; these therapies are also
more costly than corticosteroids. Of those patients who were not already taking immunosuppressants at
baseline, only one patient from the DEX arm (1.3%) received an immunosuppressant whereas eight
patients in the sham arm (10.5%) received an immunosuppressant. Of these, three patients received an
immunosuppressant for 1–2 months and the remaining five patients did not stop immunosuppressant use
within the trial period. This suggests that DEX may reduce the need for immunosuppressants. The model
includes the costs of the additional immunosuppressants provided to the proportion of patients receiving
this rescue therapy. The use of corticosteroid rescue therapy within the HURON trial48 was more similar
between the DEX group and the sham group (20.7% for DEX vs. 27.7% for sham) and such therapy is
generally provided for only 2–4 weeks based on the patient-level data. Given that corticosteroids are
inexpensive, this would result in a minimal cost difference between the groups and hence these costs have
not been incorporated within the model. Within the base case, all other treatment costs were assumed to
be the same between the DEX group and the LCP(H) group and between the ADA group and the LCP(VI)/
LCP(VII) groups. An exploratory analysis was undertaken to explore the impact of an increase in the costs
and utilities of the comparators.
Administration costs The DEX implant was assumed to be administered within one outpatient
appointment at a cost of £113.42, based on NHS Reference Costs 2014–15121 (minor vitreous retinal
procedures, ≥ 19 years). ADA was assumed to be self-administered; the base-case model assumed that
10% of patients will need help from a district nurse to administer the injections, at a cost of £44, based on
Unit Costs of Health and Social Care 2015122 (district nurse cost per hour). All other treatments would be
administered by the patient and therefore there would be no extra costs of administration for
corticosteroids or immunosuppressants.
Monitoring costs The model assumed that all patients would receive monitoring every 6 weeks,
irrespective of treatment. Monitoring consists of outpatient visits for visual function monitoring to assess
the efficacy of the treatments and to monitor the risk of AEs. The AG assumed that monitoring for AEs
was conducted alongside regular visual function monitoring follow-ups. It was also assumed that patients
receiving immunosuppressants would receive six additional blood monitoring visits annually. Both regular
monitoring and blood monitoring appointments were assumed to cost £96.11, based on NHS Reference
Costs 2014–15121 (outpatient attendance visit, ophthalmology, face-to-face visit).
Cost of adverse events The management of cataract and glaucoma was based on surgery costs taken
from NHS Reference Costs 2014–15.121 Raised IOP was assumed to be treated with two doses of bimatoprost
(Lumigan®, Allergan) on average (most patients will need just one dose but others will need many). Serious
infection was assumed to be treated with hospitalisation and the cost was based on an average of NHS
Reference Costs 2014–15 for the infections reported within the VISUAL trials.46,47 Treatment for hypertension
was based on the cost of antihypertensive treatment taken from the study by Breeze et al.123
A focused search was undertaken in October 2016 to identify cost and utility studies of blindness
(see Appendix 1 for the MEDLINE search strategy). Free-text terms for blindness and sight or vision loss
(in the titles field) were combined with either an economic filter (balance of sensitivity and sensitivity) or a
sensitive quality-of-life studies filter. The search was carried out in MEDLINE and MEDLINE-in-Process &
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Other Non-Indexed Citations (Ovid). The search for cost studies was limited from 2006 until 2016. Based
on this review, the AG considered that the most recent good-quality evidence associated with the costs of
blindness was presented within a health technology assessment of treatment for age-related macular
degeneration.124 The costs of each component included within the calculation of the total annual cost of
blindness to the NHS and PSS have been updated with the most recent data and uplifted to 2015 prices
using the Hospital & Community Health Services index,122 as shown in Table 35.
Fracture and diabetes have been shown to be the largest cost items associated with the long-term use of
corticosteroids.31 The cost of fracture was based on evidence from a HTA monograph by Davis et al.127 and
includes the costs of hospitalisations, accident and emergency visits, referrals, prescriptions and general
practitioner contacts. The cost of diabetes was based on the annual hospitalisation cost from the UK
Prospective Diabetes Study, which is the largest study of the costs of diabetes and its complications in the
UK,128 and the treatment costs from the study by Breeze et al.123 Table 36 summarises the resource use
and costs associated with the AEs included in the model.
Corticosteroid sparing An important reason for developing new technologies is that existing treatments
for non-infectious uveitis are associated with substantial AEs. In particular, long-term high-dose systemic
corticosteroid use is associated with significant morbidity, including glaucoma, raised blood pressure,
diabetes and osteoporosis.41,42 Ideally, corticosteroid-sparing benefits would be taken into account in the
comparison with current treatment. However, the VISUAL trials46,47 did not allow corticosteroid use in either
arm following the initial corticosteroid burst and taper and in the HURON trial48 there was a minimal
difference in corticosteroid usage between the arms of the trial. If corticosteroid usage is higher in clinical
practice than in the trials, the effectiveness of the comparator may also increase, as well as the AE rate.
Corticosteroid-sparing treatment was considered only within the exploratory analyses, in which the
comparator was based on the MUST trial.57
Remission Based on advice received from the clinical advisors to the AG, an additional state was added
to the model to reflect the possibility of patients achieving remission after a stable period, for example
after 2 years on ADA. This would mean that patients would discontinue treatment on achieving remission
but continue to experience the benefits of ADA until they were predicted to fail treatment from the
extrapolated survival curves. Given that there is no evidence around this, within the base case we assumed
that no patients would be taken off treatment because of remission; however, alternative assumptions
around continued benefit following discontinuation because of remission were considered within the
exploratory analyses.
TABLE 35 Costs of blindness
Component
% of patients
receiving service Cost (£) Source
Blind registrationa 95 146 Meads and Hyde125
Low-vision aidsa 33 191 Meads and Hyde125
Low-vision rehabilitationa 11 329 Meads and Hyde125
Depression 39 2378c McCrone et al.126
Hip replacement 5 4086c NHS Reference Costs 2014–15121
Community care 6 281c Curtis and Burns122 (social care for older people)
Residential care 30 21,732b,c Curtis and Burns122 (private residential care)
Annual total 7659
a One-off cost.
b This cost assumes that 30% of patients receiving this service pay for themselves.
c Annual cost.
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Mortality
Mortality rates within the model were assumed to reflect those of the general population, based on the
most recent Office for National Statistics life tables for England.129
The model assumed that AEs have no impact on mortality, although it is recognised that in practice
diabetes, osteoporosis and blindness would have some impact on mortality.
Model evaluation methods
The cost-effectiveness results for DEX and ADA compared with limited current practice are presented
based on both the probabilistic and the deterministic versions of the model. In total, 5000 probabilistic
samples were run to estimate the expected costs and QALYs. Uncertainty surrounding incremental costs,
outcomes and cost-effectiveness was represented using CEACs and cost-effectiveness planes. It should,
however, be noted that the uncertainty analysis is likely to underestimate the true uncertainty surrounding
the cost-effectiveness of each option because of the numerous structural uncertainties associated with the
model that are not captured within the PSA. A range of exploratory scenario analyses were undertaken to
explore the sensitivity of the model results to key structural assumptions. A univariate sensitivity analysis
was also undertaken to explore the impact of alternative plausible parameters on the model results.
All model results are presented for the entire patient population of interest as evidence did not allow a
subgroup analysis to be undertaken; the potential direction of the results for key subgroups such as
patients with unilateral and bilateral uveitis are considered in the discussion section.
Probabilistic sensitivity analysis
To assess the uncertainty around the parameters used in the model, the AG defined probability distributions
for most parameters using the available evidence and undertook PSA. Gamma distributions were generally
used for costs and beta distributions for utility values and probabilities. The RR of blindness for DEX was
based on a uniform distribution because of a lack of evidence. Table 37 summarises the input parameters
and their base-case mean values and distributions used in the PSA. In addition to the parameters listed in
Table 37, beta distributions were defined for utility scores at each time point in each arm, as well as the
prevalence of concomitant therapy and the incidence of AEs and rescue therapy. Multivariate normal
distributions were used for the parameters of the survival curves used to determine time to treatment
failure. A Dirichlet distribution was used for the weight distribution of the cohort, which determined the
mean dose cost of azathioprine and ciclosporin.
TABLE 36 Resource use and costs associated with the included AEs
AE Resource use Cost (£) Frequency Source
Cataract Cataract surgery 852.40 One-off cost NHS Reference Costs 2014–15121
Raised IOP Treatment with two doses
of bimatoprost
23.42 One-off cost British National Formulary49
Glaucoma Glaucoma surgery 581.25 One-off cost NHS Reference Costs 2014–15121
Serious infection Hospitalisation 5940.50 One-off cost NHS Reference Costs 2014–15121
Hypertension Antihypertensive prescription 7.04 One-off cost Breeze et al.123
Permanent
blindness
See Table 35 237 Transition See Table 35
7659 Annual
Fracture Hospitalisations, accident
and emergency visits,
referrals, prescriptions and
general practitioner contacts
2116.17–6022.62
depending on age
and sex
One-off
fracture cost
Davis et al.127
Diabetes Diabetes treatment and
hospitalisation for
complications of diabetes
1521.46 Annual Alva et al.128 and Breeze et al.123
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TABLE 37 Model input parameters for the base-case scenario
Parameter Mean Distribution Source
Age (years) 44.8 Fixed
Discount rate (costs and utilities)
(%)
3.5 Fixed NICE104
Sex, male (%) 36.7 Fixed HURON trial48
Cycle length (weeks) 2 Fixed
Utilities
Baseline VFQ-25 score for
DEX and LCP(H) arms
66.63 Beta HURON trial (data on file)
Baseline EQ-5D score for
patients with active uveitis
0.83 Beta AbbVie52
Baseline EQ-5D score for
patients with inactive uveitis
0.85 Beta AbbVie72
Blindness utility 0.38 Multivariate normal (using
variance–covariance matrix)
Czoski-Murray et al.109
Regression model for relationship between VFQ-25 and EQ-5D scores
Intercept 0.445 Multivariate normal (using
variance–covariance matrix
in Table 33)
Based on patient-level data from
the HURON trial (data on file)
Slope 0.005
Proportion of bilateral patients (%)
General population 75 Beta Assumption
DEX population 70 Beta Assumption
Active uveitis population 90.8 Beta AbbVie52
Inactive uveitis population 95.6 Beta AbbVie72
Blindness
Probability of blindness
(annual)
0.0068 Beta Dick et al.19
RR of blindness for DEX
during 6-month period
following implantation
0.5 Uniform Assumption
RR of blindness for ADA
while on treatment
0 Fixed Assumption
Remission
Rate of remission when
treatment is stopped but the
treatment effect continues
0 Fixed Assumption
Drug costs (£)
DEX 700mg 870 Fixed BNF49
ADA 40mg 352.14 Fixed BNF49
Prednisolone 1.24 Fixed BNF49
Mycophenolate mophetil 9.31 Fixed BNF49
continued
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TABLE 37 Model input parameters for the base-case scenario (continued )
Parameter Mean Distribution Source
Methotrexate 2.40 Fixed BNF49
Ciclosporin 48.50 Fixed BNF49
Azathioprine 3.24 Fixed BNF49
Bimatoprost 11.71 Fixed BNF49
Adcal D3® (NextPharma,
Göttingen, Germany)
7.49 Fixed BNF49
Omeprazole 1.17 Fixed BNF49
Administration and monitoring
Monitoring visit frequency
(weeks)
6 Jabs et al.130
Monitoring visit cost (£) 96.11 Gamma NHS Reference Costs 2014–15121
(outpatient attendance,
ophthalmology, consultant-led)
DEX implant administration
cost (£)
113.42 Gamma NHS Reference Costs 2014–15121
(minor vitreous retinal procedures)
% of self-injectors needing
district nurse for ADA
10 Beta NICE131
ADA administration cost (£)
(patients who need help
from a nurse)
44 Gamma Curtis and Burns122 and NHS
Reference Costs 2014–15121
(district nurse)
AE costs (£)
Cataract surgery 852.40 Gamma NHS Reference Costs 2014–15121
(phacoemulsification cataract
extraction and lens implant,
with CC score 4+)
Raised IOP 23.42 Gamma BNF49
Glaucoma procedure 581.25 Gamma NHS Reference Costs 2014–15121
(weighted average of glaucoma
procedures)
Serious infection 5940.50 Gamma NHS Reference costs 2014–15121
[average of infection
hospitalisations (based on the
proportions of each infection in
the VISUAL trials46,47)]
Hypertension 7.04 Gamma Breeze et al.123
Blindness (transition) 237 Gamma See Table 35
Blindness (annual) 7659 Gamma See Table 35
Fracture 2116.17–6022.62 Gamma Davis et al.127
Diabetes 1521.46 Gamma Alva et al.128 and Breeze et al.123
BNF, British National Formulary.
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Exploratory sensitivity analyses
A number of exploratory analyses were undertaken to explore the uncertainties within the model.
Although there was a lack of evidence to fully inform these exploratory analyses, the aim was to provide
an indication of the impact of alternative assumptions on the results.
1. A greater proportion of patients are treated with immunosuppressants and corticosteroids in the
comparator groups. In clinical practice it would be expected that a higher proportion of patients would
receive systemic therapy. This would result in greater efficacy associated with the comparator, with a
higher AE rate and higher costs.
As discussed in Chapter 3 (see Indirect comparison of treatments: rationale for not undertaking), it was not
possible to undertake a NMA to compare DEX or ADA with an alternative comparator, which might be
more representative of current practice. However, the comparator arm of the MUST trial57 (identified within
the systematic review) was made up of patients who received systemic corticosteroids, supplemented in
86% of cases with immunosuppressants, and was thought by the clinical experts to the AG to be
reasonably representative of clinical practice. Hence, this study was used to inform an exploratory analysis.
This exploratory analysis was not undertaken for patients with inactive uveitis because the MUST trial
included only patients with active uveitis. For active patients, data from the comparator arm of the MUST
trial were used relating to (1) an estimate of the total proportion of patients receiving (i) corticosteroids and
(ii) immunosuppressants, to estimate costs; (2) an estimate of the HRQoL of patients; and (3) the rates of
any AEs associated with substantial resource use. With respect to the total proportion of patients receiving
corticosteroids and immunosuppressants, it was unclear from the MUST trial publication exactly which
immunosuppressants were used57 and hence the composition was assumed to be the same as that for the
VISUAL I trial.46 It should be noted that using the data from the MUST trial without performing any formal
mixed treatment comparison assumes that the trial population was comparable with the populations within
the VISUAL and HURON trials and does not include any measure of uncertainty around the comparison.
Within the base-case analysis, HRQoL was assumed to return to baseline levels following treatment failure
with ADA or after 6 months following DEX implantation. Given that the comparator arm patients were
able to receive immunosuppressants and corticosteroids, it was assumed within this exploratory analysis
that patients treated with ADA or DEX were also able to receive immunosuppressants and corticosteroids,
as in the comparator arm of the MUST trial following the end of treatment with the intervention. Therefore,
the overall effectiveness of DEX and ADA was expected to increase as well as the effectiveness of the
comparator.
The analysis assumed that treatment with prednisolone includes concomitant therapy with Adcal D3
(£47.58) and 20 mg of omeprazole once daily (£15.25).
2. Incidence and HRQoL impact of blindness. As there is limited evidence around the rate of legal
blindness for this patient group, and there is no evidence around the impact of treatment on this rate,
the AG performed exploratory analyses around these parameters. This was done by varying the rate of
legal blindness in patients with uveitis who are treated with (limited) current practice (from 0 to 0.0374)
based on alternative sources11,18 (see Permanent legal blindness) and varying the RR of legal blindness
cases avoided as a result of treatments (from 0 to 1).
These analyses were also undertaken using (1) alternative utilities from Brown115 and (2) a higher cost of
blindness based on the upper bound of the 95% CI for this parameter.
3. Patients who go into remission after ADA treatment. A proportion of patients who continue treatment
with ADA may achieve remission. The base-case analysis assumed that these patients would continue to
receive ADA until treatment failure; however, the clinical advisors to the AG suggested that, after
around 2 years of stable disease, patients may no longer require treatment but because they are in
remission they may maintain the same level of HRQoL as that while on treatment. This sensitivity
analysis therefore assessed the impact of assuming that, after 2 years on treatment, a varying
proportion of patients (0–1) would no longer receive ADA but their HRQoL would decrease only with
age, until the treatment failure curve predicts failure or they die from other causes.
4. Using the VFQ-25 data from the VISUAL trials of ADA46,47 to map to EQ-5D utility data. This sensitivity
analysis assessed the impact of using the regression analysis of the HURON trial data48 to map the VFQ-25
data from the VISUAL trials46,47 to EQ-5D utilities.
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5. Extrapolation of time to treatment discontinuation for ADA. The impact of using alternative plausible
parametric distributions (Weibull, Gompertz) for time to treatment discontinuation was explored.
6. Varying the time period over which the utility decreases to that of baseline after treatment. The
treatment effect beyond 6 months for DEX and beyond treatment discontinuation for ADA is unknown.
Within the base case, patients receiving DEX were assumed to take 4 weeks to return to baseline utility
beyond the trial follow-up of 6 months. HRQoL for patients receiving ADA was assumed to return to
baseline levels immediately on treatment discontinuation. Within this exploratory analysis the treatment
effect beyond 6 months for DEX was varied from 0 to 8 weeks and the treatment effect beyond
discontinuation for ADA was increased to 4 weeks.
Univariate sensitivity analyses
Each parameter within the base case was varied to assess its impact on the model results, as shown in
Table 38.
TABLE 38 Univariate sensitivity analyses
Parameters Mean
Lower
value
Upper
value Source
Utilities
Baseline 0.79 0.77 0.80 HURON trial individual patient data (data on file)
0.83 0.81 0.85 AbbVie52
0.85 0.83 0.87 AbbVie72
Blindness 0.35 0.28 0.42 Czoski-Murray et al.109
Administration and monitoring
Monitoring visit frequency (weeks) 6 4 8 Jabs et al.130
Monitoring visit cost (£) 96.11 77.27 114.95 NHS Reference Costs 2014–15121 (outpatient
attendance, ophthalmology, consultant-led)
DEX implant administration
cost (£)
113.42 91.15 135.65 NHS Reference Costs 2014–15121 (minor vitreous
retinal procedures)
% of self-injectors needing district
nurse for ADA
10 0 20 NICE131
ADA administration cost (£)
(patients who need help
from a nurse)
44 29.96 44.56 Curtis and Burns122
AE costs (£)
Raised IOP 23.42 11.71 46.84 BNF49
Cataract surgery 852.40 658.33 1019.47 NHS Reference Costs 2014–15121
(phacoemulsification cataract extraction and
lens implant, with CC score 4+)
Glaucoma procedure 581.25 467.32 695.17 NHS Reference Costs 2014–15121 (weighted
average of glaucoma procedures)
Hypertension 7.04 5.66 8.42 Breeze et al.123
Serious infections 5940.50 4776 7105 NHS Reference Costs 2014–15121 [average of
infection hospitalisations (based on the
proportions of each infection in the VISUAL
trials46,47)]
Blindness (transition) 236.95 191 283 See Table 35
Blindness (annual) 7658.71 6158 9160 See Table 35
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Results
Dexamethasone
Base case
The base-case results are presented in Table 39. Based on the probabilistic version of the model, a single
DEX implant combined with limited current practice as provided in the HURON trial48 [DEX 700 + LCP(H)]
was estimated to produce 0.029 incremental QALYs compared with LCP(H) alone at an additional cost of
£573, resulting in an ICER of £19,509 per QALY gained. Figure 17 presents the CEAC. Assuming WTP
thresholds of £20,000 and £30,000 per QALY gained, the probability that a single DEX implant produces
more net benefit than LCP(H) is estimated to be 0.47 and 0.72 respectively. The deterministic results were
similar to those generated using the probabilistic model (Table 40), with an estimated ICER of £20,058 per
QALY gained for DEX 700 + LCP(H) compared with LCP(H). A breakdown of the results of the deterministic
analysis is provided in Appendix 7.
The small differences in both costs and QALYs between the two groups mean that the ICER is very sensitive
to alternative model parameters and assumptions, as shown within subsequent sensitivity analyses.
TABLE 39 Results of the base-case analysis comparing DEX 700 with LCP(H): probabilistic model
Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Probability of
cost-effectiveness
at WTP threshold of
£20,000 £30,000
LCP(H)a 14.599 39,992 0.53 0.28
DEX 700 + LCP(H)a 14.629 40,565 0.029 573 19,509 0.47 0.72
a Limited current practice, as provided in the HURON trial:48 25% of patients on anti-inflammatory or immunosuppressant
medication.
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FIGURE 17 Cost-effectiveness acceptability curve for DEX 700 + LCP(H) vs. LCP(H).
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Figure 18 shows the cost-effectiveness scatterplot for DEX 700 + LCP(H) compared with LCP(H). The
scatterplot shows that there is a negative correlation between incremental costs and incremental QALYs.
The AG believes that this is because blindness has a strong impact both on QALYs gained and on costs,
and the impact of DEX on blindness is very uncertain. A low RR of blindness would lead to increased QALY
gains and important cost savings.
Exploratory analyses
Exploratory analysis 1: a greater proportion of patients are treated with immunosuppressants
and corticosteroids in the comparator groups This exploratory analysis suggests that injecting a DEX
implant before applying a treatment considered to be current practice (a mix of systemic steroids and
immunosuppressants, based on the comparator within the MUST trial57) is expected to produce 0.011
additional QALYs at an incremental cost of £216 compared with current practice, resulting in an ICER of
£19,899 per QALY gained, as shown in Table 41.
Within this exploratory analysis, the total QALYs associated with DEX 700 increase compared with the base
case because of the assumption that patients would be able to receive more immunosuppressants and
corticosteroids (equivalent to the comparator group) after 6 months following the DEX implant. It should
be noted that the ICER estimated for DEX 700 compared with current practice as provided in the MUST
trial57 [CP(M)] is only slightly higher than that estimated for DEX 700 compared with LCP(H). The difference
would be higher if different rates of blindness had been applied for CP(M) and LCP(H). It is reasonable to
TABLE 40 Results of the base-case analysis comparing DEX 700 with LCP(H): deterministic model
Treatment group Total QALYs Total costs (£) Incremental QALYs Incremental costs (£) ICER (£)
LCP(H)a 14.613 39,655
DEX 700 + LCP(H)a 14.641 40,235 0.029 580 20,058
a Limited current practice, as provided in the HURON trial:48 25% of patients on anti-inflammatory or immunosuppressant
medication.
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FIGURE 18 Cost-effectiveness plane scatterplot of DEX 700 + LCP(H) vs. LCP(H).
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assume that CP(M) would lead to a lower incidence of blindness than LCP(H) because of the more
intensive treatment, but the AG assumed the same rate of blindness for both given the absence of
evidence to estimate rates for both.
Exploratory analysis 2: incidence and health-related quality-of-life impact of blindness The AG
analysed the combined impact of different blindness rates based on different sources in the literature and
assuming different RRs for blindness on DEX. As shown in Table 42, the impact of the RR of blindness on
the ICER for DEX 700 + LCP(H) compared with LCP(H) alone is very important and there is no evidence
describing the impact that DEX will have on the rate of blindness. The higher the rate of blindness, the
greater the impact of the RR on the model results. Assuming a rate of blindness from Durrani et al.11 and a
RR of 1 (i.e. a DEX implant has no effect on blindness), the ICER for DEX 700 + LCP(H) compared with LCP(H)
alone is £56,329 per QALY gained, whereas DEX 700 dominates if the RR is ≤ 0.25 based on the same rate
of blindness.
The AG also explored the impact of assuming a different source for the utility for patients following the
onset of blindness. The base case used an estimate based on the study by Czoski-Murray et al.;109 the
exploratory analysis was undertaken using an estimate reported by Brown115 The results of these
exploratory analyses are presented in Table 43, showing that the ICERs for DEX 700 + LCP(H) compared
with LCP(H) were higher than those based on the study by Czoski-Murray et al.109 (in cases in which the
rate of blindness is higher than zero and DEX 700 has an impact on the rate of blindness). This is because
the utility for blindness based on the study by Czoski-Murray et al.109 (0.38) was lower than that based on
the study by Brown115 (0.57).
TABLE 41 Results of the exploratory analysis comparing DEX 700 with LCP(H): probabilistic model
Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Probability of
cost-effectiveness
at WTP threshold of
£20,000 £30,000
CP(M)a 15.152 63,465 0.54 0.45
DEX 700 + LCP(H)b
before CP(M)a
15.163 63,681 0.011 216 19,899 0.47 0.55
a Current practice as provided in the MUST trial:57 all patients on systemic steroids and 86% on systemic
immunosuppressants.
b Limited current practice, as provided in the HURON trial:48 25% of patients on anti-inflammatory or immunosuppressant
medication.
TABLE 42 Incremental cost-effectiveness ratios (£) for DEX 700 + LCP(H) vs. LCP(H) with different blindness rates
and RRs of blindness for patients while on DEX
Annual rate of blindness (source)
RR of blindness on DEX
0 (no blindness) 0.25 0.50a 0.75 1 (no effect)
0 (assumption) 48,937 48,937 48,937 48,937 48,937
0.0038 (Tomkins-Netzer et al.18) 17,100 21,816 28,089 36,844 49,915
0.0066a (Dick et al.19) 8688 13,314 20,058a 30,805 50,627
0.0374 (Durrani et al.11) Dominates Dominates 557 10,900 56,329
a Base case.
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To explore the impact of the cost of blindness, the AG undertook an analysis using the upper bounds of
the 95% CIs for the annual cost of blindness and the cost of the transition to blindness. Table 44 presents
the result of these exploratory analyses, which lead to lower ICERs for DEX 700 + LCP(H) compared with
LCP(H) than in the analyses using the mean costs of blindness (in cases in which the rate of blindness is
higher than zero and DEX 700 has an impact on the rate of blindness).
For the above analyses, when the annual rate of blindness is set to 0, the results could be used to give an
indication of the cost-effectiveness of DEX for patients with unilateral disease (as patients with unilateral
disease are unlikely to become legally blind, unless their disease progresses to become bilateral). The ICER
when the annual rate of blindness is set to 0 is £48,937. It is important to note that the treatment effect
may also be different (expected to be reduced) for unilateral patients compared with a pooled group of
unilateral and bilateral patients; however, there is no evidence available to model this.
Exploratory analysis 6: varying the time period over which the utility decreases to that of
baseline after treatment In the base case it was assumed that the health-related gain from DEX as
measured at the end of the HURON trial48 (week 26) is maintained for 4 weeks (up to week 30) and then
falls to that of the comparator arm. Table 45 shows the impact of varying the treatment effect duration
on the cost-effectiveness estimates. The ICER for DEX 700 + LCP(H) compared with LCP(H) varies from
£24,715 per QALY gained assuming 26 weeks of treatment effect to £12,154 per QALY gained assuming
42 weeks of treatment effect.
Univariate sensitivity analyses
The AG explored the impact of different parameters on the results of the model, as shown in Table 46.
TABLE 43 Incremental cost-effectiveness ratios (£) for DEX 700+ LCP(H) vs. LCP(H) with different blindness rates
and RRs of blindness for patients on DEX and using the utility estimate for blindness from Brown115
Annual rate of blindness (source)
RR of blindness on DEX
0 (no blindness) 0.25 0.50a 0.75 1 (no effect)
0 (assumption) 48,937 48,937 48,937 48,937 48,937
0.0038 (Tomkins-Netzer et al.18) 22,015 26,972 32,988 40,440 49,915
0.0066a (Dick et al.19) 12,108 17,782 25,257a 35,550 50,627
0.0374 (Durrani et al.11) Dominates Dominates 853 15,198 56,329
a Base case.
TABLE 44 Incremental cost-effectiveness ratios (£) for DEX 700+ LCP(H) vs. LCP(H) with different blindness rates
and RRs of blindness for patients on DEX using high costs of blindness (upper bounds of the 95% CIs)
Annual rate of blindness (source)
RR of blindness on DEX
0 (no blindness) 0.25 0.50a 0.75 1 (no effect)
0 (assumption) 48,937 48,937 48,937 48,937 48,937
0.0038 (Tomkins-Netzer et al.18) 15,195 20,185 26,822 36,085 49,915
0.0066a (Dick et al.19) 6283 11,174 18,305a 29,668 50,627
0.0374 (Durrani et al.11) Dominates Dominates Dominates 8534 56,329
a Base case.
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The model results were generally robust to changes in the values of these parameters. The model was
most sensitive to assumptions around the comparator, assumptions around permanent blindness and the
duration of the treatment effect.
Adalimumab: active uveitis patients
Base case
The base-case results are presented in Table 47. In the base case, ADA + LCP(VI), as provided in the
VISUAL I trial,46 was estimated to produce 0.194 incremental QALYs compared with LCP(VI) alone in
patients with active uveitis at an additional cost of £18,321, resulting in an ICER of £94,523 per QALY
gained. The ICER generated using the deterministic version of the model (£95,506) (Table 48) was similar
to that in the probabilistic model. A breakdown of the results of the deterministic analysis is provided in
Appendix 7. Figure 19 shows the CEAC for ADA + LCP(VI) compared with LCP(VI) in patients with active
TABLE 45 Results of the exploratory analysis comparing the effect of varying durations of treatment effect on
HRQoL: deterministic model
Treatment group Total QALYs Total costs (£) Incremental QALYs Incremental costs (£) ICER (£)
LCP(H) 14.613 39,655
DEX 700: 26 weeks 14.637 40,256 0.024 600 24,715
DEX 700: 30 weeksa 14.641 40,235 0.029 580 20,058
DEX 700: 34 weeks 14.646 40,214 0.033 559 16,692
DEX 700: 42 weeks 14.655 40,173 0.043 518 12,154
a Base case.
TABLE 46 Univariate sensitivity analyses for DEX 700 + LCP(H) vs. LCP(H)a
Parameter
Base case, lower value,
upper value
ICER based on
lower value (£)
ICER based on
upper value (£)
Utilities
Baseline 0.79, 0.77, 0.80 20,346 19,783
Blindness 0.38, 0.31, 0.57 18,551 25,257
Administration and monitoring
Monitoring visit frequency (weeks) 6, 4, 8 20,545 19,814
Monitoring visit cost (£) 44, 35.80, 53.03 19,854 20,282
DEX implant administration cost (£) 113.42, 91.15, 135.65 19,326 20,863
AE costs (£)
Raised IOP 23.42, 19.06, 28.23 20,024 20,095
Cataract surgery 852.40, 658.33, 1019.47 19,534 20,635
Glaucoma procedure 581.25, 467.32, 695.17 20,173 19,931
Hypertension 7.04, 5.66, 8.42 20,058 20,057
Blindness (transition) 237, 191, 283 20,061 20,054
Blindness (annual) 7659, 6158, 9160 21,807 18,308
a Base-case ICER: £20,058 per QALY (deterministic analysis).
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uveitis. It should be noted that within the VISUAL I trial46 both treatment groups included an initial systemic
steroid burst, which was tapered by week 15, and around 30% of patients in both arms received
systemic immunosuppressants.
Figure 20 shows the cost-effectiveness plane for ADA + LCP(VI) compared with LCP(VI). The scatterplot
shows that there is a positive correlation between the incremental costs and the incremental QALYs.
The AG believes that this is because longer ADA treatments lead to more QALYs but also incur important
additional costs.
TABLE 47 Results of the base case analysis comparing ADA + LCP(VI) with LCP(VI) in patients with active uveitis:
probabilistic model
Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Probability of
cost-effectiveness
at WTP threshold of
£20,000 £30,000
LCP(VI)a 14.897 47,776 1.00 1.00
ADA+ LCP(VI)a 15.091 66,098 0.194 18,321 94,523 0.00 0.00
a Limited current practice as provided in the VISUAL I trial:46 initial systemic steroid burst tapered by week 15 and around
30% of patients on systemic immunosuppressants.
TABLE 48 Results of the base case analysis comparing ADA + LCP(VI) with LCP(VI) in patients with active uveitis:
deterministic model
Treatment group Total QALYs Total costs (£) Incremental QALYs Incremental costs (£) ICER (£)
LCP(VI)a 14.919 47,186
ADA+ LCP(VI)a 15.110 65,401 0.191 18,215 95,506
a Limited current practice as provided in the VISUAL I trial:46 initial systemic steroid burst tapered by week 15 and around
30% of patients on systemic immunosuppressants.
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FIGURE 19 Cost-effectiveness acceptability curve for ADA + LCP(VI) vs. LCP(VI) in patients with active uveitis.
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Exploratory analyses
Exploratory analysis 1: a greater proportion of patients are treated with immunosuppressants
and corticosteroids in the comparator groups The AG undertook an exploratory analysis (Table 49)
whereby patients who fail ADA are assumed to receive a treatment that the AG considered representative
of current practice, a mix of systemic steroids and immunosuppressants based on the MUST trial57 [CP(M)].
The analysis shows that ADA + LCP(VI) before CP(M) is expected to produce 0.0159 additional QALYs at an
incremental cost of £17,183 compared with CP(M), resulting in an ICER of £109,044 per QALY gained.
Within this exploratory analysis, the total QALYs associated with the ADA group increase compared with
the base case because of the assumption that more patients would be able to receive immunosuppressants
and corticosteroids (equivalent to the proportion in the comparator group) after ADA treatment failure.
It should be noted that the ICER estimated for ADA compared with CP(M) is only slightly higher than that
for ADA compared with LCP(VI). The difference would be higher if different rates of blindness had been
applied for CP(M) and LCP(VI). It is reasonable to assume that CP(M) would lead to a lower incidence of
blindness than LCP(VI) because of the more intensive treatment, but the AG assumed the same rate of
blindness for both given the absence of evidence to estimate rates for both.
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FIGURE 20 Cost-effectiveness plane scatterplot of ADA + LCP(VI) vs. LCP(VI) in patients with active uveitis.
TABLE 49 Results of the exploratory analysis comparing ADA+ LCP(VI) before CP(M) with CP(M) alone:
probabilistic model
Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Probability of
cost-effectiveness
at WTP threshold of
£20,000 £30,000
CP(M)a 15.655 66,171 1.00 1.00
ADA+ LCP(VI)b
before CP(M)a
15.813 83,355 0.158 17,183 109,044 0.00 0.00
a Current practice as provided in the MUST trial:57 all patients on systemic steroids and 86% on systemic
immunosuppressants.
b Limited current practice, as provided in the VISUAL I trial:46 initial systemic steroid burst tapered by week 15 and around
30% of patients on systemic immunosuppressants.
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Exploratory analysis 2: incidence and health-related quality-of-life impact of blindness The AG
analysed the combined impact of different blindness rates based on different sources in the literature and
assuming different RRs for patients before treatment failure. As shown in Table 50, the impact of the RR of
blindness on the ICER for ADA + LCP(VI) compared with LCP(VI) in patients with active uveitis is highly
influential. The higher the rate of blindness, the greater the impact of the RR. Assuming the highest rate of
blindness from the literature (based on the study by Durrani et al.11) resulted in an ICER for ADA + LCP(VI)
compared with LCP(VI) of £202,592 per QALY gained for a RR of 1 (i.e. ADA has no effect on blindness)
and £33,003 per QALY gained for a RR of 0 (i.e. no patient goes blind before treatment failure).
The AG also explored the impact of assuming a different source for the utility for patients following the
onset of blindness. In the base case the utility estimate was based on the study by Czoski-Murray et al.;109
the exploratory analysis was undertaken using the utility estimate reported by Brown115 The results of this
exploratory analysis are shown in Table 51. The ICERs for ADA + LCP(VI) compared with LCP(VI) were
higher using the utility estimate from Brown115 than when using the utility estimate from Czoski-Murray
et al.109 This is because the utility estimate for blindness is lower in the study by Czoski-Murray et al.109
(0.38) than in the study by Brown115 (0.57).
To explore the impact of the cost of blindness, the AG undertook an analysis using the upper bounds of
the 95% CIs for the annual cost of blindness and the cost of the transition to blindness. Table 52 presents
the results of this exploratory analysis, which show that the ICERs for ADA + LCP(VI) compared with LCP(VI)
are lower than in the analyses using the mean costs of blindness, except when a blindness rate of 0 or a RR
before treatment failure of 1 is assumed.
TABLE 50 Incremental cost-effectiveness ratios (£) for ADA + LCP(VI) vs. LCP(VI) with varying blindness rates and
RRs of blindness for patients before treatment failure
Annual rate of blindness (source)
RR of blindness before treatment failure
0 (no blindness)a 0.25 0.50 0.75 1 (no effect)
0 (assumption) 192,808 192,808 192,808 192,808 192,808
0.0038 (Tomkins-Netzer et al.18) 121,908 134,773 150,325 169,503 193,740
0.0066a (Dick et al.19) 95,506a 110,263 129,611 156,077 194,471
0.0374 (Durrani et al.11) 33,003 44,570 63,587 100,494 202,592
a Base case.
TABLE 51 Incremental cost-effectiveness ratios (£) for ADA + LCP(VI) vs. LCP(VI) with varying blindness rates and
RRs of blindness for patients before treatment failure and using the utility estimate for blindness from Brown115
Annual rate of blindness (source)
RR of blindness before treatment failure
0 (no blindness)a 0.25 0.50 0.75 1 (no effect)
0 (assumption) 192,808 192,808 192,808 192,808 192,808
0.0038 (Tomkins-Netzer et al.18) 142,399 152,827 164,646 178,154 193,740
0.0066a (Dick et al.19) 119,012a 132,539 148,886 169,031 194,471
0.0374 (Durrani et al.11) 48,876 63,923 86,679 124,952 202,592
a Base case.
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Exploratory analysis 3: patients who go into remission after adalimumab treatment In the base
case, the AG assumed that patients would stay on ADA until treatment failure. However, based on clinical
advice received by the AG, an additional analysis was undertaken assuming that, after 2 years of successful
treatment, a proportion of patients discontinue treatment as they are in remission and retain the benefits
of treatment. Table 53 presents the results for different annual discontinuation rates for patients who have
completed 2 years of successful treatment. As expected, only the cost of treatment with ADA varies with
the different rates of treatment discontinuation after remission: the cost of ADA treatment decreases as
the rate of discontinuation increases and therefore the ICER for ADA + LCP(VI) compared with LCP(VI) also
decreases. If all patients who have not failed treatment (according to the discontinuation criteria defined in
the VISUAL trials46,47) by 2 years could discontinue ADA and retain the benefits accrued from treatment,
the ICER for ADA + LCP(VI) compared with LCP(VI) would be £35,299 per QALY gained.
It should be noted that the clinical advisors to the AG suggested that the treatment failure criteria for the
VISUAL trials46,47 are more strict than would be used in clinical practice and hence it is possible that a
greater proportion of patients would still be receiving ADA treatment at 2 years. However, there is no
evidence around the extent of the benefit of ADA in these patients.
TABLE 52 Incremental cost-effectiveness ratios (£) for ADA + LCP(VI) vs. LCP(VI) with varying blindness rates and
RRs of blindness for patients before treatment failure using high costs of blindness (upper bounds of the 95% CIs)
Annual rate of blindness (source)
RR of blindness before treatment failure
0 (no blindness)a 0.25 0.50 0.75 1 (no effect)
0 (assumption) 192,808 192,808 192,808 192,808 192,808
0.0038 (Tomkins-Netzer et al.18) 120,637 133,725 149,546 169,056 193,712
0.0066a (Dick et al.19) 93,765a 108,775 128,453 155,372 194,422
0.0374 (Durrani et al.11) 30,187 41,936 61,245 98,713 202,352
a Base case.
TABLE 53 Results of the exploratory analysis of different annual discontinuation rates for patients who have
completed 2 years of successful treatment
Annual rate of treatment
discontinuation Treatment group
Total
QALYs
Total
costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
0.00a LCP(VI)b 14.919 47,186
ADA+ LCP(VI)b 15.110 65,401 0.191 18,215 95,506
0.10 LCP(VI)b 14.919 47,186
ADA+ LCP(VI)b 15.110 60,034 0.191 12,848 67,363
0.25 LCP(VI)b 14.919 47,186
ADA+ LCP(VI)b 15.110 57,239 0.191 10,052 52,707
1.00 LCP(VI)b 14.919 47,186
ADA+ LCP(VI)b 15.110 53,918 0.191 6732 35,299
a Base case.
b Limited current practice, as provided in the VISUAL I trial:46 initial systemic steroid burst tapered by week 15 and around
30% of patients on systemic immunosuppressants.
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Exploratory analysis 4: using the Visual Function Questionnaire data from the VISUAL trials of
adalimumab46,47 to map to EuroQol-5 Dimensions utility data The AG undertook an exploratory
analysis using EQ-5D scores mapped from VFQ-25 scores captured in the VISUAL I trial46 instead of directly
measured EQ-5D scores. This analysis resulted in a higher incremental QALY gain and therefore a slightly
lower ICER for ADA + LCP(VI) compared with LCP(VI) than in the base case (Table 54).
Exploratory analysis 5: extrapolation of the time to treatment discontinuation for
adalimumab To assess the impact of uncertainty around the extrapolation of time to treatment failure,
the AG undertook an exploratory analysis using alternative parametric curves (Table 55). The ICER for
ADA + LCP(VI) compared with LCP(VI) was considerably higher when using a Gompertz distribution
(£101,429 per QALY) and a Weibull distribution (£103,369 per QALY) than when using a log-normal
distribution, as in the base case (£95,506 per QALY).
Univariate sensitivity analyses
The AG explored the impact of different parameters on the results of the model, as shown in Table 56.
Of those parameters tested within the univariate sensitivity analysis, the parameters relating to baseline
utility and the utility of blindness had the greatest impact on the ICER for ADA + LCP(VI) compared with
LCP(VI). However, the model was most sensitive to assumptions around the comparator, assumptions
around permanent blindness and the proportion of patients who would discontinue treatment on
achieving remission and retain the benefits of treatment.
TABLE 54 Results of the exploratory analysis using EQ-5D scores captured in the VISUAL I trial46
Treatment group Total QALYs Total costs (£) Incremental QALYs Incremental costs (£) ICER (£)
LCP(VI)a 14.350 47,186
ADA+ LCP(VI)a 14.546 65,401 0.196 18,215 92,884
a Limited current practice, as provided in the VISUAL I trial:46 initial systemic steroid burst tapered by week 15 and around
30% of patients on systemic immunosuppressants.
TABLE 55 Results of the exploratory analysis of different parametric curves to extrapolate time to
treatment failure
Parametric curve Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Log-normala LCP(VI)b 14.919 47,186
ADA+ LCP(VI)b 15.110 65,401 0.191 18,215 95,506
Gompertz LCP(VI)b 14.947 47,186
ADA+ LCP(VI)b 15.569 110,215 0.621 63,029 101,429
Weibull LCP(VI)b 14.917 47,186
ADA+ LCP(VI)b 15.031 58,938 0.114 11,751 103,369
a Base case.
b Limited current practice, as provided in the VISUAL I trial:46 initial systemic steroid burst tapered by week 15 and around
30% of patients on systemic immunosuppressants.
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Adalimumab: inactive uveitis patients
Base case
In the base case, ADA plus limited current practice as provided in the VISUAL II trial47 [LCP(VII)] was
estimated to produce 0.118 incremental QALYs compared with LCP(VII) alone at an extra cost of £37,432,
resulting in an ICER of £317,547 per QALY gained in patients with inactive uveitis, as shown in Table 57.
The deterministic analysis produced a slightly higher ICER (£321,405), as shown in Table 58. A breakdown
of the results of the deterministic analysis is provided in Appendix 7. Figure 21 shows the CEAC for
ADA + LCP(VII) compared with LCP(VII) in patients with inactive uveitis and Figure 22 shows the cost-
effectiveness plane scatterplot of ADA + LCP(VII) compared with LCP(VII). The scatterplot shows a positive
correlation between incremental costs and incremental QALYs, as was the case for patients with active
uveitis. However, in patients with inactive uveitis, the comparator was more effective than the intervention
arm. It should be noted that around 47% of patients in both arms received systemic immunosuppressants.
TABLE 56 Univariate sensitivity analyses for ADA + LCP(VI) vs. LCP(VI) in patients with active uveitisa
Parameters
Base case, lower value,
upper value
ICER based on
lower value (£)
ICER based on
upper value (£)
Utilities
Baseline 0.83, 0.81, 0.85 97,804 93,419
Blindness 0.38, 0.31, 0.57 88,602 119,012
Administration and monitoring
Monitoring visit frequency (weeks) 6, 4, 8 95,983 95,267
Monitoring visit cost (£) 96.11, 77.27, 114.95 95,290 95,744
ADA administration cost (£) (help from a nurse) 44, 35.80, 53.03 95,272 95,763
% of self-injectors needing district nurse for ADA 10, 0, 20 94,253 96,758
AE costs (£)
Cataract surgery 852.40, 658.33, 1019.47 95,465 95,551
Glaucoma procedure 581.25, 467.32, 695.17 95,487 95,527
Serious infections 5940, 4776, 7105 95,272 95,763
Hypertension 7.04, 5.66, 8.42 95,505 95,506
Blindness (transition) 237, 191, 283 95,510 95,502
Blindness (annual) 7659, 6158, 9160 97,243 93,769
a Base-case ICER: £95,506 (deterministic model).
TABLE 57 Results of the base-case analysis comparing ADA + LCP(VII) with LCP(VII) in patients with inactive uveitis:
probabilistic model
Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Probability of
cost-effectiveness
at WTP threshold of
£20,000 £30,000
LCP(VII)a 15.221 48,642 1.00 1.00
ADA+ LCP(VII)a 15.339 86,074 0.118 37,432 317,547 0.00 0.00
a Limited current practice, as provided in the VISUAL II trial:47 on systemic steroids at baseline, which were tapered by
week 19, and around 47% of patients on systemic immunosuppressants.
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TABLE 58 Results of the base-case analysis comparing ADA + LCP(VII) with LCP(VII) in patients with inactive uveitis:
deterministic model
Treatment group Total QALYs Total costs (£) Incremental QALYs Incremental costs (£) ICER (£)
LCP(VII)a 15.244 48,111
ADA+ LCP(VII)a 15.361 85,462 0.116 37,351 321,405
a Limited current practice, as provided in the VISUAL II trial:47 on systemic steroids at baseline, which were tapered by
week 19, and around 47% of patients on systemic immunosuppressants.
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FIGURE 21 Cost-effectiveness acceptability curve for ADA + LCP(VII) compared with LCP(VII) in patients with
inactive uveitis.
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FIGURE 22 Cost-effectiveness plane scatterplot of ADA+ LCP(VII) compared with LCP(VII) in patients with
inactive uveitis.
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Exploratory analyses
Exploratory analysis 2: incidence and health-related quality-of-life impact of blindness The AG
analysed the combined impact of different blindness rates based on different sources in the literature and
assuming different RRs for patients before treatment failure. As shown in Table 59, the impact of the RR of
blindness on the ICER for ADA + LCP(VII) compared with LCP(VII) in patients with inactive uveitis is very
important. The higher the rate of blindness, the greater the impact of the RR. Assuming the highest rate of
blindness from the literature (based on the study by Durrani et al.11) resulted in an ICER for ADA + LCP(VII)
compared with LCP(VII) of £7,411,362 per QALY gained for a RR of 1 (i.e. assuming that ADA has no
effect on blindness) and an ICER of £85,544 per QALY for a RR of 0 (i.e. assuming that no patient goes
blind before treatment failure).
The AG also explored the impact of assuming a different source for the utility for patients following the
onset of blindness. In the base case the utility estimate was based on the study by Czoski-Murray et al.;109
the exploratory analysis was undertaken using the utility estimate reported by Brown.115 The results of this
exploratory analysis are shown in Table 60. The ICERs for ADA + LCP(VII) compared with LCP(VII) were
higher using the utility estimate from Brown115 than when using the utility estimate from Czoski-Murray
et al.109 This is because the utility estimate for blindness is lower in the study by Czoski-Murray et al.109
(0.38) than in the study by Brown115 (0.57).
To explore the impact of the cost of blindness, the AG undertook an analysis using the upper bounds of
the 95% CIs for the annual cost of blindness and the cost of the transition to blindness. Table 61 presents
the results of this exploratory analysis, which show that the ICERs for ADA + LCP(VI) compared with LCP(VI)
are lower than in the analyses using the mean costs of blindness, except when a blindness rate of 0 or a RR
before treatment failure of 1 is assumed.
TABLE 59 Incremental cost-effectiveness ratios (£) for ADA + LCP(VII) vs. LCP(VII) with varying blindness rates and
RRs of blindness for patients before treatment failure
Annual rate of blindness (source)
RR of blindness before treatment failure
0 (no blindness)a 0.25 0.50 0.75 1 (no effect)
0 (assumption) 4,814,459 4,814,459 4,814,459 4,814,459 4,814,459
0.0038 (Tomkins-Netzer et al.18) 527,056 679,863 956,162 1,606,857 4,988,973
0.0066a (Dick et al.19) 321,405a 420,805 607,928 1,089,865 5,133,625
0.0374 (Durrani et al.11) 85,544 112,594 167,837 331,006 7,411,362
a Base case.
TABLE 60 Incremental cost-effectiveness ratios (£) for ADA + LCP(VII) vs. LCP(VII) with varying blindness rates and
RRs of blindness for patients before treatment failure and using the utility estimate for blindness from Brown115
Annual rate of blindness (source)
RR of blindness before treatment failure
0 (no blindness)a 0.25 0.50 0.75 1 (no effect)
0 (assumption) 4,814,459 4,814,459 4,814,459 4,814,459 4,814,459
0.0038 (Tomkins-Netzer et al.18) 821,798 1,040,149 1,414,808 2,206,843 4,988,973
0.0066a (Dick et al.19) 514,958a 665,947 940,350 1,593,079 5,133,625
0.0374 (Durrani et al.11) 141,538 185,892 275,797 536,245 7,411,362
a Base case.
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Exploratory analysis 3: patients who go into remission after adalimumab treatment In the base
case, the AG assumed that patients would stay on ADA until treatment failure. However, based on clinical
advice received by the AG, a further analysis was undertaken assuming that, after 2 years of successful
treatment, a proportion of patients discontinue treatment as they are in remission and retain the benefits
of treatment. Table 62 presents the results for different annual discontinuation rates for patients after
2 years of successful treatment. As expected, only the cost of treatment with ADA varies with the different
rates of treatment discontinuation after remission: the cost of ADA treatment decreases as the rate of
discontinuation increases and therefore the ICER for ADA + LCP(VII) compared with LCP(VII) also decreases.
It is worth noting that, if all patients could discontinue ADA treatment after 2 years and still retain the
benefits of treatment, the ICER for ADA + LCP(VII) compared with LCP(VII) would be £84,132 per
QALY gained.
Exploratory analysis 4: using the Visual Function Questionnaire data from the VISUAL trials of
adalimumab46,47 to map to EuroQol-5 Dimensions utility data The AG undertook an exploratory
analysis using EQ-5D scores mapped from VFQ-25 scores captured in the VISUAL II trial47 instead of directly
measured EQ-5D scores. This analysis resulted in lower QALY gains and therefore a higher ICER for
ADA + LCP(VII) compared with LCP(VII) than in the base case (Table 63).
TABLE 61 Incremental cost-effectiveness ratios (£) for ADA + LCP(VII) vs. LCP(VII) with varying blindness rates and
RRs of blindness for patients before treatment failure using high costs of blindness (upper bounds of the 95% CIs)
Annual rate of blindness (source)
RR of blindness before treatment failure
0 (no blindness)a 0.25 0.50 0.75 1 (no effect)
0 (assumption) 4,814,459 4,814,459 4,814,459 4,814,459 4,814,459
0.0038 (Tomkins-Netzer et al.18) 523,933 676,848 953,341 1,604,491 4,988,973
0.0066a (Dick et al.19) 318,140a 417,608 604,860 1,087,124 5,133,625
0.0374 (Durrani et al.11) 82,177 109,245 164,519 327,767 7,411,362
a Base case.
TABLE 62 Results of the exploratory analysis of different annual discontinuation rates for patients who have
completed 2 years of successful treatment
Rate of remission Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
0.00a LCP(VII)b 15.244 48,111
ADA+ LCP(VII)b 15.361 85,462 0.116 37,351 321,405
0.10 LCP(VII)b 15.244 48,111
ADA+ LCP(VII)b 15.361 71,241 0.116 23,130 199,031
0.25 LCP(VII)b 15.244 48,111
ADA+ LCP(VII)b 15.361 64,710 0.116 16,599 142,832
1.00 LCP(VII)b 15.244 48,111
ADA+ LCP(VII)b 15.361 57,888 0.116 9777 84,132
a Base case.
b Limited current practice, as provided in the VISUAL II trial:47 on systemic steroids at baseline, which are tapered by
week 19, and around 47% of patients on systemic immunosuppressants.
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Exploratory analysis 5: extrapolation of the time to treatment discontinuation for
adalimumab To assess the impact of uncertainty around the extrapolation of the time to treatment
failure, the AG undertook an exploratory analysis using alternative parametric curves. The ICER for
ADA + LCP(VII) compared with LCP(VII) was lower when using a Gompertz distribution (£297,746 per
QALY) or a Weibull distribution (£235,916 per QALY) than when a log-normal distribution was used, as in
the base case (£321,405 per QALY) (Table 64).
Univariate sensitivity analyses
The AG explored the impact of different parameters on the results of the model, as shown in Table 65.
As for patients with active disease, of those parameters tested within the univariate sensitivity analysis, the
parameters relating to the baseline utility and the utility of blindness had the greatest impact on the ICER
for ADA + LCP(VII) compared with LCP(VII). However, the ICER for ADA + LCP(VII) compared with LCP(VII)
in patients with inactive uveitis did not fall below £84,000 per QALY gained for any of the analyses
considered.
Discussion
Model results and key uncertainties
The base-case analysis undertaken by the AG estimated the ICER for one DEX implant in one eye for a
combination of patients with unilateral and bilateral uveitis compared with limited current practice, as per
the HURON trial,48 to be £19,509 per QALY gained. The ICER for ADA (systemic, therefore treatment for
both eyes) for patients with mainly bilateral uveitis compared with limited current practice, as per the
VISUAL trials,46,47 was estimated to be £94,523 and £317,547 per QALY gained in patients with active and
inactive uveitis respectively.
TABLE 63 Results of ADA + LCP(VII) compared with LCP(VII) in patients with inactive uveitis using EQ-5D scores
captured in the VISUAL II trial
Treatment group Total QALYs Total costs (£) Incremental QALYs Incremental costs (£) ICER (£)
LCP(VII)a 15.100 48,111
ADA+ LCP(VII)a 15.207 85,462 0.107 37,351 348,094
a Limited current practice, as provided in the VISUAL II trial:47 on systemic steroids at baseline, which are tapered by
week 19, and around 47% of patients on systemic immunosuppressants.
TABLE 64 Results of the exploratory analysis of different parametric curves to extrapolate time to
treatment failure
Rate of remission Treatment group Total QALYs Total costs (£)
Incremental
QALYs
Incremental
costs (£) ICER (£)
Log-normala LCP(VII)b 15.244 48,111
ADA+ LCP(VII)b 15.361 85,462 0.116 37,351 321,405
Gompertz LCP(VII)b 15.305 48,101
ADA+ LCP(VII)b 15.628 144,266 0.323 96,166 297,746
Weibull LCP(VII)b 15.225 48,114
ADA+ LCP(VII)b 15.325 71,577 0.099 23,463 235,916
a Base case.
b Limited current practice, as provided in the VISUAL II trial:47 on systemic steroids at baseline, which were tapered by
week 19, and around 47% of patients on systemic immunosuppressants.
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The results of the model are highly uncertain because of the limited availability of evidence. There are
three major issues with the existing evidence: (1) there is no evidence comparing DEX or ADA with current
practice; (2) long-term outcomes, in particular the incidence of permanent blindness, are uncertain; and
(3) there is no evidence around the proportion of patients who would experience remission and be taken
off ADA (or an alternative) treatment or around long-term outcomes for these patients. These are structural
uncertainties within the model and the complexity of these issues in combination with the lack of data
meant that it was not possible to appropriately quantify the uncertainty associated with them within the
PSA, as would be ideal. Instead, the potential impacts of these factors on the model results have been dealt
with using exploratory analysis.
These analyses suggest that the rate of blindness in the comparator group and the RR of blindness for DEX
and ADA substantially affect the ICER. The cost per QALY gained compared with the comparator within
the HURON trial48 ranged from dominating to £56,329 for DEX. Under all assumptions tested for these
parameters, the ICER associated with ADA compared with (limited) current practice remained above
£30,000 and £82,000 for patients with active and inactive uveitis respectively. The choice of comparator
did not have a substantial impact on the ICER, although it should be noted that the rate of blindness was
assumed to be the same for all comparators independent of the proportion of patients receiving systemic
treatment, which may have slightly overestimated the QALYs associated with the placebo and sham
groups and hence the ICERs for these comparisons may be slightly overestimated. The exploratory analyses
also suggest that the proportion of patients who would be taken off ADA treatment following remission
and who would maintain the same quality of life is a key driver of the model results. Under the assumption
that all patients who remain on ADA at 2 years achieve remission and are taken off treatment while
retaining quality of life, the ICER for ADA compared with (limited) current practice decreases to £35,299
and £84,132 per QALY for patients with active and inactive uveitis respectively.
TABLE 65 Univariate sensitivity analyses for ADA + LCP(VII) vs. LCP(VII) in patients with inactive uveitisa
Parameters
Base case, lower value,
upper value
ICER based on
lower value (£)
ICER based on
upper value (£)
Utilities
Baseline 0.85, 0.83, 0.87 334,704 309,733
Blindness 0.38, 0.31, 0.57 279,904 514,958
Administration and monitoring
Monitoring visit frequency (weeks) 6, 4, 8 322,313 320,952
Monitoring visit cost (£) 96.11, 77.27, 114.95 320,956 321,900
ADA administration cost (£) (help from a nurse) 44, 35.80, 53.03 320,628 322,262
% of self-injectors needing district nurse for ADA 10, 0, 20 317,234 325,577
AE costs (£)
Cataract surgery 852.40, 658.33, 1019.47 321,741 321,035
Glaucoma procedure 581.25, 467.32, 695.17 321,405 321,405
Serious infections 5940, 4776, 7105 321,620 321,169
Hypertension 7.04, 5.66, 8.42 321,405 321,406
Blindness (transition) 237, 191, 283 321,409 321,402
Blindness (annual) 7659, 6158, 9160 324,667 318,144
a Base-case ICER: £321,405 (deterministic model).
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Use of adalimumab and dexamethasone in clinical practice
The clinical advisors to the AG suggested that there are several differences between the way in which the
treatments are provided within the RCTs and the way in which they would be provided in practice. The
clinical experts suggested that the proportion of patients who remain on ADA treatment is likely to be
underestimated within the clinical trial because of the strict criteria for treatment failure. If more people
were to remain on treatment, the additional group of patients on treatment would incur the same costs as
those who remain on treatment in the VISUAL trial, whereas the effectiveness of ADA is likely to be
reduced in these patients who were considered to have failed treatment in the trial and hence the ICER
would increase for these patients.
The model predicts that ADA would have a substantially higher ICER for inactive patients than active
patients. The VISUAL II trial47 captures the benefits of ADA over placebo for preventing the recurrence of
uveitis symptoms in patients who were inactive while on high-dose steroids, once the steroids have been
tapered and discontinued. However, our clinical advisors suggested that, for the ‘inactive’ group of
patients, ADA is more likely to be used in patients who have to discontinue existing immunosuppressants
because they are ineffective or not tolerated. However, there are no clinical data for this group of patients.
The model assumes that only one DEX implant would be provided to patients. There is no RCT evidence to
assess the comparative effectiveness or safety of more than one DEX implant; however, there are several
non-randomised trials with 12–24 months’ follow-up that have allowed repeat implants.18,50,51 These
studies consistently report that, after around 6 months, patients’ outcomes return to those at baseline and
that up to three repeat implants are each likely to have a similar treatment effect. Each additional implant
is associated with a higher incidence of AEs such as raised IOP and cataract.18,50,51 The univariate sensitivity
analyses suggested that the model is not sensitive to the costs of treating raised IOP or cataract and,
hence, given that the cost of each implant is the same, the cost-effectiveness of up to three consecutive
implants is expected to be similar to the cost-effectiveness of one implant. The ICER would be expected to
decrease if there was also a cumulative impact on the reduction in blindness or if patients were to achieve
remission after consecutive implants. The clinical experts to the AG suggested that the maximum number
of implants likely to be provided to one eye per patient is four because of the increasing rate of raised IOP
for each implant. Clinicians suggested that the increasing rate of cataract would not affect their decision
regarding additional implants because the condition is reversible with surgery. If DEX implants were
repeated at < 6 months following the previous implant, the DEX implants would be less cost-effective than
currently predicted.
The clinical advisors suggested that patients would not usually receive an implant in both eyes because
they are more likely to have a systemic treatment if both eyes require treatment; however, this may occur
in some cases. There was insufficient evidence to assess the cost-effectiveness of using DEX implants in
both eyes; however, because the costs would essentially be doubled (with the exception of some
monitoring costs) and the increment in HRQoL is likely to be lower for the second eye, it is expected to be
less cost-effective than treatment in one eye for a patient with bilateral disease.
The clinical experts to the AG suggested that ADA and DEX are likely to be provided alongside other
treatment options in practice. In the clinical trials, around one-third of patients did receive other treatments
in both arms. However, it is unclear whether or not the relative effectiveness of ADA and DEX predicted
within the trials would be the same if the use of alternative treatments in both the intervention group and
the comparator group was increased. If the relative effectiveness and costs remained the same, then the
ICER would not change from the base-case predicted ICER. However, because of the lack of evidence for a
comparator that represents current practice, it is unclear how both ADA and DEX may have an impact on
the use of other treatments. The model incorporates the impact of DEX on use of rescue therapy, but this
is based on the analysis using a sham comparator. If treatment with DEX or ADA led to a reduction in the
use of immunosuppressants and/or corticosteroids without this having an impact on efficacy in these
treatment groups, then DEX and ADA would be more cost-effective than currently predicted.
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Potentially important subgroups
The model includes a heterogeneous population and it may be that the interventions are more
cost-effectiveness in some groups than others. However, there was insufficient evidence to undertake any
formal subgroup analyses. This discussion considers the key subgroups for which the interventions may be
more cost-effective. Almost all patients receiving ADA will have bilateral uveitis; however, DEX may be
given to patients with unilateral and bilateral uveitis. DEX is likely to be more cost-effective when given in
one eye to patients with bilateral uveitis because BCVA in the better-seeing eye is the best predictor of
quality of life and hence bilateral uveitis patients are generally able to benefit more from treatment than
unilateral uveitis patients, for the same cost of treatment. When the annual rate of blindness is set to 0,
the results can be used to give an indication around the cost-effectiveness of DEX for patients with
unilateral disease (as patients with unilateral disease are unlikely to become legally blind, unless their
disease progresses to become bilateral). The ICER in this case was £48,937. It is important to note that the
treatment effect may also be different (expected to be reduced) for unilateral patients compared with a
pooled group of unilateral and bilateral patients; however, there was no evidence available to model this.
Patients also have the potential to benefit more from treatment with ADA or DEX if they have more severe
uveitis and hence the treatments are likely to be more cost-effective as the baseline disease worsens. In
addition, patients with macular oedema are more likely to go blind and therefore the interventions of
interest, in particular ADA, because of the longer duration of treatment, are more likely to prevent cases of
blindness and hence are likely to be more cost-effective in this group.
Model perspective
The base-case analysis took a NHS and PSS perspective. However, sight problems and sight damage
caused by uveitis can affect every aspect of daily life. The quality-of-life measures used within the health
economic model aimed to largely capture these effects. However, if a societal perspective was taken,
the cost-effectiveness of the interventions would be reduced. A societal perspective would capture the
additional cost savings associated with increased leisure time and workplace productivity resulting from
the benefits of the interventions. Given that non-infectious uveitis affects a working-age population, these
cost savings would not be negligible. Therefore, there are likely to be additional non-NHS and -PSS cost
savings of the interventions that are not captured within our analyses; however, analysis of these
additional cost savings are beyond the scope of this NICE appraisal.
ASSESSMENT OF COST-EFFECTIVENESS
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
Many uveitis treatments used in clinical practice are not licensed for uveitis and injections oftriamcinolone are contraindicated in the eye [Kenalog® formulation (Bristol-Myers Squibb
Pharmaceuticals Ltd, Princeton, NJ, USA)] or are not available in the UK [Trivaris® (Allergan, Irvine, CA,
USA)/Triesence® (Alcon Canada Inc., Mississauga, ON, Canada) formulation]. DEX implants and ADA are
both used variably in current practice, depending on funding availability. Posterior segment-involving
uveitis covers a broad spectrum of patients. DEX implants and ADA would generally be used in different
populations in clinical practice (DEX for local disease or local flare-up and in unilateral cases; ADA for
severe refractory disease, often bilateral and/or related to a systemic condition). There are few trial data
relating to patients who have very severe uveitis or who are unresponsive to or contraindicated
for immunosuppressants.
The prevalence of non-infectious posterior segment-involving uveitis is estimated to be between 3 and 10
in 100,000 people in the European Union, based on a population of 506,500,000, including people from
the UK.132 The mid-2015 estimate for the adult population of England is 43,108,471.133 This results
in an estimated prevalence of non-infectious posterior segment-involving uveitis in adults in England of
between 1293 and 4311. Within its submission to NICE,55 Allergan, however, estimated a higher
prevalence of non-infectious posterior segment-involving uveitis in adults of 16.14 per 100,000, based on
a US study, which would result in a higher estimate of 6958 adults affected by non-infectious posterior
segment-involving uveitis in England. In its submission,43 AbbVie predicted that 5389 adults would be
affected by non-infectious posterior segment-involving uveitis in England. The proportion of patients who
would receive DEX and ADA within this patient group is highly uncertain. Within its submission to NICE,55
Allergan predicted that 589 patients would be eligible for DEX annually (8.0% of the predicted number of
patients with non-infectious posterior segment-involving uveitis), whereas, within its submission,43 AbbVie
predicted that 175 patients would be eligible for ADA annually (3.2% of the predicted number of patients
with non-infectious posterior segment-involving uveitis).
The provision of ADA and DEX does not usually engender significant additional management costs compared
with current practice. Therefore, the burden on the NHS is generally related to the additional drug acquisition
costs and differences in the treatment of AEs. Allergan and AbbVie submitted estimates of the annual
additional cost to the NHS of DEX and ADA respectively. DEX was predicted by Allergan to cost an additional
£74,672–1,057,706 in the first year, depending on whether the comparator was an immunosuppressant
or a corticosteroid, rising to an additional £599,537–5,514,704 in year 5. These estimates were based on
the costs of DEX (assuming that patients with unilateral and bilateral disease would have 1.64 implants and
3.28 implants on average annually respectively) minus the costs of immunosuppressants or corticosteroids,
which assumes that DEX would eradicate the need for these comparators, and hence they are likely to be
underestimates. They also include a reduction in monitoring costs for patients receiving DEX, but do not
include the costs of the treatment of AEs. The increase in costs over time occurs because of the assumption
that patients will continue to receive DEX implants, which is unlikely to be the case, and hence the first year
cost is likely to be the most reasonable estimate.
Adalimumab was predicted by AbbVie to cost £1.55M in the first year, rising to £4.77M in year 5. This
was based on the costs of ADA minus the costs of prednisolone (assuming that ADA would be given as
third-line treatment and would eradicate the need for corticosteroids). It does not include the costs of the
treatment of AEs. The increase in costs over time occurs because of an expected increase by the company
in the use of biologics in this patient population. The calculation did not account for patients failing on
treatment and hence the increase in costs over the 5 years is likely to have been overpredicted.
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Given the substantial uncertainties around prevalence, the number of patients who would receive ADA
and DEX, the impact of the interventions on existing immunosuppressant and corticosteroid use, the
impact of the interventions on blindness, the number of DEX implants that patients would receive (bilateral
and consecutive) in practice and whether or not patients would stop receiving ADA following remission,
the AG has not undertaken an analysis of its own as the extent to which it could improve on the
companies’ estimates is unclear.
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Chapter 6 Discussion
Statement of principal findings
One RCT of ADA in patients with active uveitis (VISUAL I;46 n = 223, follow-up of up to 80 weeks) showed
significant benefits over placebo for time to treatment failure as well as visual acuity, inflammation (VH and
AC cell grade), macular oedema (change in central retinal thickness) and VFQ-25 score. Another RCT of
ADA in patients with inactive uveitis controlled with corticosteroids (VISUAL II;47 n = 229, follow-up of up
to 80 weeks) showed significant benefits over placebo for time to treatment failure but not for the other
outcomes. There were some concerns regarding the use of LOCF to account for missing data after patients
experienced treatment failure in the ADA studies as these data were not missing at random as more
patients experienced treatment failure in the placebo arms than in the ADA arms. The ICERs for ADA
(systemic, therefore treatment of both eyes) for patients with mainly bilateral uveitis compared with limited
current practice, as in the VISUAL trials,46,47 were estimated to be £94,523 and £317,547 per QALY gained
in patients with active and inactive uveitis respectively.
A 26-week study of DEX 700 compared with a sham procedure (HURON;48 n = 153 for relevant groups)
showed significant improvements in the DEX 700 group for measures of visual acuity, inflammation
(VH and AC cell grade), macular oedema (central retinal thickness) and VFQ-25 score. The base-case
analysis undertaken by the AG estimated that the ICER for one DEX implant in one eye for a combination
of patients with unilateral and bilateral uveitis compared with limited current practice, as in the HURON
trial,48 was £19,509 per QALY gained.
Exploratory analyses suggest that two of the factors that have the largest impact on the ICERs, both of which
are highly uncertain, are (1) the rate of blindness in the comparator group and (2) the RR of blindness for
ADA and DEX. The ICER for DEX compared with (limited) current practice varied from dominating to £56,329
per QALY gained under different assumptions for these parameters. Setting the rate of legal blindness to
zero was used to explore the potential cost-effectiveness of DEX for patients with unilateral uveitis; the ICER
in this case was £50,627 per QALY gained. Under all assumptions tested for these parameters, the ICER
associated with ADA compared with (limited) current practice remained above £30,000 and £82,000 per
QALY gained for patients with active and inactive uveitis respectively. The proportion of patients taken off
ADA treatment following remission and maintaining the same quality of life had the largest impact on the
ICER for ADA, with ICERs of £35,299 and £84,132 per QALY gained for patients with active and inactive
uveitis, respectively, when it was assumed that all patients go into remission after 2 years on ADA.
Strengths and limitations of the assessment
We have attempted to compare the two interventions being assessed with current practice; however, there
is no RCT evidence comparing any two treatments within the scope of the assessment. ADA was compared
with placebo in both studies of ADA identified (patients in both arms also received initial systemic
corticosteroids, which were then tapered, and some also received an immunosuppressant) and DEX was
compared with a sham procedure in the one study of DEX identified (25% also continued with a stable dose
of systemic corticosteroids or immunosuppressants and 22% received rescue therapy, either a local steroid
injection or new/increased systemic therapy, in both the DEX 700 arm and the sham arm). The placebo/sham
arms could be considered to represent standard practice to some extent because other therapies were
permitted in both the active treatment and the placebo arms in all three studies. However, the main
comparison was with placebo/sham procedure as opposed to active management with other therapies.
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It was not possible to conduct meta-analyses or NMAs because of clinical heterogeneity, lack of common
comparators (disconnected network) and differences in the reported outcomes.
The health economic model is the first model that has attempted to assess the cost-effectiveness of ADA
or DEX for the treatment of non-infectious uveitis. However, the results are highly uncertain because of
the limited availability of evidence and the differences between the trial evidence and clinical practice (as
discussed in Chapter 4, Independent economic assessment).
The model includes a heterogeneous population and it may be that the interventions are more cost-
effective in some groups than others. However, there was no evidence from the trials to allow subgroup
analyses to be undertaken. Patients have the potential to benefit more from treatment with ADA or DEX if
they have more severe uveitis and hence the treatments are likely to be more cost-effective as the baseline
disease worsens. In addition, patients with macular oedema are more likely to go blind and hence the
interventions of interest, in particular ADA, because of the longer duration of treatment, are more likely to
prevent cases of blindness and hence are likely to be more cost-effective in this group. The exploratory
analysis in which the rate of blindness was varied to represent patients with unilateral uveitis suggests that
the ICER for DEX compared with (limited) current practice increases substantially for this patient group;
however, the treatment effect for this subgroup is assumed to remain unchanged.
The analysis presented here takes a NHS and PSS perspective. However, non-infectious uveitis affects a
working-age population and can reduce workplace productivity. In addition, the disease can affect leisure
time. Therefore, there are likely to be additional non-NHS and -PSS costs and benefits of the interventions
not captured within our analyses.
Uncertainties
The key uncertainties associated with this evaluation are:
l the comparative effectiveness and cost-effectiveness of DEX and ADA and their effectiveness and
cost-effectiveness compared with those of systemic immunosuppressants and corticosteroids, as would
be used in practice
l how short-term improvements in visual acuity and inflammation relate to long-term effects on vision
loss and blindness
l how ADA and DEX would be used in practice, particularly with regard to taking patients off treatment
following remission and the number of DEX implants that would be provided
l the impact of the expected differences between clinical practice and the trial evidence on
estimated outcomes
l the effectiveness and cost-effectiveness of ADA and DEX in subgroups of patients, including patients
with unilateral and bilateral uveitis, those with more and less severe uveitis, patients who are
unresponsive to or who are contraindicated for immunosuppressants, patients with macular oedema
and patients with underlying autoimmune or inflammatory diseases
l the long-term impacts of corticosteroids.
Other relevant factors
The number of patients who would be eligible for these treatments is low. DEX implants and ADA are
currently generally used in very different patient populations in clinical practice.
DISCUSSION
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Chapter 7 Conclusions
Two RCTs of systemic ADA and one RCT of a unilateral, single DEX implant showed significant benefitsover placebo or a sham procedure for outcomes including visual acuity, inflammation (VH and AC cell
grade), macular oedema (central retinal thickness), VFQ-25 score and time to treatment failure. One DEX
implant in a mixed group of unilateral and bilateral patients had an estimated ICER of £19,509 per QALY
gained compared with (limited) current practice. The ICER associated with ADA compared with (limited)
current practice did not fall below £30,000 per QALY gained in any of the analyses carried out.
There is substantial uncertainty around the evidence, in particular with regard to the comparative
effectiveness and cost-effectiveness of DEX and ADA and their effectiveness and cost-effectiveness
compared with those of systemic immunosuppressants and corticosteroids, as would be used in practice,
and how short-term improvements in visual acuity and inflammation relate to long-term effects on vision
loss and blindness. In addition, the way in which ADA and DEX would be used in practice and the impact
of the expected differences between clinical practice and the trial evidence on estimated outcomes are
uncertain. Finally, there are important subgroups for which the interventions may be more or less effective
and cost-effective; however, there was insufficient evidence to make robust conclusions around this.
Implications for service provision
The provision of ADA and DEX does not usually engender significant additional management costs.
Therefore, the burden on the NHS is generally related to the drug acquisition costs and the treatment
of AEs.
Suggested research priorities
l Development of guidance on which outcomes should be used and how they should be reported in
trials of non-infectious uveitis, outlining primary clinical outcomes as well as considering a standardised
way of reporting reduction in corticosteroid use.
l Primary research comparing:
¢ DEX with immunosuppressants over the long term in patients with localised (uveitis affecting one
eye or a flare in one eye) active uveitis
¢ ADA with immunosuppressants and other anti-TNFs over the long term in patients with systemic
bilateral active uveitis
¢ ADA, DEX, immunosuppressants and other anti-TNFs over the long term in patients with systemic
unilateral uveitis (or a flare in one eye).
l Researchers should consult a statistician and follow the Consolidated Standards of Reporting Trials
(CONSORT) statement134 when designing and undertaking RCTs.135
l Research on how short-term improvements in visual acuity or inflammation relate to long-term effects
on moderate-to-severe vision loss and blindness.
l An assessment of the impact of treatments within important subgroups, including patients with
unilateral and bilateral uveitis, those with severe uveitis, patients who are unresponsive to or who are
contraindicated for immunosuppressants, patients with macular oedema and patients with specific
underlying autoimmune or inflammatory diseases.
l A study of the long-term impacts of corticosteroids to gain further data on health and utility
decrements and costs.
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Appendix 1 Literature search strategies
Clinical effectiveness searches
MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations,
MEDLINE(R) Daily and MEDLINE(R) (1946 to 2016) (via Ovid)
Date searched: 13 June 2016.
# Searches
1 exp Uveitis/
2 uveiti*.mp.
3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*).tw.
4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*).tw.
5 ((vogt or harada or behcet* or blau* or jabs or reiter*) adj (disease or syndrome)).tw.
6 (vogt koyanagi harada or triple symptom complex).tw.
7 (ophthalm* adj2 sympathetic).tw.
8 exp Retinitis/
9 (retinitis or vitritis* or uveoretinitis or neuroretinitis).tw.
10 or/1-9
11 Meta-Analysis as Topic/
12 meta analy$.tw.
13 metaanaly$.tw.
14 Meta-Analysis/
15 (systematic adj (review$1 or overview$1)).tw.
16 exp Review Literature as Topic/
17 or/11-16
18 cochrane.ab.
19 embase.ab.
20 (psychlit or psyclit).ab.
21 (psychinfo or psycinfo).ab.
22 (cinahl or cinhal).ab.
23 science citation index.ab.
24 bids.ab.
25 cancerlit.ab.
26 or/18-25
27 reference list$.ab.
28 bibliograph$.ab.
29 hand-search$.ab.
30 relevant journals.ab.
31 manual search$.ab.
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# Searches
32 or/27-31
33 selection criteria.ab.
34 data extraction.ab.
35 33 or 34
36 Review/
37 35 and 36
38 Comment/
39 Letter/
40 Editorial/
41 animal/
42 human/
43 41 not (41 and 42)
44 or/38-40,43
45 17 or 26 or 32 or 37
46 45 not 44
47 Randomized Controlled Trials as Topic/
48 randomized controlled trial/
49 Random Allocation/
50 Double Blind Method/
51 Single Blind Method/
52 clinical trial/
53 clinical trial, phase i.pt.
54 clinical trial, phase ii.pt.
55 clinical trial, phase iii.pt.
56 clinical trial, phase iv.pt.
57 controlled clinical trial.pt.
58 randomized controlled trial.pt.
59 multicenter study.pt.
60 clinical trial.pt.
61 exp Clinical Trials as topic/
62 or/47-61
63 (clinical adj trial$).tw.
64 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw.
65 PLACEBOS/
66 placebo$.tw.
67 randomly allocated.tw.
68 (allocated adj2 random$).tw.
69 or/63-68
70 62 or 69
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# Searches
71 case report.tw.
72 letter/
73 historical article/
74 or/71-73
75 70 not 74
76 10 and (46 or 75)
EMBASE (1974–2016) (via Ovid)
Date searched: 13 June 2016.
# Searches
1 exp uveitis/
2 uveiti*.mp.
3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*).tw.
4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*).tw.
5 ((vogt or harada or behcet* or blau* or jabs or reiter*) adj (disease or syndrome)).tw.
6 (vogt koyanagi harada or triple symptom complex).tw.
7 (ophthalm* adj2 sympathetic).tw.
8 exp retinitis/
9 (retinitis or vitritis* or uveoretinitis or neuroretinitis).tw.
10 or/1-9
11 exp Meta Analysis/
12 ((meta adj analy$) or metaanalys$).tw.
13 (systematic adj (review$1 or overview$1)).tw.
14 or/11-13
15 cancerlit.ab.
16 cochrane.ab.
17 embase.ab.
18 (psychlit or psyclit).ab.
19 (psychinfo or psycinfo).ab.
20 (cinahl or cinhal).ab.
21 science citation index.ab.
22 bids.ab.
23 or/15-22
24 reference lists.ab.
25 bibliograph$.ab.
26 hand-search$.ab.
27 manual search$.ab.
28 relevant journals.ab.
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# Searches
29 or/24-28
30 data extraction.ab.
31 selection criteria.ab.
32 30 or 31
33 review.pt.
34 32 and 33
35 letter.pt.
36 editorial.pt.
37 animal/
38 human/
39 37 not (37 and 38)
40 or/35-36,39
41 14 or 23 or 29 or 34
42 41 not 40
43 Clinical trial/
44 Randomized controlled trial/
45 Randomization/
46 Single blind procedure/
47 Double blind procedure/
48 Crossover procedure/
49 Placebo/
50 Randomi?ed controlled trial$.tw.
51 Rct.tw.
52 Random allocation.tw.
53 Randomly allocated.tw.
54 Allocated randomly.tw.
55 (allocated adj2 random).tw.
56 Single blind$.tw.
57 Double blind$.tw.
58 ((treble or triple) adj blind$).tw.
59 Placebo$.tw.
60 Prospective study/
61 or/43-60
62 Case study/
63 Case report.tw.
64 Abstract report/ or letter/
65 or/62-64
66 61 not 65
67 10 and (42 or 66)
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Web of Science® Core Collection, Science Citation Index Expanded (1900–2016),
Conference Proceedings Citation Index – Science (1990–2016) (Thomson Reuters)
Date searched: 13 June 2016.
# Searches
#1 TOPIC: (uveiti*)
#2 TOPIC: ((panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*))
#3 TOPIC: ((iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*))
#4 TOPIC: (((vogt or harada or behcet* or blau* or jabs or reiter*) near (disease or syndrome)))
#5 TOPIC: ((vogt koyanagi harada or triple symptom complex))
#6 TOPIC: ((ophthalm* near/2 sympathetic))
#7 TOPIC: ((retinitis or vitritis* or uveoretinitis or neuroretinitis)
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#9 TOPIC: ((“clinic* trial*” or “randomi* controlled trial*”)) OR TOPIC: (((singl* or doubl* or treb* or tripl*) and (blind*
or mask*))) OR TOPIC: ((placebo*)) OR TOPIC: ((allocat* and random*))
#10 TOPIC: ((meta-analysis or meta analy* or metaanaly*)) OR TOPIC: ((“review literature” or “literature review”)) OR
TOPIC: ((“systematic review*” or “systematic overview*”)) OR TOPIC: ((cochrane or embase or psychlit or psyclit or
psychinfo or psycinfo or cinahl or cinhal or science citation index or bids or cancerlit)) OR TOPIC: ((“reference list*”
or bibliograph* or hand-search* or “relevant journals” or “manual search*”)) OR TOPIC: (((“selection criteria” or
“data extraction”) and review))
#11 #10 OR #9
#12 #11 AND #8
Cochrane Database of Systematic Reviews (CDSR) (1996–2016), Cochrane Central
Register of Controlled Trials (CENTRAL) (1898–2016), Health Technology Assessment
(HTA) database (1995–2016), Database of Abstracts of Reviews of Effects (DARE)
(1995–2015), NHS Economic Evaluation Database (NHS EED) (1995–2015)
(Wiley Online Library)
Date searched: 13 June 2016.
# Searches
#1 MeSH descriptor: [Uveitis] explode all trees
#2 uveiti*:ti,ab,kw
#3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*):ti,ab,kw
#4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*):ti,ab,kw
#5 ((vogt or harada or behcet* or blau* or jabs or reiter*) near (disease or syndrome)):ti,ab,kw
#6 (vogt koyanagi harada or triple symptom complex):ti,ab,kw
#7 (ophthalm* near/2 sympathetic):ti,ab,kw
#8 MeSH descriptor: [Retinitis] explode all trees
#9 (retinitis or vitritis* or uveoretinitis or neuroretinitis):ti,ab,kw
#10 #1 or #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9
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Cumulative Index to Nursing and Allied Health Literature (CINAHL)
(1982–2016) (EBSCOhost)
Date searched: 6 October 2016.
# Searches
S1 (MH “Uveitis+”)
S2 uveiti*
S3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*)
S4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*)
S5 ((vogt or harada or behcet* or blau* or jabs or reiter*) N1 (disease or syndrome))
S6 (vogt koyanagi harada or triple symptom complex)
S7 (ophthalm* N2 sympathetic)
S8 (MH “Retinitis+”)
S9 (retinitis or vitritis* or uveoretinitis or neuroretinitis)
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S11 (MH “Meta Analysis”)
S12 TI ( ( Meta analys* or Metaanaly* ) ) or AB ( ( Meta analys* or Metaanaly* ) )
S13 (MH “Literature Review+”)
S14 systematic N2 review or systematic N2 overview
S15 S11 or S12 or S13 or S14
S16 PT Commentary or PT Letter or PT Editorial
S17 (MH “Animals”)
S18 S16 or S17
S19 S15 not S18
S20 (MH “Clinical Trials+”)
S21 PT Clinical trial
S22 TI Randomi?ed control* trial* or AB Randomi?ed control* trial*
S23 (MH “Random Assignment”)
S24 (MH “Quantitative Studies”)
S25 TI Allocat* random* or AB Allocat* random*
S26 TI Random* allocat* or AB Random* allocat*
S27 TI Placebo* or AB Placebo*
S28 TI Placebos or AB Placebos
S29 TI ( (singl* or doubl* or trebl* or tripl*) and (blind* or mask*) ) or AB ( (singl* or doubl* or trebl* or tripl*) and
(blind* or mask*) )
S30 TI clinic* N1 trial* or AB clinic* N1 trial*
S31 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30
S32 S10 and (S19 or S31)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
Cost-effectiveness studies
MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations,
MEDLINE(R) Daily and MEDLINE(R) (1946–2016) (Ovid)
Date searched: 7 June 2016.
# Searches
1 exp Uveitis/
2 uveiti*.mp.
3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*).tw.
4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*).tw.
5 ((vogt or harada or behcet* or blau* or jabs or reiter*) adj (disease or syndrome)).tw.
6 (vogt koyanagi harada or triple symptom complex).tw.
7 (ophthalm* adj2 sympathetic).tw.
8 exp Retinitis/
9 (retinitis or vitritis* or uveoretinitis or neuroretinitis).tw.
10 or/1-9
11 Economics/
12 “costs and cost analysis”/
13 Cost-benefit analysis/
14 Cost control/
15 Cost savings/
16 Cost of illness/
17 Cost sharing/
18 “deductibles and coinsurance”/
19 Medical savings accounts/
20 Health care costs/
21 Direct service costs/
22 Drug costs/
23 Employer health costs/
24 Hospital costs/
25 Health expenditures/
26 Capital expenditures/
27 Value of life/
28 exp economics, hospital/
29 exp economics, medical/
30 Economics, nursing/
31 Economics, pharmaceutical/
32 exp “fees and charges”/
33 exp budgets/
34 (low adj cost).mp.
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# Searches
35 (high adj cost).mp.
36 (health?care adj cost*).mp.
37 (fiscal or funding or financial or finance).tw.
38 (cost adj estimate*).mp.
39 (cost adj variable).mp.
40 (unit adj cost*).mp.
41 (economic* or pharmacoeconomic* or price* or pricing).tw.
42 or/11-41
43 10 and 42
EMBASE (1974–2016) (Ovid)
Date searched: 7 June 2016.
# Searches
1 exp uveitis/
2 uveiti*.mp.
3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*).tw.
4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*).tw.
5 ((vogt or harada or behcet* or blau* or jabs or reiter*) adj (disease or syndrome)).tw.
6 (vogt koyanagi harada or triple symptom complex).tw.
7 (ophthalm* adj2 sympathetic).tw.
8 exp retinitis/
9 (retinitis or vitritis* or uveoretinitis or neuroretinitis).tw.
10 or/1-9
11 Socioeconomics/
12 Cost benefit analysis/
13 Cost effectiveness analysis/
14 Cost of illness/
15 Cost control/
16 Economic aspect/
17 Financial management/
18 Health care cost/
19 Health care financing/
20 Health economics/
21 Hospital cost/
22 (fiscal or financial or finance or funding).tw.
23 Cost minimization analysis/
24 (cost adj estimate*).mp.
25 (cost adj variable*).mp.
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# Searches
26 (unit adj cost*).mp.
27 or/11-26
28 10 and 27
Web of Science® Core Collection, Science Citation Index Expanded (1900–2016),
Conference Proceedings Citation Index – Science (1990–2016) (Thomson Reuters)
Date searched: 7 June 2016.
# Searches
#1 TOPIC: (uveiti*)
#2 TOPIC: ((panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*))
#3 TOPIC: ((iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*))
#4 TOPIC: (((vogt or harada or behcet* or blau* or jabs or reiter*) near (disease or syndrome)))
#5 TOPIC: ((vogt koyanagi harada or triple symptom complex))
#6 TOPIC: ((ophthalm* near/2 sympathetic))
#7 TOPIC: ((retinitis or vitritis* or uveoretinitis or neuroretinitis))
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#9 TOPIC: ((cost* and (effective* or utilit* or benefit* or minimi*))) OR TOPIC: (cost*) OR TOPIC: ((economic* or
pharmacoeconomic* or pharmaco-economic*)) OR TOPIC: ((financial or finance or finances or financed)) OR TOPIC:
((fee or fees)) OR TOPIC: ((value and (money or monetary))) OR TOPIC: ((economic* and (hospital or medical or
nursing or pharmaceutical))) OR TOPIC: ((“quality adjusted life year” or “quality adjusted life years”)) OR TOPIC:
((qaly or qalys)) OR TOPIC: (budget*) OR TOPIC: ((price* or pricing*))
#10 #9 AND #8
Cochrane Database of Systematic Reviews (CDSR) (1996–2016), Health Technology
Assessment (HTA) database (1995–2016), Database of Abstracts of Reviews of Effects
(DARE) (1995–2015), NHS Economic Evaluation Database (NHS EED) (1995–2015)
(Wiley Online Library)
Date searched: 7 June 2016.
# Searches
#1 MeSH descriptor: [Uveitis] explode all trees
#2 uveiti*:ti,ab,kw
#3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*):ti,ab,kw
#4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*):ti,ab,kw
#5 ((vogt or harada or behcet* or blau* or jabs or reiter*) near (disease or syndrome)):ti,ab,kw
#6 (vogt koyanagi harada or triple symptom complex):ti,ab,kw
#7 (ophthalm* near/2 sympathetic):ti,ab,kw
#8 MeSH descriptor: [Retinitis] explode all trees
#9 (retinitis or vitritis* or uveoretinitis or neuroretinitis):ti,ab,kw
#10 #1 or #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9
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Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982–2016) (EBSCOhost)
Date searched: 6 October 2016.
# Searches
S1 (MH “Uveitis+”)
S2 uveiti*
S3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*)
S4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*)
S5 ((vogt or harada or behcet* or blau* or jabs or reiter*) N1 (disease or syndrome))
S6 (vogt koyanagi harada or triple symptom complex)
S7 (ophthalm* N2 sympathetic)
S8 (MH “Retinitis+”)
S9 (retinitis or vitritis* or uveoretinitis or neuroretinitis)
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S11 (MH “Costs and Cost Analysis+”)
S12 (MH “Economics”)
S13 (MH “Economics, Pharmaceutical”)
S14 (MH “Fees and Charges+”)
S15 (MH “Budgets”)
S16 budget*
S17 cost*
S18 AB cost* and (effective* or utilit* or benefit* or minimi*)
S19 TI economic* or pharmacoeconomic* or pharmaco-economic*
S20 price* or pricing*
S21 financial or finance or finances or financed
S22 fee or fees
S23 value and (money or monetary)
S24 qaly or qalys
S25 quality adjusted life year or quality adjusted life years
S26 S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25
S27 S10 AND S26
Quality-of-life studies
MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations
MEDLINE(R) Daily and MEDLINE(R) (1946–2016) (Ovid)
Date searched: 9 June 2016.
# Searches
1 exp Uveitis/
2 uveiti*.mp.
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# Searches
3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*).tw.
4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*).tw.
5 ((vogt or harada or behcet* or blau* or jabs or reiter*) adj (disease or syndrome)).tw.
6 (vogt koyanagi harada or triple symptom complex).tw.
7 (ophthalm* adj2 sympathetic).tw.
8 exp Retinitis/
9 (retinitis or vitritis* or uveoretinitis or neuroretinitis).tw.
10 or/1-9
11 “Quality of Life”/
12 (qol or (quality adj2 life)).ab,ti.
13 (value adj2 (money or monetary)).tw.
14 value of life/
15 quality adjusted life year/
16 quality adjusted life.tw.
17 (qaly* or qald* or qale* or qtime*).tw.
18 disability adjusted life.tw.
19 daly*.tw.
20 health status indicators/
21 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).tw.
22 (sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
23 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
24 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short form
sixteen).tw.
25 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty).tw.
26 (euroqol or euro qol or eq5d or eq 5d).tw.
27 (hql or hqol or h qol or hrqol or hr qol).tw.
28 (hye or hyes).tw.
29 health* year* equivalent*.tw.
30 health utilit*.tw.
31 (hui or hui1 or hui2 or hui3).tw.
32 disutilit*.tw.
33 rosser.tw.
34 (quality adj2 wellbeing).tw.
35 qwb.tw.
36 (willingness adj2 pay).tw.
37 standard gamble*.tw.
38 time trade off.tw.
DOI: 10.3310/hta21680 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 68
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Squires et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
139
# Searches
39 time tradeoff.tw.
40 tto.tw.
41 letter.pt.
42 editorial.pt.
43 comment.pt.
44 41 or 42 or 43
45 or/11-40
46 45 not 44
47 10 and 46
EMBASE (1974–2016) (Ovid)
Date searched: 9 June 2016.
# Searches
1 exp uveitis/
2 uveiti*.mp.
3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*).tw.
4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*).tw.
5 ((vogt or harada or behcet* or blau* or jabs or reiter*) adj (disease or syndrome)).tw.
6 (vogt koyanagi harada or triple symptom complex).tw.
7 (ophthalm* adj2 sympathetic).tw.
8 exp retinitis/
9 (retinitis or vitritis* or uveoretinitis or neuroretinitis).tw.
10 or/1-9
11 “Quality of Life”/
12 (qol or (quality adj2 life)).ti,ab.
13 (value adj2 (money or monetary)).tw.
14 socioeconomics/
15 quality adjusted life year/
16 (qaly$ or qald$ or qale$ or qtime$).tw.
17 disability adjusted life.tw.
18 daly$.tw.
19 health survey/
20 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).tw.
21 (sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
22 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
23 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short form
sixteen).tw.
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# Searches
24 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty).tw.
25 (euroqol or euro qol or eq5d or eq 5d).tw.
26 (hql or hqol or h qol or hrqol or hr qol).tw.
27 (hye or hyes).tw.
28 health$ year$ equivalent$.tw.
29 health utilit$.tw.
30 (hui or hui1 or hui2 or hui3).tw.
31 disutilit$.tw.
32 rosser.tw.
33 (quality adj2 wellbeing).tw.
34 qwb.tw.
35 (willingness adj2 pay).tw.
36 standard gamble$.tw.
37 time trade off.tw.
38 time tradeoff.tw.
39 tto.tw.
40 letter.pt.
41 editorial.pt.
42 comment.pt.
43 40 or 41 or 42
44 or/11-39
45 44 not 43
46 10 and 45
Web of Science® Core Collection, Science Citation Index Expanded (1900–2016),
Conference Proceedings Citation Index – Science (1990–2016) (Thomson Reuters)
Date searched: 9 June 2016.
# Searches
#1 TOPIC: (uveiti*)
#2 TOPIC: ((panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*))
#3 TOPIC: ((iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*))
#4 TOPIC: (((vogt or harada or behcet* or blau* or jabs or reiter*) near (disease or syndrome)))
#5 TOPIC: ((vogt koyanagi harada or triple symptom complex))
#6 TOPIC: ((ophthalm* near/2 sympathetic))
#7 TOPIC: ((retinitis or vitritis* or uveoretinitis or neuroretinitis))
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
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# Searches
#9 TOPIC: ((qol or “quality of life” or “quality adjusted life”)) OR TOPIC: ((qaly* or qald* or qale* or qtime*)) OR
TOPIC: ((“disability adjusted life” or daly*)) OR TOPIC: ((sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix
or sf thirty six or shorform thirtysix or shortform thirty six or short form thirtysix or short form thirty six)) OR TOPIC:
((sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six)) OR TOPIC: ((sf12 or sf
12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve)) OR TOPIC:
((sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short form sixteen))
OR TOPIC: ((sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short
form twenty)) OR TOPIC: ((euroqol or euro qol or eq5d or eq 5d)) OR TOPIC: ((hql or hqol or h qol or hrqol or hr
qol)) OR TOPIC: ((hye or hyes)) OR TOPIC: ((“health* year* equivalent*”)) OR TOPIC: ((“health utilit*”)) OR TOPIC:
((hui or hui1 or hui2 or hui3)) OR TOPIC: ((disutilit* or rosser)) OR TOPIC: ((“quality of wellbeing” or qwb or
“willingness to pay”)) OR TOPIC: ((“standard gamble*” or “time trade off” or “time tradeoff” or tto))
#10 #9 AND #8
Cochrane Database of Systematic Reviews (CDSR) (1990–2016), Cochrane Central Register
of Controlled Trials (CENTRAL) (1898–2016), Health Technology Assessment (HTA)
database (1995–2016), Database of Abstracts of Reviews of Effects (DARE) (1995–2015),
NHS Economic Evaluation Database (NHS EED) (1995–2015) (Wiley Online Library)
Date searched: 9 June 2016.
# Searches
#1 MeSH descriptor: [Uveitis] explode all trees
#2 uveiti*:ti,ab,kw
#3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*):ti,ab,kw
#4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*):ti,ab,kw
#5 ((vogt or harada or behcet* or blau* or jabs or reiter*) near (disease or syndrome)):ti,ab,kw
#6 (vogt koyanagi harada or triple symptom complex):ti,ab,kw
#7 (ophthalm* near/2 sympathetic):ti,ab,kw
#8 MeSH descriptor: [Retinitis] explode all trees
#9 (retinitis or vitritis* or uveoretinitis or neuroretinitis):ti,ab,kw
#10 #1 or #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9
Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982–2016) (EBSCOhost)
Date searched: 6 October 2016.
# Searches
S1 (MH “Uveitis+”)
S2 uveiti*
S3 (panuveitis or pars planitis or panophthalmitis or uveomeningoencephaliti*)
S4 (iridocycliti* or heterochromic cycliti* or anterior scleritis or iriti* or choroiditi* or retinochoroiditi* or
retinochoroidopath* or chorioretinitis or chorioretinopath*)
S5 ((vogt or harada or behcet* or blau* or jabs or reiter*) N1 (disease or syndrome))
S6 (vogt koyanagi harada or triple symptom complex)
S7 (ophthalm* N2 sympathetic)
S8 (MH “Retinitis+”)
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# Searches
S9 (retinitis or vitritis* or uveoretinitis or neuroretinitis)
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S11 (MH “Quality of Life”)
S12 TI ( qol or (quality N2 life) ) or AB ( qol or (quality N2 life) )
S13 TI value and TI ( money or monetary ) or AB value and AB ( money or monetary )
S14 (MH “Economic Value of Life”)
S15 (MH “Quality-Adjusted Life Years”)
S16 TI ( qaly* or qald* or qale* or qtime* ) or AB ( qaly* or qald* or qale* or qtime* )
S17 TI disability adjusted life or AB disability adjusted life
S18 TI daly* or AB daly*
S19 (MH “Health Status Indicators”)
S20 TI ( sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform
thirty six or short form thirtysix or short form thirty six ) or AB ( sf36 or sf 36 or short form 36 or shortform 36 or sf
thirtysix or sf thirty six or shorform thirtysix or shortform thirty six or short form thirtysix or short form thirty six )
S21 TI ( sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six ) or AB ( sf 6 or sf6
or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six )
S22 TI quality adjusted life or AB quality adjusted life
S23 TI ( sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve )
or AB ( sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form
twelve )
S24 TI ( sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short form
sixteen ) or AB ( sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or
short form sixteen )
S25 TI ( sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty ) or AB ( sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or
short form twenty )
S26 TI ( euroqol or euro qol or eq5d or eq 5d ) or AB ( euroqol or euro qol or eq5d or eq 5d )
S27 TI ( hql or hqol or h qol or hrqol or hr qol ) or AB ( hql or hqol or h qol or hrqol or hr qol )
S28 TI ( hye or hyes ) or AB ( hye or hyes )
S29 TI health* year* equivalent* or AB health* year* equivalent*
S30 TI health utilit* or AB health utilit*
S31 TI ( hui or hui1 or hui2 or hui3 ) or AB ( hui or hui1 or hui2 or hui3 )
S32 TI disutilit* or AB disutilit*
S33 TI rosser or AB rosser
S34 TI quality N2 wellbeing or AB quality N2 wellbeing
S35 TI qwb or AB qwb
S36 TI willingness N2 pay or AB willingness N2 pay
S37 TI standard gamble* or AB standard gamble*
S38 TI time trade off or AB time trade off
S39 TI time tradeoff or AB time tradeoff
S40 TI tto or AB tto
S41 PT letter
S42 PT editorial
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# Searches
S43 PT comment
S44 S41 or S42 or S43
S45 S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or
S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40
S46 S45 NOT S44
S47 S10 AND S46
Costs and utilities of blindness
MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations,
MEDLINE(R) Daily and MEDLINE(R) (1946–2016) (Ovid)
Date searched: 20 October 2016.
# Searches
1 blindness.ti.
2 ((sight or visual or vision) adj1 loss).ti.
3 1 or 2
4 exp “costs and cost analysis”/
5 costs.tw.
6 cost effective:.tw.
7 or/4-6
8 3 and 7
9 limit 8 to yr=“2006 -Current”
10 “Quality of Life”/
11 (qol or (quality adj2 life)).ab,ti.
12 (value adj2 (money or monetary)).tw.
13 value of life/
14 quality adjusted life year/
15 quality adjusted life.tw.
16 (qaly$ or qald$ or qale$ or qtime$).tw.
17 disability adjusted life.tw.
18 daly$.tw.
19 health status indicators/
20 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).tw.
21 (sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
22 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
23 (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form six D).tw.
24 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty).tw.
25 (euroqol or euro qol or eq5d or eq 5d).tw.
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# Searches
26 (hql or hqol or h qol or hrqol or hr qol).tw.
27 (hye or hyes).tw.
28 health$ year$ equivalent$.tw.
29 health utilit$.tw.
30 (hui or hui1 or hui2 or hui3).tw.
31 disutilit$.tw.
32 rosser.tw.
33 (quality adj2 wellbeing).tw.
34 qwb.tw.
35 (willingness adj2 pay).tw.
36 standard gamble$.tw.
37 time trade off.tw.
38 time tradeoff.tw.
39 tto.tw.
40 letter.pt.
41 editorial.pt.
42 comment.pt.
43 40 or 41 or 42
44 or/10-39
45 44 not 43
46 3 and 45
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Appendix 2 Table of excluded studies
with reasons
Reference Intervention/conditions Reason(s) for exclusion
Population not non-infectious uveitis (intermediate/posterior/panuveitis) (n = 28)
Allegri 2014136 Indomethacin in macular oedema Includes patients with anterior and postinfective
uveitis (includes other ocular disease)
Alpsoy 2002137 Interferon-alpha-2a in Behçet’s disease Not a homogeneous group of patients with
Behçet’s uveitis
Biryukova 2015138 Simvastatin Includes patients with anterior uveitis
Blumenkranz 2010139 DEX for macular oedema Most patients did not have uveitis; no separate
data
Boscia 2005140 Intravitreal triamcinolone for cystoid
macular oedema
Not a RCT; not specific to uveitis
Buggage 2007141 Daclizumab in Behçet’s disease Uveitis or retinal vasculitis; no separate data.
Daclizumab (anti-interleukin-2) not in scope
Dada 2007142 Triamcinolone post cataract n= 28/40 anterior uveitis; no separate data
Davatchi 2004143 Cyclophosphamide in Behçet’s disease Population uveitis or retinal vasculitis; no separate
data. Posterior uveitis recorded as an outcome
not a population
Davatchi 2009144 Colchicine in Behçet’s disease Not specific to uveitis
Davatchi 2010145 Rituximab in Behçet’s disease Posterior uveitis recorded as an outcome not a
population
Foster 1996146 Rimexolone vs. prednisolone Anterior segment uveitis
Gupta 2013147 DEX in cataract Population included patients with tuberculous
uveitis and anterior uveitis; DEX administered
during cataract surgery
Kuppermann 2007148 DEX in macular oedema Patients (aged > 12 years) with macular oedema;
not specific to uveitis
Landewé 2014149 Certolizumab pegol in axial
spondyloarthritis
Data for new cases of uveitis only
Louis 2016150 ADA in Crohn’s disease No data for uveitis only
Parodi 2010151 Bevacizumab vs. photodynamic therapy Neither treatment in scope; for treating
neovascularisation. Population multifocal
choroiditis
Perkins 1956152 Pyrimethamine Includes patients with anterior uveitis and
infectious uveitis. Intervention not in scope
Perkins 1965153 Indomethacin Mostly anterior uveitis; some infectious uveitis
Roesel 2009154 Triamcinolone, two routes in cataract
surgery
Includes patients with anterior uveitis and
patients undergoing cataract surgery
Roesel 2010155 Triamcinolone vs. prednisolone in
cataract surgery
Includes patients with anterior uveitis and
patients undergoing cataract surgery
Rosenbaum 2004156 Etanercept and iritis Summary of iritis cases across trials of etanercept
in ankylosing spondylitis
Rudwaleit 2014157 Certolizumab pegol in axial
spondyloarthritis
Not uveitis population. Data relate to uveitis
flares (nine cases in total)
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Reference Intervention/conditions Reason(s) for exclusion
Rudwaleit 2016158 Certolizumab pegol in axial
spondyloarthritis
Not uveitis population. Data relate to uveitis
flares (seven cases in total)
Schlaegel 1969159 Isoniazid Mostly infectious uveitis (tuberculosis)
Sieper 2010160 Etanercept uveitis rates in trials of
ankylosing spondylitis
Summary of uveitis cases across trials of
etanercept in ankylosing spondylitis
Van den Bosch 2002161 Infliximab Uveitis reported only as an AE (in one patient)
Williams 2009162 DEX Patients with macular oedema as a result of
uveitis or Irvine–Gass syndrome
Yates 2015163 Etanercept in ankylosing spondylitis Uveitis reported only as an AE (in three patients)
Intervention not relevant (n = 25)
Callanan 2008164 Fluocinolone (two doses, USA) Compared with non-licensed dose
Choi 2005165 Vitrectomy vs. immunomodulatory
treatment
Not in scope
de Smet 1992166 Ciclosporin and ketoconazole High-dose ciclosporin vs. lower-dose ciclosporin
plus ketoconazole
Dick 2013167 Secukinumab (three trials vs. placebo) Not in scope
Farber 1994168 Acetazolamide in macular oedema Not in scope
Haller 2009169 DEX RCT comparing the effect of the insertion
procedure
Ibrahim 2015170 SAVE trial Not in scope
Jaffe 2006171 Fluocinolone (two doses, USA) Compared with non-licensed dose
Lashay 2003172 Acetazolamide in uveitic macular
oedema in Behçet’s disease
Not in scope
Letko 2015173 Secukinumab (one trial of three doses) Not in scope
Neri 2006174 Echinacea Not in scope
Nguyen 2013175 SAVE trial Not in scope
Nussenblatt 1997176 Retinal antigens Not in scope
Nussenblatt 2006177 Vitamin E Not in scope
Quinones 2010178 Vitrectomy Not in scope
Rahimi 2012179 Bevacizumab vs. triamcinolone in uveitic
macular oedema
Not in scope
Sangwan 2015180 Fluocinolone (two doses, Asia) Compared with non-licensed dose; most data not
from RCT
Soheilian 2010181 Bevacizumab vs. triamcinolone in uveitic
macular oedema
Not in scope
Soheilian 2010182 Bevacizumab vs. triamcinolone in uveitic
macular oedema
Not in scope
Soheilian 2013183 Diclofenac vs. triamcinolone in uveitic
macular oedema
Not in scope
Soheilian 2013184 Diclofenac vs. triamcinolone in uveitic
macular oedema
Not in scope
Tranos 2006185 Vitrectomy Not in scope
van Kooij 2006186 Lisinopril Not in scope
Vigil 2015187 SAVE trial Not in scope
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Reference Intervention/conditions Reason(s) for exclusion
Whitcup 1996188 Acetazolamide in uveitic macular
oedema
Not in scope
No relevant outcomes or data (n = 15)
Bodaghi 200116 Various treatments Retrospective analysis of causes of uveitis
Goldstein 2007189 Fluocinolone Analysis of the results of three RCTs of
fluocinolone
Holbrook 2016190 Fluocinolone (MUST trial) Outcome was dissociation of the drug pellet
Mackensen 2008191 Methotrexate vs. interferon in uveitic
macular oedema
Secondary publication; intermediate results only
Masuda 1989192 Ciclosporin vs. colchicine in Behçet’s
disease
Outcomes were ‘frequency of ocular attack’ and
‘severity of ocular attack’ but these were not
defined
Mercante 2007193 Fluocinolone (two doses) No comparison of data between groups
Muller 2004194 Fluocinolone (two doses) In German; duplicate publication. Same as
Sangwan et al.180
Multicenter Uveitis Steroid
Treatment Trial Research
Group 2010102
Fluocinolone (MUST) study design Secondary publication; no additional data
Nussenblatt 1993195 Ciclosporin A and G Compares two subtypes of same drug; cannot
connect to network
Parekh 2015196 Fluocinolone (IOP risk in three trials) Analysis of the results of three RCTs of
fluocinolone
Pavesio 2006197 Fluocinolone Secondary publication; preliminary data. Final
data in Pavesio et al.58
Sheppard 2012198 Fluocinolone (two doses) No comparison of data between groups.
Secondary publication of Sangwan et al.180
Soheilian 2007199 Bevacizumab vs. triamcinolone in uveitic
macular oedema
Secondary publication. Same as Soheilian
et al.181,182
Waheed 2002200 Etanercept (abstract) Secondary publication of Foster et al.61
Williams 2003201 DEX (Posurdex™, Oculex
Pharmaceuticals, Sunnyvale, CA, USA)
Secondary publication of Kuppermann et al.;148
no results reported
Not a RCT (n = 33)
Abu El-Asrar 2012202 Mycophenolate mofetil in VKH Not a RCT
Barreiro-de-Acosta
2012203
ADA for Crohn’s disease Not a RCT
Benitez-del-Castillo
2005204
Infliximab Not a RCT
Bollinger 2009205 Management of IOP with fluocinolone
implant
Review of three RCTs reporting the adverse
effects of fluocinolone acetonide
Callejas-Rubio 2008206 ADA Not a RCT (single-arm study)
Castellino 1994207 Ciclosporin Not a RCT
Chavis 1992208 Ciclosporin Not a RCT
Chinchurreta Capote
2014209
ADA in serpiginous choroiditis Letter
Coskun 2015210 DEX in Behçet’s disease uveitis Retrospective analysis of a single DEX implant
(posterior uveitis as a result of Behçet’s disease)
Davatchi 2003211 Methotrexate in Behçet’s disease Not a RCT (controlled study)
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Reference Intervention/conditions Reason(s) for exclusion
Denniston 2016212 ADA News article
Ermertcan 2014213 ADA Case report of patients with psoriatic uveitis
Frick 201239 Fluocinolone (MUST) No RCT data, only baseline data. Reports visual
acuity and quality of life
Giardina 2011214 Infliximab in Behçet’s disease Not a RCT
Hamuryudan 1997215 Azathioprine in Behçet’s disease Reanalysis of patients in RCT by Yazici et al.62
Helveston 1996216 Intravenous immunoglobulin Case report
Jaffe 2000217 DEX Case report
Jaffe 2008218 Fluocinolone Not a RCT
Khalil 2015219 Methotrexate in Behçet’s disease Case series
Mehryar 2001220 Sulfasalazine vs. cyclophosphamide in
Behçet’s disease
Not a RCT
Mochizuki 1993221 Tacrolimus (FK506) in Behçet’s disease Not a RCT. Also compares doses only
(no placebo/other group). Same as Sakane et al.227
Multicenter Uveitis Steroid
Treatment Trial Research
Group 2014101
Fluocinolone (MUST) Not a RCT; cost-effectiveness analysis
Murphy 2007222 Ciclosporin vs. tacrolimus Not a RCT
Naik 2013223 DEX (HURON) Not a RCT. Comparison of PROMs using baseline
data from the HURON trial and national data
Nguyen 2009224 Fluocinolone Not a RCT. Expert perspectives
Ozsahin 2012225 TNF inhibitor Case report
Ozyazgan 1992226 Ciclosporin vs. cyclophosphamide Not a RCT. Patients randomised but then could
choose treatment
Sakane 1995227 Tacrolimus (FK506) Not a RCT. Also compares doses only
(no placebo/other group) and non-English-language
study (Japanese). Same as Mochizuki221
Sen 2012228 Fluocinolone (MUST) Not a RCT. Prevalence of hypotony at baseline in
the MUST trial
Sen 2016229 Fluocinolone (MUST) Not a RCT. Nested cohort study of visual acuity
outcomes after cataract surgery
Suhler 2013230 ADA Single-arm study
Tay-Kearney 2006231 Triamcinolone Not a RCT. Clinical summary
Zlatanovic´ 2012232 TNF-alpha antagonist Not a RCT. Non-English publication (Serbian)
Other (n = 16)
Anonymous 2012233 Fluocinolone (MUST) Letter to editor; erratum
Cunningham 2010234 TNF inhibitors Editorial
Cunningham 2012235 TNF inhibitors Editorial
Farber 1992236 Acetazolamide Clinical trial record
Fraser-Bell 2008237 Various Review of treatments in patients with uveitis
Goldstein 2009238 TNF inhibitors Letter
Gonzalez 2005239 Fluocinolone Editorial
Hall 2015240 Fluocinolone Letter to editor (difference between Retisert and
Iluvien)
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Reference Intervention/conditions Reason(s) for exclusion
Lai 2005241 Periocular corticosteroids Letter
Masuda 1986242 Ciclosporin Non-English-language study (Chinese). Other
report of this study192 was excluded as the
outcomes were not sufficiently robust
Puchalska-Niedbał 1989243 FIBS preparation (not defined) Non-English-language study (Polish). Some
patients with infectious uveitis; unlikely to be
relevant intervention
Rho 1996244 Acetazolamide Letter
Shimakawa 2002245 Corticosteroids (oral vs. topical) Non-English-language study (Chinese). Likely
non-RCT
Wiederholt 1986246 Ciclosporin vs. prednisolone Non-English-language study (German). Only eight
patients and data difficult to interpret
Wirostko 1997247 Scleritis-associated uveitis Letter
Zhou 2010248 Traditional Chinese medicine Non-English-language study (Chinese).
Intervention not in scope
SAVE, Sirolimus as therapeutic Approach to uVEitis.
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Appendix 3 Data extraction form
Reviewer:
Study reference Study name Author year Setting(s)
Study population
Inclusion and exclusion criteria:
Age: Percentage males:
Sample size (number of patients randomised): Sample size (number of eyes randomised):
Type of uveitis (intermediate uveitis, posterior uveitis, panuveitis/active, non-active/bilateral or unilateral):
Cause of uveitis (‘known systemic condition’, ‘no known systemic condition’, ‘not reported’, ‘unclear’):
State known systemic condition(s):
Prior treatment received (including treatment for any associated systemic condition)? Yes/no
List prior treatment(s):
Concomitant treatment(s) (‘ALL’ if treatment was received by all patients or ‘PRN’ if treatment was given as needed):
List concomitant treatment(s):
Baseline BCVA: Baseline IOP:
Baseline VH grade: Baseline central macular thickness:
Outcomes
Outcomes reported in the study: Follow-up schedule for assessments:
Treatment arm and comparator arm
Allocated treatment (dosing routine and duration of treatment):
Number randomised (patients/eyes):
Number analysed (patients/eyes):
Details of any excluded/lost/withdrawn post randomisation and reasons:
Vision or visual acuity outcomes reported:a
Outcomes of intraocular inflammation activity (e.g. VH grade or AC cell grade) reported:a
Reported outcomes of uveitis-related tissue damage or complications (e.g. cataract, macular oedema):a
Other outcomes reported (e.g. composite outcomes):a
Patient-reported outcomes reported:a
Ocular and systemic adverse effects reported:a
Relevance for network meta-analysis
Clinically relevant? Yes/no
Connects relevant treatments via network? Yes/no
PRN, pro re nata.
a Comparisons between study arms were abstracted or calculated.
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Appendix 4 Criteria for assessment of the
methodological quality of included studies
Quality item
Reviewer’s
judgement Details
1. Were participants assigned to study
groups using an acceptable random
method?
Yes Use of centrally generated random numbers, random number
tables, throwing dice
No Use of case record numbers, date of birth or alternation or
rotation
Unclear Insufficient details to assess quality item
2. Was allocation concealment
adequately conducted?
Yes Allocation to study arms achieved by using interactive or
web-based system or sequentially numbered opaque envelopes
No Allocation to study arms achieved without appropriate
measures, e.g. unsealed, transparent envelopes, date of birth,
alternation or rotation or other unconcealed methods
Unclear Insufficient details to assess quality item
3. Were eligibility criteria specified for
selecting participants?
Yes Eligibility criteria for study participants specified at study entry
No Eligibility criteria for study participants not specified at study
entry
Unclear Insufficient details to assess quality item
4. Was the study adequately powered? Yes Sample size considered to be adequate (i.e. ≥ 80%) based on
the a priori sample size calculation and significance level to
detect a minimally clinically significant difference in the primary
outcome of interest
No Sample size considered to be inadequate (i.e. < 80%) based on
the a priori sample size calculation and significance level to
detect a minimally clinically significant difference in the primary
outcome of interest
Unclear Insufficient details to assess quality item
5. Were study groups comparable for
most prognostic indicators at baseline?
Yes Key prognostic variables (e.g. age, visual acuity, IOP) were
reported to be similar in relevant treatment groups at baseline
No Key prognostic variables (e.g. age, visual acuity, IOP) were
reported to be different between relevant treatment groups at
baseline
Unclear Insufficient details to assess quality item
6. Were patients and investigators/
outcome assessors blinded to treatment
allocation?
Yes Patients, investigators and/or outcome assessors could not
identify administered study treatments
No Patients, investigators and/or outcome assessors may possibly
identify administered study treatments
Unclear Insufficient details to assess quality item
7. Was follow-up adequate (≥ 70%
randomised patients analysed)?
Yes ≥ 70% of randomised patients (or eyes) were included in the
analysis
No <70% of randomised patients (or eyes) were included in the
analysis
Unclear Insufficient details to assess quality item
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Quality item
Reviewer’s
judgement Details
8. Were reasons for attrition/exclusions
stated?
Yes Number of patients lost to follow-up (including withdrawals and
those excluded from analysis) was reported to ensure
completeness of data
No Incomplete data reporting noted because number of patients
lost to follow-up (including withdrawals and those excluded
from analysis) was not reported
Unclear Insufficient details to assess quality item
9. Was an intention-to-treat analysis
included?
Yes Outcome data for all patients initially randomised to a specific
study arm were included in the analysis of the specified
outcome
No Outcome data for selected patients initially randomised to a
specific study arm were included in the analysis of the specified
outcome
Unclear Insufficient details to assess quality item
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Appendix 5 Effectiveness data from non-
randomised studies of the dexamethasone implant
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Study and design
Number of
patients/eyes,
follow-up and
number of
implants BCVA VH CRT Repeat implantations Other
Adán 201385
retrospective study
of DEX 700 after
vitrectomy for
uveitic macular
oedema, Spain
l 13 patients,
17 eyes
l 12 months
l Single: 9 eyes;
repeat: 8 eyes
Median improvement in
BCVA at 1 month was
one line (range 0–3;
n= 15 eyes; p< 0.01),
increasing to two lines
by 3 months; 52.9% of
eyes improved by two
or more lines (p < 0.01).
Improvement was
maintained in 5 eyes
(29.4%) at 6 months. No
eyes lost more than one
line of BCVA from
baseline (p = 0.003)
NR Mean (SD) CRT at baseline
was 461.6 (121.7) µm,
decreasing to 277.2
(66.5) µm at 1 month
(p< 0.01); at 3 and
6 months mean (SD) CRT
was 349.9 (143.2) µm
(p= 0.01) and 394.1
(138.4) µm (p= 0.14)
respectively. Reduction in
CRT of > 100 µm in 10 eyes
(62%) at 1 month, 8 eyes
(47.1%) at 3 months
and 5 eyes (29.4%) at
6 months
NR Duration of response:
over follow-up (mean 9.6
months, range 6–17
months), relapse of CMO
(CRT increase of
> 150 µm from lowest
level post implant) in 8/17
eyes (47.1%) after mean
of 6.5 months (range
3–11 months) follow-up.
These eyes had a repeat
implant
Khurana 201586
retrospective
review of DEX 700
for cystoid macular
oedema secondary
to non-infectious
uveitis, single
centre, USA
l 13 patients,
18 eyes
l 3 months
l 1: 8 eyes;
2–4: 10 eyes
Mean BCVA at baseline
0.449 logMAR (Snellen
20/60); improved to
0.238 logMAR (20/30) by
1 month. Significant
improvement at 1 month
(2.0 lines; p= 0.0016),
3 months (2.1 lines;
p= 0.0051), 6 months
(2.1 lines; p= 0.014) and
12 months (1.4 lines;
p= 0.11). Improvement
of two or more lines in
47% of eyes at 1 month
and 50% at 3 months
Baseline VH was grade 1
in 33% of eyes and
grade 2 in 11% of eyes.
Mean VH was grade 0
at 1, 3, 6 and 12
months of follow-up
After first implant, complete
resolution of CMO in 89%
of eyes at 1 month and
72% of eyes at 3 months.
In eyes without epiretinal
membrane, CRT decreased
at 1 month (190 µm;
p= 0.00048) and 3 months
(228 µm; p= 0.0039). In
eyes with epiretinal
membrane, mean change
was not significant at 1
month (100 µm; p= 0.063)
or 3 months (33 µm;
p= 0.50). In all patients,
median± SE time to CMO
recurrence was 201±
62 days
Repeat implantation in
patients with recurrence
of CMO and decrease in
VA from previous visit.
Number of implants per
patient during follow-up
ranged from one to four;
56% (10/18 eyes) needed
two or more implants.
Among those with a
second implant, median
time to retreatment was
300 ± 71 days
NR
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Study and design
Number of
patients/eyes,
follow-up and
number of
implants BCVA VH CRT Repeat implantations Other
Lam 201581
retrospective
review of DEX
700 for macular
oedema,
multicentre,
Canada
l 20 patients,
23 eyes
l 1–6 months
l Mean
implants:
1.7± 0.2
After first implant, 17/21
eyes (81%) gained one or
more line of vision, 13
(62%) gained two or
more lines and 12 (57%)
gained three or more
lines
NR 17/23 eyes showed
improvement in CRT,
with a mean (SE) peak
improvement of 255.6
(43.6) µm. Eyes without
prior pars plana vitrectomy
showed a greater mean
peak improvement than
eyes with prior pars plana
vitrectomy (295.1± 54.0 µm
vs. 161.0± 20.4 µm)
l Mean ± SE number
of implants was
1.7± 0.2. Mean ± SE
time from first to
second implant was
4.7± 0.3 months
and from second to
third implant was
3.4± 0.4 months
l BCVA: second implant
– 9 (90%), 7 (70%)
and 5 (50%) out of
10 eyes gained one or
more, two or three
lines of vision
respectively; third
implant – 4/5 eyes
(80%) gained three or
more lines of vision
NR
Miserocchi 201279
retrospective study
of DEX 700 for
posterior uveitis,
single centre, Italy
l 12 patients,
14 eyes
l 11 months
l 15 implants in
14 eyes
Mean BCVA was 20/80
(0.6 logMAR) before
implant and 20/40
(0.3 logMAR) at the end of
follow-up (6–11 months).
Mean improvement in
BCVA of 3.3 lines at the
end of follow-up (range
0–6 lines)
NR CRT was 496 (123) µm at
baseline, improving to 226
(66) µm by the end of
follow-up
NR Concomitant systemic
immunosuppressants
or corticosteroids: all
patients were on systemic
immunosuppressants or
corticosteroids; 3/12
patients reduced
corticosteroid dose after
receiving DEX 700
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Study and design
Number of
patients/eyes,
follow-up and
number of
implants BCVA VH CRT Repeat implantations Other
Nobre-Cardoso
201683
retrospective
review of DEX 700
for non-infectious
uveitic macular
oedema, single
centre, France
l 31 patients,
41 eyes
l 12 months
l 1: 18 eyes;
2: 10 eyes;
3: 2 eyes;
4: 1 eye
Significant improvement
in mean BCVA at 1 month
after first implant, from
0.84 ± 0.81 logMAR
(Snellen 20/140) at
baseline to 0.74± 0.84
logMAR (20/110)
(p< 0.01). Mean BCVA
remained improved from
baseline at 12 months
Percentage with VH = 0
increased from 51.2%
at baseline to 71.1% at
month 1 (p < 0.001) and
75.6% at month 3
(p < 0.01). Percentage
with VH = 0 at month
12 was higher than at
baseline (64.7%)
After first implant,
significant improvement
in mean CRT, from
461 ± 158 µm at baseline
to 308± 93 µm at 1 month
(p< 0.001). Mean CRT was
340 ± 110 µm at 3 months
(p< 0.001) and 442 ± 172
µm at 6 months. After one
implant, 6 eyes were
free of relapse in MO at
12 months
In 13 eyes with relapse
after a positive response to
first implant, mean time to
second implant was
7.1 ± 2.9 months after the
first implant. Repeat
implantations improved
BCVA (+0.08 logMAR)
and CRT (–304 µm) at 1
month post implant. After
repeat implant, mean time
to relapse was 5.0 ± 1.6
months, similar to that for
first implant (p= 0.689)
Mean time to relapse:
after first implant
(increase of ≥ 50 µm in
CRT from month 1) was
6.7 ± 3.7 months; at
12 months the overall
relapse rate was 83.3%
Palla 201580
retrospective
review of DEX 700
for non-infectious
uveitis, single
centre, India
l 15 patients,
20 eyes
l 12 months
l NR
Mean BCVA improved
from 0.666 logMAR
(Snellen 20/93) at
baseline to 0.479 logMAR
(20/60) at 6 weeks (stated
as statistically significant)
Proportion achieving
VH = 0 was 60%, 45%
and 30% at 6 weeks,
6 months and the last
visit respectively
Mean CRT improved from
563.1 µm at baseline to
361.4 µm at 6 weeks.
Trend continued at each
follow-up. Two eyes with
epiretinal membrane at
baseline had minimal CRT
improvement
NR NR
Pelegrín 201551
retrospective
review of DEX 700
for macular
oedema secondary
to non-infectious
uveitis, single
centre, Spain
l 32 patients,
42 eyes
l 24 months
l 1: 23 eyes;
2: 12 eyes;
3: 5 eyes;
4: 2 eyes
BCVA improved in
vitrectomised and
non-vitrectomised eyes.
Maximum improvement
at month 3 in both
groups, maintained
throughout follow-up.
Difference between
vitrectomised and non-
vitrectomised eyes was
statistically significant only
at 24 months (favoured
non-vitrectomised eyes;
p= 0.04)
VH at baseline from +0.5
to +3.0 in 21 eyes (50%).
Two-step improvement
or change from +0.5 to 0
in 66.7% at 1 month,
62% at 3 months,
76.2% at 6 months and
80.1% at 12 months.
Changes in maximum VH
score were similar in
non-vitrectomised and
vitrectomised eyes at all
follow-up points
(p= 0.706)
Maximum decrease in
CRT at month 1 in
non-vitrectomised and
vitrectomised eyes (251.2
and 229.9 µm respectively).
Maintained throughout
follow-up: at 24 months
mean CRT improved by
189.1 and 273.8 µm in
non-vitrectomised and
vitrectomised eyes
respectively (difference
significant only at
24 months; p = 0.02)
Repeat implants required in
19 eyes (45.2%). No
difference in frequency of
repeat implants between
non-vitrectomised and
vitrectomised eyes. Median
time to repeat implantation
was 5 months (IQR
5–6 months). Twelve eyes
(28.6%) required two
implants, five (11.9%)
required three implants and
two (4.8%) received four
implants
Concomitant systemic
corticosteroid treatment:
at baseline, 40.3% were
receiving systemic
prednisone and 53.1%
second-line agents.
Prednisone was reduced
to < 10mg/day in all
patients at 1 month; dose
reduction was maintained
in 78% at 12 months.
Prednisone was
discontinued in 31.8% at
12 months
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Study and design
Number of
patients/eyes,
follow-up and
number of
implants BCVA VH CRT Repeat implantations Other
Pleyer 201482
prospective case
series, single DEX
700 implant for
intermediate or
posterior uveitis,
two centres,
Germany
l 84 patients,
84 eyes
l 6 months
l NR
Mean BCVA 0.68± 0.47
logMAR (Snellen 20/100)
at baseline, improving to
0.53 ± 0.54 logMAR
(20/63) by 4 weeks
(p= 0.001) and
0.51 ± 0.49 logMAR
(20/63) by 12 weeks
(p< 0.001). BCVA
improvement lost by
week 24 (p= 0.999)
Percentage with VH = 0
increased from baseline
to 4 weeks (19% vs.
61%; p< 0.001);
percentage remained
significantly above
baseline throughout
follow-up. Mean VH
remained below
baseline level (p < 0.001
at weeks 4, 12 and 24)
Mean CRT improved from
463 ± 165 µm at baseline
to 300± 110 µm by week
4 (p< 0.001). Improvement
remained significant
throughout the follow-up
period (p < 0.001 at 12
and 24 weeks)
NR Concomitant systemic
immunosuppressants
or corticosteroids:
32 patients (38%)
on systemic
immunosuppressants
(± corticosteroids) at
baseline. Systemic
corticosteroids
discontinued in 8 (25%)
and reduced (to < 10mg)
in a further 6 (19%)
Tomkins-Netzer
201418
retrospective
review of
treatment and
retreatment with
DEX 700 for
non-infectious
uveitis, two
centres, UK
l 27 patients,
38 eyes
l 24 months
l 1: 14 eyes;
2: 14 eyes;
3: 7 eyes;
4: 2 eyes;
6: 1 eye
Mean BCVA improved
significantly after first
implantation, from 0.47
(SEM 0.05) logMAR
(Snellen 20/60) at
baseline to 0.27 (0.07)
logMAR (20/37) at
2 months (p < 0.001);
deteriorated to 0.43
(0.12) logMAR (20/54) by
6 months
Significant improvement
in the percentage of
eyes with VH = 0 after
first implantation, from
58% at baseline to 83%
at 1 month (p= 0.03);
remained until month 6
(85%; p = 0.02) but
decreased by 12 months
(53%)
Mean (SEM) CRT decreased
significantly from 453
(34) µm at baseline to
263 (44) µm at 1 month
after first implantation
(p= 0.003). Macular
oedema persisted in 50%
of eyes but remaining eyes
had a decrease in CRT of
127 (52) µm at 6 months
(p= 0.01); improvement
was maintained up to
12 months
l BCVA: second implant –
improved from 0.55
(0.1) logMAR (20/70) to
0.22 (0.07) logMAR
(20/33) at 1 month
(p= 0.004), decreased
after 1 month; third
implant – similar trend,
not significant; fourth
implant – BCVA
improved from 0.83
(0.17) logMAR (20/135)
at baseline to 0.32
(0.09) logMAR (20/42)
at 1 month. One eye
had six implants: BCVA
improved within
1 month
l CRT: second implant –
decreased by 187 (SEM
52.9) µm at 2 months
(p= 0.043); third
implant – improved but
not significantly; fourth
implant – decrease of
225.67 (109.85) µm at
1 month
l Median time to
relapse: 6 months
(range 2–42 months)
after first implant
(relapse in 69% of
eyes) and 6 months
after second implant
(1–12 months) (relapse
in 48% of eyes)
l Reducing other
treatment: after first
implant – systemic or
local treatment
reduced or stopped
in 33 eyes of 21
patients (78%)
l Implants in both eyes:
11 patients had
implants in both eyes;
second implant was
administered
113 ± 32 days after
the first. Three of
11 patients had a
response in the
second eye (reduced
CRT, improved BCVA)
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Study and design
Number of
patients/eyes,
follow-up and
number of
implants BCVA VH CRT Repeat implantations Other
l VH: improvement in
percentage with
VH = 0 after second
implant not significant
(72.7% at baseline,
91.7% at 1 month);
similar trend after
third implant
Tsang 201684
retrospective
review of DEX 700
for uveitic macular
oedema, Canada
l 15 patients,
25 eyes
l 12 months
l Single: 18
eyes; repeat:
7 eyes
BCVA improved in 20/25
eyes (80%). Significant
improvement in mean
BCVA at 3 months, from
0.614± 0.089 logMAR
(Snellen 20/82) at
baseline to 0.35± 0.10
logMAR (20/45) at month
3. Five of 25 eyes (20%)
had worsening of VA
during follow-up
NR CRT improved in 32/35
eyes (91.4%), from
590 ± 28 µm at baseline to
380 ± 28 µm at 1 month
and 370 ± 3 µm at 3
months (p< 0.001);
maintained throughout
follow-up
For 7 eyes with
repeat implant: BCVA
improvement at 1 month
after first implant
0.069± 0.179 logMAR;
improvement after second
implant 0.184 ± 0.171
logMAR (difference not
significant). CRT reduced
by 268± 76 µm at 1
month after first implant
and by 291 ± 74 µm at
1 month after repeat
implant (difference not
significant). Median time
to treatment failure
(increase in CRT > 10%
and ≥ 50 µm or need
for repeat implant) was
6 months
NR
A
PPEN
D
IX
5
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
162
Study and design
Number of
patients/eyes,
follow-up and
number of
implants BCVA VH CRT Repeat implantations Other
Zarranz-Ventura
201450
retrospective
review of DEX
700 for non-
infectious uveitis,
multicentre, UK
and Spain
l 63 patients,
82 eyes
l Mean
15.4 months
l 1: 43 eyes;
2: 24 eyes;
≥ 3: 15 eyes
Mean VA was 0.68
(SD 0.4) logMAR (Snellen
20/90) at baseline,
improving to 0.59 (0.4)
logMAR (20/78) after 2
weeks, 0.49 (0.4) logMAR
(20/62) at 1 month, 0.49
(0.5) logMAR (20/62) at
3 months, 0.60 (0.5)
logMAR (20/80) at
6 months and 0.52 (0.5)
logMAR (20/66) at
12 months (all p< 0.01)
VH analysed in only 39
eyes with vitritis at
baseline (VH≥+0.5).
Probability of VH
improvement (two-step
improvement or change
from +0.5 to 0) was 41%
at 2 weeks, 63% at
1 month, 73% at
3 months, 79%
at 6 months and 88%
at 12 months. The
median time to
improvement in VH
was 1 month (95% CI
0.6 to 1.3 months)
CRT analysed in only 59
eyes with CMO. Mean (SD)
CRT at baseline was 469
(193) µm, improving to 326
(81) µm at 2 weeks, 267
(74) µm at 1 month, 318
(149) µm at 3 months, 366
(140) µm at 6 months and
355 (160) µm at 12 months
(all p < 0.01)
Median time to second
implant: 10 months (95% CI
6.3 to 13.6 months)
Concomitant systemic
immunosuppressants or
corticosteroids: probability
of dose reduction
(≥ 5mg of steroids or
any reduction in
immunosuppressants) was
36% at 1 month, 42%
at 3 months, 46% at
6 months and 62% at
12 months. Probability of
steroid discontinuation:
8% at 1 and 3 months,
11% at 6 months and
36% at 12 months
CMO, cystoid macular oedema; CRT, central retinal thickness; IQR, interquartile range; MO, macular oedema; NR, not reported; SE, standard error; SEM, standard error of the mean;
VA, visual acuity.
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Appendix 6 Safety data from non-randomised
studies of the dexamethasone implant
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Study Design
Number of
patients/eyes Follow-up
Number of
implants Increased IOP Cataracts Other AEs
Adán 201385 Retrospective study
of DEX 700 after
vitrectomy for uveitic
macular oedema,
Spain
13 patients,
17 eyes
12 months Single: 9 eyes;
repeat: 8 eyes
l IOP 22–30 mmHg: 41%
l IOP 30–40 mmHg: 1 (6%)
l IOP > 40mmHg: 0
l All treated with topical
medication and normalised
within 8 weeks
l Surgery for IOP: 1 patient
l Cataract surgery
for pre-existing
cataract: 1 (6%)
l Hypotony (transient,
resolved without
treatment): 2 (12%)
l Retinal detachment:
1 (6%), 5 months
post implant
l No cases of
endophthalmitis or
vitreous haemorrhage
Khurana
201586
Retrospective review
of DEX 700 for
cystoid macular
oedema secondary to
non-infectious uveitis,
single centre, USA
13 patients,
18 eyes
3 months 1: 8 eyes;
2–4: 10 eyes
l IOP ≥ 25mmHg: 2 (11%)
over 3 months
l IOP ≥ 35mmHg: 0
l All managed with
topical medications
l None required surgery
l Progression of pre-
existing cataract:
1/10 phakic eyes
l No cases of retinal
detachment, hypotony
or migration of implant
to AC
l No SAEs
Lam 201581 Retrospective chart
review of DEX 700
for macular oedema,
multicentre, Canada
101 patients,
120 eyes
1–6 months Mean implants:
1.7
l Raised IOP in 2/20 (10%)
l Of eyes with a history of
steroid response, 37.5%
had an IOP ≥ 25mmHg
and 12.5% had an
IOP ≥ 35mmHg
l Topical IOP-lowering
medications required for
62.5% of eyes with a
history of steroid response
l Cataract: 1/11
(9%) phakic eyes
l Cataract surgery:
5/11 (45%)
phakic eyes
l Retinal detachment:
1/20 (5%)
l Serious uveitis flare:
1/20 (5%)
Miserocchi
201279
Retrospective study of
DEX 700 for chronic
posterior non-
infectious uveitis,
single centre, Italy
12 patients,
14 eyes
11 months 15 implants in
14 eyes
l Raised IOP in 3/14 eyes
(21%) within 2 weeks, all
transient, all controlled
with topical IOP-
lowering medication
l No cataracts or
cataract surgery
reported
l Subconjunctival
haemorrhage: one case
l Vitreous haemorrhage:
one case in patient
on anticoagulants
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Study Design
Number of
patients/eyes Follow-up
Number of
implants Increased IOP Cataracts Other AEs
Nobre-Cardoso
201683
Retrospective review
of DEX 700 for non-
infectious uveitic
macular oedema,
single centre, France
31 patients,
41 eyes
12 months 1: 18 patients;
2: 10 patients;
3: 2 patients;
4: 1 patient
l IOP > 21mmHg: 36%
l IOP > 25mmHg: 31%
l IOP > 30mmHg: 6.9%
l All cases responded to
topical IOP-lowering
medication
l Ocular hypertension: 15
eyes; 10 had a history of
steroid response
l Cataract surgery:
3 eyes (all with
repeat implants)
l Vitreous haemorrhage:
one case, patient on
antiplatelet medication
Palla 201580 Retrospective review
of DEX 700 for non-
infectious uveitis,
single centre, India
15 patients,
20 eyes
12 months NR l IOP > 21mmHg in 3 eyes
(15%) and IOP ≥ 25mmHg
in 2 eyes (10%) by week 6
l All manageable with
medication
l Cataract surgery:
2 (10%) within
6 months, 5 (25%)
within 1 year
l Pars planitis: 1 (5%)
Pelegrín 201551 Retrospective review
of DEX 700 for
macular oedema
secondary to non-
infectious uveitis,
single centre, Spain
32 patients,
42 eyes
NR 1: 23 eyes;
2: 12 eyes;
3: 5 eyes;
4: 2 eyes
l IOP > 21mmHg: 20 (48%)
– 8 non-vitrectomised eyes
(36.4%) and 12
vitrectomised eyes (60%)
l New hypotensive treatment
required in 9 eyes
l Pre-existing
cataracts
progressed in 4/4;
3 required surgery
l Implant migration to
AC: 2 (4.7%; one
aphakic, one with iris
claw intraocular lens)
l Hypotony (transient,
resolved without
treatment): 3 (7.1%)
l Vitreous haemorrhage:
3 (7.1%)
Pleyer 201482 Prospective case
series of single DEX
700 implants for
non-infectious
intermediate or
posterior uveitis, two
centres, Germany
84 patients,
84 eyes
6 months NR l IOP ≥ 25mmHg: 13 (16%)
l IOP ≥ 35mmHg: 3 (4%)
l IOP-lowering medication:
21% at baseline, 42%
at 12 weeks, 28% at
24 weeks
l Larger IOP increase in
intermediate than in
posterior uveitis (p= 0.003)
l Cataract: 7
phakic eyes
l Pre-existing
cataracts
progressed in 2/3
l No surgery
required
l Conjunctival
haemorrhage in ‘few
patients’ (n NR),
cleared rapidly
l No cases of
endophthalmitis or
uveitis flare-up
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Study Design
Number of
patients/eyes Follow-up
Number of
implants Increased IOP Cataracts Other AEs
Tomkins-
Netzer 201418
Retrospective review
of treatment and
retreatment with DEX
700 in non-infectious
uveitis, two centres,
UK
27 patients,
38 eyes
24 months 1: 14 eyes;
2: 14 eyes;
3: 7 eyes;
4: 2 eyes;
6: 1 eye
l First implant: 3 eyes had
IOP of > 21mmHg within
2 months
l Second implant: 4 eyes had
IOP of > 25mmHg within
2 months
l Third implant: no eyes with
increased IOP
l Frequency of increased IOP:
0.13 per eye-year
l First implant:
cataract in 1/21
phakic eyes
l Second implant:
no new cataracts
l Third implant: one
further cataract
Implant migration in 1 eye
that had undergone cataract
extraction
Tsang 201684 Retrospective review
of DEX 700 for uveitic
macular oedema,
Canada
15 patients,
25 eyes
12 months Single: 18 eyes;
repeat: 7 eyes
l No patients had IOP
> 21mmHg or an increase
of > 10mmHg (patients
with IOP of > 21mmHg
were excluded)
l No new cataracts
l Pre-existing
cataracts
progressed in 2/15
l Implant injected into
lens in 1 eye
l Macular hole: 1
l Epiretinal membrane: 3
l No cases of
endophthalmitis or
retinal detachment
Zarranz-
Ventura 201450
Retrospective review
of DEX 700 for
non-infectious uveitis,
multicentre, UK and
Spain
63 patients,
82 eyes
12 months 1: 43 eyes;
2: 24 eyes;
≥ 3: 15 eyes
l IOP ≥ 21 mmHg in 33/82
eyes (40.2%)
l IOP ≥ 35 mmHg in 7% at
months 1 and 3
l IOP-lowering medication
required in 32 eyes (39%)
l Cataract surgery in
4/40 (10%) phakic
eyes during
follow-up
l Implant migration to
AC: 2/142 implant
injections (1.4%),
1 aphakic eye,
1 pseudophakic eye
l Vitreous haemorrhage:
3 (2.1%)
l Hypotony: 3 (2.1%)
l Endophthalmitis:
1 (0.7%)
NR, not reported.
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Appendix 7 Breakdown of the cost-effectiveness
analysis results for the base case
TABLE 67 Breakdown of the results of the base-case analysis for ADA vs. limited clinical practice in patients with
active uveitis: deterministic model
Outcome Placebo ADA Increment
Life-years
On treatment 0.620 2.081 1.460
Failed treatment 17.565 16.323 –1.242
Remission 0.000 0.000 0.000
Blind 2.343 2.125 –0.218
Total 20.529 20.529 0.000
QALYs
On treatment 0.524 1.799 1.274
Failed treatment 13.603 12.595 –1.008
Remission 0.000 0.000 0.000
Blind 0.792 0.716 –0.076
Total 14.919 15.110 0.191
continued
TABLE 66 Breakdown of the results of the base-case analysis for DEX vs. limited clinical practice:
deterministic model
Outcome Sham DEX Increment
Life-years
On treatment 18.669 18.703 0.034
Blind 1.859 1.826 –0.034
Total 20.529 20.529 0.000
QALYs
On treatment 13.904 13.946 0.042
Blind 0.709 0.696 –0.013
Total 14.613 14.641 0.029
Costs (£)
Drugs 2449.61 3324.03 874.42
Administration and monitoring 17,452.41 17,597.44 145.04
AEs 5186.39 5255.04 68.64
Rescue therapy 285.26 35.25 –250.01
Blindness 14,281.54 14,023.09 –258.46
Total 39,655.21 40,234.85 579.64
ICER (£/QALY) 20,057.73
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TABLE 67 Breakdown of the results of the base-case analysis for ADA vs. limited clinical practice in patients with
active uveitis: deterministic model (continued )
Outcome Placebo ADA Increment
Costs (£)
Drugs 2813.59 21,961.73 19,148.14
Administration and monitoring 18,352.07 18,811.80 459.73
AEs 8037.18 8338.60 301.43
Blindness 17,983.53 16,289.21 –1694.32
Total 47,186.36 65,401.34 18,214.98
ICER (£/QALY) 95,505.74
TABLE 68 Breakdown of the results of the base-case analysis for ADA vs. limited clinical practice in patients with
inactive uveitis: deterministic model
Outcome Placebo ADA Increment
Life-years
On treatment 2.937 4.223 1.286
Failed treatment 15.137 14.104 –1.034
Remission 0.000 0.000 0.000
Blind 2.454 2.202 –0.252
Total 20.529 20.529 0.000
QALYs
On treatment 2.458 3.519 1.061
Failed treatment 11.957 11.100 –0.856
Remission 0.000 0.000 0.000
Blind 0.830 0.742 –0.088
Total 15.244 15.361 0.116
Costs (£)
Drugs 4990.76 43,855.57 38,864.81
Administration and monitoring 19,944.05 20,708.76 764.71
AEs 4345.10 4002.68 –342.42
Blindness 18,830.87 16,894.93 –1935.94
Total 48,110.78 85,461.94 37,351.16
ICER (£/QALY) 321,405.45
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